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Abstract 
The aim of this PhD is to better understand the epidemiology of respiratory function in very 
old people and specifically examine the relationship between respiratory function and both 
cognitive function and disability in this age group. Data from the Newcastle 85+ study, a 
longitudinal cohort study of 85 year olds (born in 1921) were used in this thesis. Very few 
studies have investigated lung function and especially its impact on disability and mortality in 
the very old, and the unique point of this study was the multiple measurements of three lung 
function parameters: FEV1, FVC and PEF, between the ages of 85 and 88 years.  
Four sub-studies constituted the substantive results chapters of this thesis. The first sub-study 
described the prevalence of respiratory disease in the very old and the applicability of 
indicators of poor lung function and their cutpoints in this age group. The second sub-study 
explored the predictive ability of lung function for subsequent survival. The third sub-study 
quantified how lung function changes with further ageing in 85 year olds. The fourth sub-
study examined the relationship between lung function and disability, particularly the 
direction of causality, and the potential mediating role of cognitive function. 
In the very old significant differences were observed between physician-diagnosed COPD and 
the obstructive classification of spirometry using the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) and Global lung initiative (GLI) prediction models. Lung function was 
predictive of mortality in women only. When investigating lung function trajectories of 
change, smoking and cognitive impairment were associated with lower FEV1. Bidirectional 
causality between lung function and disability revealed that higher FEV1 at ages 85, 86.5 and 
88 was associated with lower disability at subsequent follow-ups (ages 86.5, 88 and 90) whilst 
higher disability scores at age 85 were associated with lower FEV1 at age 86.5. 
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Chapter 1. Introduction 
1.1 Ageing demography 
The world’s population and the UK in particular are facing challenging times. As life 
expectancy is increasing in combination with a decline in fertility rates we will be witnessing 
a higher proportion of older people in the future (United Nations, 2002). One sector of this 
population is the very old, referred to as those older than 85 years of age by some and above 
80 by others, who are the fastest growing sector of our population. In 2014 this age group 
formed only 2.3% (1.5 million) of the population, but it is projected to rise to 4.8% (3.6 
million) by 2039 (Office for National Statistics, 2015). Because of the strong relationship 
between most chronic diseases and age, the very old have a high burden of disease which 
includes multimorbidity (the presence of two or more conditions) and the highest health 
expenditure per capita compared to other age group (Summerfield and Babb, 2004). It is 
therefore crucial to understand the health and disease of this age group in order to recognise 
their needs for the future and to find ways to slow down functional decline. The World Health 
Organisation (WHO) has started this process in their healthy ageing strategy  which focuses 
on extending healthy life expectancy rather than simply  extending life expectancy (WHO, 
2012). However, at least for the UK, gains in healthy life expectancy and disability-free years 
are progressing at a slower rate than life expectancy (Jagger et al., 2016).   
1.2 Functional capacity of the very old  
The WHO healthy ageing concept is based on the relationship between an individual’s 
intrinsic capacity and functional ability. Functional ability relates to a person’s capacity to 
perform tasks they wish to do independently, often measured by  the ability to carry out basic 
activities of daily living (BADLs) such as dressing, toileting, and instrumental activities of 
daily living (IADLs) such as shopping or housework (McGee et al., 1998). The intrinsic 
capacity refers to objective measures of health such as strength, balance and which includes 
respiratory function. As intrinsic capacity declines with age, it becomes more difficult to 
sustain functional ability (Figure 1.1) (Beard et al., 2016). 
This relationship between respiratory function and functional ability is clearly shown by the 
development of scales such as the MRC breathlessness scale. This scale was devised to 
measure the exercise capacity of each subject and which grades patients from 1 to 5 with one 
meaning that the patient is not troubled by breathlessness and 5 indicating that patients are left 
2 
 
without breath whilst undressing, rendering them to be homebound (Fletcher et al., 1959; 
Stenton, 2008).  
1.3   The ageing lung  
In keeping with respiratory function being part of the intrinsic capacity of an individual, 
previous studies have found that the lung’s elastic and resistive properties decline with age 
(Pride, 2005; Vaz Fragoso and Gill, 2012). However  total lung capacity does not appear to be 
affected by the ageing process, rather the functional residual capacity and residual volume 
change as people age (Pride, 2005).  The physiological processes of ageing are associated 
with decreased lung function in three ways: decreased strength of the respiratory muscles; 
decrease in lung recoil; and increased stiffness of the chest wall (Vignola et al., 2003). 
Moreover  reduced chest wall compliance appears to cause an increase in the functional 
residual capacity (Janssens, 2005). In addition to this, the presence of certain ageing 
biomarkers and disease burden have been shown to be associated with lung function (Martin-
Ruiz et al., 2011). 
Chronic Obstructive Pulmonary Disease (COPD) is one of the major challenges in the modern 
healthcare, ranked 4th in terms of mortality and leading cause of disease, and claiming 3 
million lives annually (WHO, 2004). Its risk factors include a range of genetic, environmental 
and life style or behavioural factors. Age and sex also contribute to this although it may be 
argued that the reason behind this is the accumulation of exposures through life (Vestbo et al., 
2013) though pulmonary function may deteriorate as a result of the ageing process (Ito, 2007). 
As a result many studies have been conducted with subjects at the latter stages of their life in 
order to distinguish the effects and associations of ageing and COPD, although these have 
been predominantly in patients in hospital(Ranieri et al., 2001; Ito, 2007; Almagro et al., 
2010).  
1.4 Lung function measures 
There are many different tests available for clinicians to identify lung efficiency. Tests can be 
used to check inspiration and expiration, airflow obstruction, gas transfer, lung volume, effect 
of medication and exercise on lungs and lung function during rest periods.  
The main tests used to determine lung efficiency come under this heading and apply different 
measurement methods to the air exhaled by the patients after maximal inspiration (Global 
Initiative for Chronic Obstructive Lung Disease (GOLD), 2010). Peak Expiratory Flow (PEF) 
measures maximum speed of expiration and indicates if patients have constricted airways, 
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though this is not seen to be accurate as spirometry tests (Stephen J. Bourke, 2011). The main 
measures from spirometry tests are Forced Expiratory Volume in 1 second (FEV1) and Forced 
Vital Capacity (FVC). FEV1 is the maximum amount of air that a patient forcefully exhales in 
1 second. A reduction in this value is seen if the patient has either restrictive or obstructive 
lung disease. FVC is the total amount of air that patients expire and reduction in this is 
indicative of a patient with restrictive lung disease.  
There have been studies exploring the age-related rate of lung function decline, expressing a 
faster decline in FEV1 than FVC with higher rates observed for smokers (Beck et al., 1981; 
Kerstjens et al., 1997; Anthonisen et al., 2002; Mannino and Davis, 2006; Yohannes and 
Tampubolon, 2014). A review of various studies of lung function decline reported yearly 
average reductions of between 10 and 35 ml in FEV1 in both men and women (Kerstjens et 
al., 1997). Age-related rate of decline from the English Longitudinal Study of Ageing (ELSA) 
reported a mean decline of 32.92 (SD: 0.96) ml per year for FEV1 in a population of people 
aged 50 and over (Yohannes and Tampubolon, 2014). The most recent lung function 
equations from the Global Lung Initiative (GLI) reported marginally different rates of lung 
function decline between men and women aged 85 (Quanjer et al., 2012). Men were observed 
to have a mean decline of 30 ml per year for both FEV1 and FVC, whilst the mean rate of 
decline for women was reported as 30 ml per year for FEV1 and 20 ml per year for FVC 
(Quanjer et al., 2012). 
The values obtained from these tests are used in various formulae to diagnose patients. 
Patient’s height, age and sex are used to work out predicted or expected values for their FEV1 
and FVC (Table 1.1). Another parameter that aids this is the FEV1 to FVC ratio (FEV1/FVC).  
FEV1 and FVC of above 80% predicted and a FEV1/FVC value of above 0.7 indicates normal 
spirometry whilst FEV1 below 80% of their predicted value, normal or reduced FVC and a 
FEV1/FVC value of below 0.7 indicates obstructive spirometry. Normal or slightly reduced 
FEV1, an FVC of below 80% predicted and a FEV1/FVC of above 0.7 indicates restrictive 
spirometry (Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2010).     
Table 1.1: ERS 1993 formulae for predicted FEV1 and FVC  
FEV1 (Females) (3.95*(height
#))-(0.025*age)-2.60 
FEV1 (Males) (4.3*(height))-(0.029*age)-2.49 
FVC (Females) (4.66*(height))-(0.024*age)-3.28 
FVC (Males) (6.1*(height))-(0.028*age)-4.65 
# Height measured in metres; (Rabe et al., 2007)  
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1.5 Literature review of respiratory epidemiology in the very old 
I addressed the issue of the current knowledge base on respiratory function in very old 
populations in two ways. Firstly, I reviewed the known studies of ageing that included very 
old participants (aged 85+ years) and ascertained which, if any, had lung function measures 
included. Secondly, I conducted a wider systematic literature review as described later.  
As mentioned previously, few studies of very old populations include measures of respiratory 
function. Studies of older population more generally have included people aged 85+ but rarely 
in numbers large enough to draw robust conclusions. Such examples are: Baltimore 
Longitudinal Study of Aging (BLSA) (age range 17 – 96 years) (Shock, 1984); the Berlin 
Aging Study (BASE) (age range 70+) (Evans, 1999); the English Longitudinal Study of 
Ageing (ELSA) (age range 50+) (Higgs et al., 2004); and the Longitudinal Study of Aging 
Danish Twins (LSADT) (age range 75 - 102) (Skytthe et al., 2006). Of these only BLSA, 
LSADT and BLSA include respiratory function measures. There are 3 existing single birth 
cohort studies of those aged 85 years, with the first being the model for  the others: the Leiden 
85+ initiated in 1987 with a second cohort in 1997 (Lagaay et al., 1992); the Newcastle 85+ 
study (N85+) initiated in 2006 (Collerton et al., 2007); and the Life and Living in Advance 
Age study (LiLACS) in New Zealand  (Hayman et al., 2012). Of these, only the N85+ and 
LiLACS include respiratory function measures. Five other studies include a different age 
range but focus on the very old: the Tokyo Oldest Old Survey on Total Health study (Arai et 
al., 2010); the Swedish Adoption/Twin Study of Aging (SATSA) (Finkel and Pedersen, 
2004); the Jerusalem Longitudinal Cohort Study (JLCS) (Jacobs et al., 2009); the Vitality 90+ 
study (age range 90 - 106) (Jylha and Hervonen, 1999) and Danish 1905-Cohort (DCS-1905) 
(age 93) (Nybo et al., 2001).  Of these SATSA, JLCS and DCS-1905 include respiratory 
function measures. Therefore, in total there are only 8 studies exclusively of the very old that 
have the potential to examine lung function, its determinants and its disabling consequences. 
This thesis is based on the most comprehensive of these, the Newcastle 85+ Study. 
The focus of the literature review was research on respiratory epidemiology in the older 
population, specifically the very old. The search was focused on studies which either solely 
had participants of the age 75 and over or other studies which had an array of age categories 
including reasonable numbers aged 75+ and more importantly 85 year olds and over. Two 
article abstract and citation databases were utilised: Scopus and PubMed. The search began 
with just 3 terms, respiratory, old and epidemiology. The search parameters included the 
keywords: old, old age, oldest old, very old, geriatric and advanced age for returning relevant 
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samples for age. Epidemiology, lung function, COPD, respiratory, LLN, FEV1, FVC, and 
PEFR were included to return research in this field. A 15-year limit was set at the start of this 
PhD meaning all publications since 1998 would be included. The search was not limited to 
longitudinal studies in order to be as comprehensive as possible and to identify subject areas 
which have been given varying degrees of exposure.  
The search across both of the databases returned 929 articles and abstracts. In addition, further 
searches were made by referring to the bibliography of the more relevant articles. A total of 
1199 articles, abstracts, reviews and study protocols were transferred into the citation 
manager EndNote and all of the abstracts were imported for ease of reviewing the papers.  
Three main groups were created in EndNote: Guidelines/Reviews, Cross-sectional and 
longitudinal studies. For the latter two categories, sub-groups were created to differentiate 
between the studies and their outcomes/predictors. As an example, all studies which had 
associations with COPD either as outcome or predictor were grouped in a sub-folder titled 
with COPD.  
All the abstracts were then reviewed and grouped according to relevance. There were 120 
papers found to be within the scope of this literature review of which, 54 were from 
longitudinal studies and 66 reported cross-sectional findings. These papers will be discussed 
under three broad headings: lung function and lung disease; respiratory function as a predictor 
of other outcomes; predictors of respiratory function. As expected, papers in which COPD 
was used as a predictor or outcome formed the largest proportion of these papers (19/120 
(16%)).  
1.5.1 Lung function and lung disease 
Whilst prediction models exist to evaluate how close a subject’s lung function is to that 
predicted, these formulae rely on three non-respiratory parameters: age, sex and height. Race 
has also been suggested by the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guidelines (Vestbo et al., 2013), and other factors, such as Total lung capacity 
(TLC), nutrition, health and environmental status have been suggested (Pellegrino et al., 
2005). Such discussions may indicate that there may be a need for more comprehensive 
formulae that would be more accurate in predicting lung function. In  a relatively large sample 
of 592 non-smokers population of 42 – 89 year olds quantile regression was used to produce 
equations for median and lower limit of normal lung function (Karrasch et al., 2013).  These 
formulae produced different results to other prediction formulae  suggesting there may be 
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regional differences even within the Caucasian population of this age group in Europe 
(Gottdiener et al., 2000). Additional measures to facilitate the identification of patients with 
Obstructive Lung Disease  have been  suggested, including diagnostic values of airway 
impedance (Zrs) worked from forced oscillation technique, though these have been used 
exclusively in hospitalised patients (Janssens et al., 2001).  
Other studies have also investigated prediction methods and how the comparison to the 
GOLD guidelines. (Guder et al., 2012; Runarsdottir et al., 2013; Scholes et al., 2014). 
Comparison of  the difference in expert panel diagnosis with GOLD classification and Lower 
Limits of Normal (LLN) formulae found that GOLD criteria misclassified 28% of the patients 
whereas LLN equations misclassified COPD by at least 39% (Guder et al., 2012). In addition 
the GOLD criteria led to more false positives whereas the LLN produces more false negative 
results when compared to the expert panel findings, with the expert panel classification seen 
to be most accurate (Guder et al., 2012).   
In  a non-smoking Icelandic population of 66 – 92 year olds,  the GOLD criteria identified a 
substantial number (38%) of non-symptomatic subjects as having COPD, and more than 
would have been identified  if the LLN formulae had been used (Runarsdottir et al., 2013).  
Similar findings were reported from wave 2 of the UK household survey where prevalence of 
obstruction was higher in 75 – 95 years old using GOLD (45.0%) in comparison to LLN 
(17.2%) (Scholes et al., 2014). These findings have been confirmed in those aged 75 and over 
with higher COPD prevalence using GOLD (26.4%) than LLN (5.6%) (Karrasch et al., 2016). 
Almagro and colleagues investigated gender differences in COPD patients and found that men 
had a larger mean average FEV1 but a lower FEV1/FVC, higher number of comorbidities and 
they observed that more men had severe or very severe COPD compared to women (Almagro 
et al., 2010).  
1.5.2 Respiratory function as a predictor of other outcomes 
Of the 120 studies reviewed, 30 examined respiratory function as a predictor of other 
outcomes. In eight of the studies the outcome was cognitive impairment (Schaub et al., 2000; 
Murray et al., 2005; Li et al., 2006; Allaire et al., 2007; Guo et al., 2007a; Weuve et al., 
2011; Emery et al., 2012; Vidal et al., 2013); in a further 5 the outcome was disability (Ho et 
al., 2001; Buchman et al., 2009; Kingston et al., 2014; Lahousse et al., 2016; Hegendorfer et 
al., 2017c); physical activity in three studies (Buchman et al., 2008; Abe et al., 2011; Nyssen 
et al., 2013); 4 studied mortality  (Cooper et al., 2002; Lyyra et al., 2005; Shipley et al., 2007; 
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Buchman et al., 2008; Buchman et al., 2009); and a further two respiratory function as a 
cause of other morbidity (Bourdel-Marchasson et al., 1998; Lawlor et al., 2004). 8 studies 
investigated the different lung function formulae and their effectiveness in diagnosing COPD 
(Janssens et al., 2001; Guder et al., 2012; Karrasch et al., 2013; Runarsdottir et al., 2013; 
Miller et al., 2014; Scholes et al., 2014; Marcus et al., 2015; Karrasch et al., 2016). Brief 
details of the studies under these subheadings are given below.  
From the literature, there seems to be a well-established link between lung function and 
cognitive impairment. Schaub et al using the Berlin Ageing Study (BASE) conducted a cross 
sectional analyses of demented and non-demented participants with mean age of 84.3 years 
whom 53.8% (235) were men. When looking at the two groups defined by dementia, they 
found differences between the groups in VC, FEV1, PEFR, FVC and Maximal Expiratory 
Flow  suggesting that those with dementia performed worse than those without (Schaub et al., 
2000). Analysis of the National Health and Nutrition Examination Survey III (NHANESIII) 
found no association between memory impairment and lung function though they did find an 
association between hearing impairment and poor lung function (Li et al., 2006). Another 
study of older African American adults with an age range of 50-89 years of whom 38% were 
male, found a statistically significant inverse correlation between average PEFR (APEFR) and 
6 cognitive tests (Immediate Memory, Delayed Memory, Backward Digit Span, Alpha Span, 
Digit Symbol and Telephone Interview of Cognitive Status  (Allaire et al., 2007)).  
Brain White Matter Hyperintensities is a potential risk factor of cerebral ischemia and a study 
of 106 subjects of the 1921 birth cohort at age of 78-79 years found a negative correlation 
between white matter hyperintensity and three lung function measures (FEV1, FVC and 
PEFR) suggesting that these measures could be predictors of cerebral ischemia (Murray et al., 
2005).  
One of the shortcomings of cross sectional studies lies with the fact that they only indicate an 
association between outcomes and explanatory variables. However, longitudinal studies 
provide researchers with the ability to infer causation between two or more variables and thus 
produce causal pathways. In the Swedish Adoption/Twin Study of Aging, the relationship 
between pulmonary function and cognitive impairment was investigated by Structural 
Equation Modelling (SEM)  in a  sample of 832 (40% males) over a period of 19 years 
(Emery et al., 2012). They concluded that decline in pulmonary measures FEV1 and FVC 
leads to decline in cognitive function with a more pronounced decline in psychomotor speed 
and spatial abilities (Emery et al., 2012).  
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Another study of multiple cohorts followed longitudinally, though using only female subjects, 
found that better lung function (FEV1, FVC and PEFR) during midlife reduces the risk of 
dementia later in life (Guo et al., 2007b). These associations remained significant even after 
adjusting for many potential confounders such that of age, height, Body Mass Index (BMI), 
physical activity, respiratory and cardiovascular related conditions. To show that this effect is 
not just found in females, Weuve et al (Weuve et al., 2011) looked at FEV1 and cognitive 
decline in ageing men and also confirmed that better lung function results in slower decline of 
cognitive abilities. Subjects with lower lung function (FEV1 /height) during midlife have been 
shown to be  more likely to develop mild cognitive impairment or dementia some 23 years 
after (Vidal et al., 2013).  
The association of respiratory function with living conditions, disability and care needs of the 
ageing population has been the subject of a number of studies (Ho et al., 2001; Buchman et 
al., 2009; Kingston et al., 2014; Lahousse et al., 2016; Hegendorfer et al., 2017c). In a 
population aged 70 years and older,  dyspnoeic subjects  (compared to non-dyspnoeic) had 
significantly poorer functional status mean scores which included mobility (9.8 vs 14.5), 
kitchen duties (13.8 vs 14.5), domestic tasks (7.6 vs 10.2) and leisure activities (10.6 vs 13.3) 
(Ho et al., 2001). 
Pulmonary function, respiratory muscle strength and leg strength in a clinical population 
separately predicted incident mobility disability (gait) over 4 years after adjusting for certain 
confounders such as age, sex and education, although the effect of pulmonary function  was 
lost later as more confounders were added (Buchman et al., 2009). Furthermore, a study of 
those aged 80 years and older found that those with excessive respiratory function 
(FEV1/Height
3) decline during an average follow-up period of 1.7 years revealed an increased 
risk (odds ratio:2.02, 95% CI: 1.10 – 3.68) of new or worsened activities of daily living 
(ADLs) in comparison to all other participants (Hegendorfer et al., 2017c). The other studies 
in this subset confirmed similar findings in terms of respiratory disease and increased risk of 
becoming disabled (Kingston et al., 2014) and those with COPD showing an increased risk of 
frailty prevalence (Lahousse et al., 2016).    
Physical activity is often used as a measure of wellbeing and thought to delay the effects or 
symptoms of ageing (Lacour et al., 2002). A Portuguese study on respiratory function 
investigated the role of physical activity by dividing COPD patients into 2 groups defined by 
the average number of steps logged by a pedometer: with “severe physical inactivity” (<4580 
steps) or without (≥4580 steps). The two groups did not differ on Body-mass index, airflow 
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Obstruction, Dyspnoea, and Exercise (BODE) index or percent predicted FEV1. However no 
association was found, perhaps due to the small study size (n = 30) or the cut point used for 
physical inactivity (Nyssen et al., 2013).  
A number of studies have explored lung function as a predictor of other disease and 
conditions. FEV1 and FVC have been found to be inversely related to insulin resistance and 
diabetes after adjusting for known and potential confounders (Lawlor et al., 2004), although 
the authors also recognised that those of advanced age and/or having a history of smoking 
found it harder to provide adequate lung function and spirometry measures. 
There have been studies investigating the associations between lung function and respiratory 
conditions with cardiovascular disease (Sin and Man, 2003; Sin et al., 2005; Mannino and 
Davis, 2006; Agarwal et al., 2012; Nilsson et al., 2017). Reduced FEV1 has been associated 
with increased risk of heart failure when comparing the lowest and highest quartiles (Agarwal 
et al., 2012).Prevalence of COPD has been observed to be associated with increased risk of 
hypertension (OR: 1.6, 95% CI 1.3 – 1.9) and cardiovascular disease (OR: 24, 95% CI 1.9 – 
3.0) (Mannino and Davis, 2006). Furthermore both reduced lung function and COPD 
prevalence has been found to be associated with increased rates of cardiovascular mortality 
(Sin and Man, 2003; Sin et al., 2005; Nilsson et al., 2017).  
The only longitudinal study found examined the 5 year mortality of patients with or without 
diabetes (Bourdel-Marchasson et al., 1998). As this study’s main aim was to look at different 
predictors in diabetic patients, the only respiratory symptom investigated was dyspnoea. 
However this study reported that dyspnoea was associated with an increased relative risk of 
mortality in diabetic (RR=2.4 in 65-75 year olds, RR=1.9 in 75+) and non-diabetic patients 
(RR=1.5 for 65 – 75 year olds, RR=1.3 for 75+), although this appeared to be  due to smoking 
since the association was lost once models were adjusted for smoking (Bourdel-Marchasson 
et al., 1998). 
Mortality has been looked at in conjunction with other outcomes in a number of studies 
already described. The relationship between pulmonary function and mortality of at least 2 
years (mean 2.2 years) was investigated  specifically in old age by Buchman (Buchman et al., 
2008) where the mean age of the subjects who died was 85.3 in contrast to 80.1 for the 
surviving subjects. VC, FEV1 and PEF were converted into z-scores and combined to create a 
composite variable called pulmonary function. Cox Proportional hazard modelling using the 
25th and 75th percentile was used to compare survival rates. Higher pulmonary function was 
associated with a lower risk (47% less) of death after adjustment for age, sex, education and 
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BMI (Buchman et al., 2009). The same study found that extremity and respiratory muscle 
strength had no significant effect on survival once all covariates were adjusted for (Buchman 
et al., 2008).  
Respiratory related death as a specific cause of mortality was addressed in another study 
where  a decline in different cognitive abilities over a long period of time (7 years of follow-
up) was observed to increase the risk of death from respiratory disease (Shipley et al., 2007).. 
Similar findings were confirmed when it reported that poor respiratory function in a cohort of 
75 year olds increase the chance of death by 52% and 49% for lowest and middle tertile 
respectively when using the top tertile as reference (Lyyra et al., 2005). Similar effects were 
seen in muscle strength and walking speed (Lyyra et al., 2005). 
        
1.5.3 Predictors of lung function, lung diseases and respiratory related mortality 
The GOLD report recognises that nutritional state is linked to prognosis of COPD and that 
nutritional markers, such as BMI, are known to have an effect on the mortality of COPD 
patients (Vestbo et al., 2013). Nutritional markers have been investigated in relation to lung 
function and respiratory related conditions cross-sectionally (Sergi et al., 2006; van den Borst 
et al., 2012; Abbatecola et al., 2013). Resting energy expenditure has been found to be higher 
and Fat-Free Mass (FFM) lower in COPD patients (Sergi et al., 2006). Abbatecola et al 
investigated this further in COPD patients only, and found as expected that men were heavier 
and had a higher lean mass than women (Abbatecola et al., 2013). They also found that 
participants in the upper tertile of gait speed had lower BMI and fat mass and better 
respiratory function. They concluded that gait speed is directly related to FEV1 (Abbatecola et 
al., 2013). Visceral Fat Area has also been found to have an association when comparing 
patients with Obstructive Lung Disease and those without (van den Borst et al., 2012). 
However, as these are cross-sectional studies, causality cannot be inferred. 
There were only three longitudinal studies of the association between nutritional markers and 
pulmonary function with one of these only looking at ill health with pulmonary function as 
one of its outcome (Ramsay et al., 2006). This study which re-examined participants 20 years 
after the first study (and aged 60 – 79 years at recall) observed reduced risk of low FEV1 for 
those with a waist circumference of 89 – 94cm compared to the reference group (57 – 88cm) 
and  they further confirmed previous findings of lower fat free index leading to lower lung 
function (Ramsay et al., 2006).  
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The other two longitudinal studies were conducted by Rossi et al (Rossi et al., 2008; Rossi et 
al., 2011) and examined body composition. The first on only a sample of 77 (30/77, 39% 
men) subjects and the second on 1981 (957, 48% men) subjects, with the 7 and 5 year follow-
up respectively. They confirmed previous findings between FEV1 and FVC against Sagittal 
abdominal diameter, FFM, FM and waist size, with  an increase in SAD predicting a decrease 
in FEV1 and FVC and a decrease in FFM directly affecting FVC (Rossi et al., 2008). The 
latter of the two studies, found that increased fat mass is a predictor of decline in FEV1 and 
FVC (Rossi et al., 2011). 
Only five studies examined the effect of blood-based biomarkers on lung function, all 
longitudinal in design (Finkel et al., 2003; Shaaban et al., 2006; Gimeno et al., 2011; 
Ahmadi-Abhari et al., 2014; Hancox et al., 2016). Finkel and colleagues used twin data to 
investigate whether there was any genetic influence on FEV1. Using genetic latent growth 
models they reported gender differences in FEV1 and found phenotypic correlations between 
the twins and their FEV1, concluding that this was due to genetic and environmental 
influences (Finkel et al., 2003).  
Results from a longitudinal study with 8.5-year follow-up examined the relationship between 
C - reactive protein (CRP) and FEV1 in 531 participants at two French centres for respiratory 
conditions. The study found that increases in CRP over time was associated with decline in 
FEV1 levels (Shaaban et al., 2006). Similarly, in the Whitehall II study, negative associations 
were revealed between CRP and Interleukin-6 (IL-6) over a 12-year period in participants 
with no self -reported respiratory problems at baseline (n=1,657) (Gimeno et al., 2011).   
Furthermore, the effect of CRP on lung function was investigated over a period of 13 years in 
18,110 participants (age range 40 – 79 years) with findings that an increase in CRP levels was 
associated with a reduction in FEV1 from the longitudinal data but this was not evident from 
the baseline data alone. They concluded that systemic inflammation resulted in a decrease in 
lung function (Ahmadi-Abhari et al., 2014). A study investigated longitudinal change in FEV1 
as a predictor of CRP, finding that lower lung volumes were associated with higher CRP over 
a 6-year follow-up (Hancox et al., 2016). 
Respiratory medication use in the elderly has scarcely been investigated with only one study 
found which looked at inhaled anticholinergic in the elderly population with COPD and 
whether there was any increased risk of mortality. The study, a retrospective longitudinal 
panel data collected on 2610 individuals of 65 years and older, found an increased risk of 
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mortality before adjustment which was lost after accounting for the different confounders 
(Ajmera et al., 2013).  
Ranieri et al investigated one-year mortality differences supplemented by probing further into 
other socio-demographic and clinical associations. They found that patients with COPD were 
older and more likely to be men (Ranieri et al., 2001). Patients without cor pulmonale (CP) 
had a 1.9 times higher risk of death after one year and those with cor pulmonale had were 4.2 
times more likely to die (Ranieri et al., 2001). The only other difference seen between the 
COPD and non-COPD group was the lower count of associated disease and lower medication 
use in the COPD group.   
Smoking has long been known as a cause for many respiratory conditions and a contributor to 
poor physical and lung function. In 2001, 16% of the older population in the UK smoked, a  
large improvement on the  44% in 1974 (Allen, 2009). Allen also reported that mortality rates 
could be reduced if smoking cessation happened even  at very old age and he believed that, 
with correct interventions, the prevalence of smoking amongst the older population could be 
reduced (Allen, 2009). Hsu et al took this one step further and investigated the effect of 
smoking cessation on both respiratory-related morbidity and mortality, in a cohort followed 
from 1989  and of whom 17.0% were 75 years of age and older. Smokers were found to have  
a higher relative risk of lower respiratory tract disease which was similar to that of former 
smokers (Hsu and Pwu, 2004). 
1.6 Aim of this thesis 
Given the paucity of studies examining lung function, its determinants and consequences in 
very old general populations, the primary aim of this study was to investigate the relationship 
of lung function with disability and mortality in the very old using the Newcastle 85+ study.  
1.7 Specific objectives  
In order to achieve the study aim, this thesis will: 
1. Describe the study population of the Newcastle 85+ study.  
2. Explore the sociodemographic characteristics, health behaviours, and lung function 
and disease prevalence of the very old. 
3. Investigate whether longitudinal measures of lung function can still predict mortality 
at an advanced age whilst accounting for other sociodemographic and health 
characteristics. 
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4. Investigate how lung function changes with further ageing in the very old and the 
determinants of these changes. 
5. Explore and investigate the causal pathways between lung function and disability in 
the very old and possible mediators. 
1.8 Summary 
This chapter has presented the clear need for further investigation of lung function 
determinants and consequences at a very old age. Although ageing studies have investigated 
the burden of disabling diseases and conditions in general, and certain conditions in particular 
(cardiovascular disease, cognition/dementia, arthritis, stroke), respiratory disease and 
respiratory function have been little studied. Moreover, associations between respiratory 
function and outcomes established in younger age groups may no longer hold, or hold 
differently, in the very old. An example of this is the relationship between telomere length and 
mortality with shorter telomere length predictive of mortality at younger ages (Cawthon et al., 
2003) but not in the very old (Martin-Ruiz et al., 2005; Houben et al., 2011).   
The following chapter will describe the Newcastle 85+ study, its components and participants.
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Figure 1.1: Physical functioning across the life course, stratified by ability to manage on 
current income (Beard et al., 2016) 
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Chapter 2. Newcastle 85+ Study 
2.1 Aims of the chapter 
This chapter aims to: 
1. Outline the Newcastle 85+ study rationale, design and recruitment 
2. Describe the two data collection components of the study 
3. Describe in detail the available spirometric data  
4. Discuss the creation of composite variables  
5. Describe the overall sociodemographic characteristics of Newcastle 85+ population 
2.2 Introduction 
The literature review in the previous chapter highlighted the lack of research into lung 
function, its determinants and consequences in the very old. In order for society to adapt to 
the dynamic population progression, it is wise to try and understand the demands which it will 
face from the fastest growing sector of its population, those aged 85 years and older (United 
Nations, 2002). A prospective cohort study of the very old is an approach that can be taken to 
address this issue.  
This chapter will describe in detail the Newcastle 85+ study from design to implementation 
providing a foundation for the subsequent chapters seeking to an answer to impact of lung 
function on disability and mortality.  
2.3 Study rationale, design and recruitment 
The Newcastle 85+ study (N85+) is a longitudinal cohort study of people born in 1921 and 
living in Newcastle and North Tyneside in the north east of the United Kingdom (UK) who 
were aged 85 years at study inception (2006) (Collerton et al., 2007). The study was preceded 
by a pilot study conducted in 2003 – 2004 following a careful review of the Leiden 85+ study 
and collaboration with the Leiden group.  The aims of the N85+ study were to “expose 
spectrum of health” and “examine, in unprecedented detail, health trajectories and outcomes 
as the cohort ages and their associations with underlying biological, medical and social 
factors”(Collerton et al., 2007) (Bootsma-van der Wiel et al., 2002).    
The Newcastle 85+ study recruited participants by approaching general practices within 
Newcastle and North Tyneside Primary Care Trusts, to gain permission to contact 
participants. The inclusion criteria for participation required the participants to have been born 
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in 1921 and registered with a General Practitioner (GP). Invitation for participation were sent 
to those who met the inclusion criteria regardless of their living arrangement (home or 
institutional care) and included information pack with their GP’s ‘letter of support’. These 
were followed up by a research nurse through a phone call or a home visit for a detailed 
discussion about the study. Individuals who showed an interest in taking part were visited at 
their place of residence by a member of research team and written informed consent obtained. 
Individuals who were recognised to have end stage terminal illness by their GP were excluded 
The study comprised of two parts, a multidimensional health assessment (MDHA) and the 
General Practitioner Record Review (GPRR). The MDHA included a series of questions to 
the participant (or their proxy) in addition to the administration of various functional tests. 
The baseline data was collected from 2006 – 2007 with three follow-ups at 18, 36 and 60 
months (Appendix A). Complete health assessment was conducted at baseline, 18 and 36 
months followed by a reduced health assessment at 60 months. The GPRR was conducted at 
baseline, phases 3 and 4 (Collerton et al., 2007). Participants could opt in for either MDHA, 
GPRR or both.        
2.3.1 Multidimensional health assessment  
The MDHA including questionnaires, measurements, function tests and blood samples, was 
conducted by the study nurse over a series of visits. The questionnaires collected information 
about participant’s “living arrangements, physical health, psychological health, disability, 
lifestyle, social support and participation and use of the social care” (Collerton et al., 2007). 
The questionnaires thus had the following sections: 
1) Sociodemographic factors: date of birth, sex, ethnic origin, and socio-economic status 
comprised of years in education, National Statistics Socio-economic Class and current 
financial income. 
2) Lifestyle: smoking, alcohol consumption and exercise 
3) Family data: marital status, age at parent’s death, siblings and children with vital 
status 
4) Physical health: self-rated health status, self-reported longstanding illness, angina, 
shortness of breath, generalised pain, joint pain, fractures, incontinence, falls, vision 
and hearing, and oral health 
5) Non-prescribed medication 
6) Depression: based on Geriatric Depression Scale 
7) Disability: difficulty with instrumental/activities of daily living (I/ADLs) 
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8) Nutrition: two separate 24 hour multiple pass recall assessment  
9) Social support and social participation 
10) Use of health and social care 
Data from measurements and function tests data collected from the participants included: 
anthropometrics: bio-impedance, weight, demispan, waist and hip circumference; tooth count; 
cognitive function tests: Mini-Mental State Examination (MMSE) and Cognitive Drug 
Research (CDR) computerised assessment system; 12 lead electrocardiogram (ECG); walking 
test (timed ‘up and go’); handgrip strength, and spirometry and oximetry.  
Blood samples were taken at the participant’s home after an overnight fast at baseline and 36 
months but not 18 months. The blood assays included (Collerton et al., 2007): 
1) Routine haematology and biochemistry: full blood count; creatinine and electrolytes; 
liver panel; bone panel; glucose; glycosylated haemoglobin. 
2) Lipid profile: cholesterol, triglycerides, high and low-density lipoproteins, 
apolipoproteins (A1, B and E). 
3) Thyroid function: free T4, free T3, reverse T3, TSH and TPO antibodies. 
4) Inflammatory markers: High sensitivity CRP, rheumatoid factor, cytokines (TNFα and 
IL-6). 
5) Cortisol  
6) Nutritional markers: Vitamins B2, B6, B12, C and D, ferritin, red cell folate and 
homocysteine. 
7) Biomarkers: Deoxyribonucleic acid (DNA) repair capacity, telomere length, F2-
isoprostane (marker of oxidative stress). 
8) Markers of immunosenescence: T cell oligoclonality and lymphocyte subpopulation 
distributions (senescent T-cells, memory T-cells and NKcells). 
2.3.2 General practitioner record review  
The GPRR comprised of four sections: 
1) Medications list of participants were recorded with the drugs later coded to the British 
National Formulary (BNF). The drug dosage and duration were not collected. 
2) Key diagnoses since birth and certain interventions were recorded with the date. The 
disease categories included cardiovascular, cancer, endocrine, eye disease, fractures 
(since 1971), liver disease, musculoskeletal disease, neurological disease, psychiatric 
and respiratory disease.  
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3) Last 40 consultations (date, professional seen and where seen.) 
2.4 Health measures variables 
2.4.1 Cognitive impairment 
The Standardised Mini-Mental State examination (SMMSE) was administered with 12 
questions and 30 point score (Molloy et al., 1991; Molloy and Standish, 1997) with zero 
points awarded for wrong or missing items. The total score was categorised based on the 
Cognitive Function and Ageing Studies (CFAS) group to define cognitive impairment 
severity (Xie et al., 2008): 
i. 0 – 17: Severe cognitive impairment 
ii. 18 – 21: Moderate cognitive impairment 
iii. 22 – 25: Mild cognitive impairment 
iv. 26 – 30: No cognitive impairment 
2.4.2 Depression 
Participants were screened for depression using the 15 Item Geriatric Depression Scale, a 
reduced version of the original questionnaire (Yesavage et al., 1982). This version of the 
questionnaire has been found to be reliable in recognising depression within the very old 
(Alden et al., 1989; Almeida and Almeida, 1999; Osborn et al., 2002). If participants scored 
less than 15 on their SMMSE they were exempt from depression screening as it was deemed 
unreliable (Burke et al., 1991). A three category variable was derived were participants were 
placed into these groups based on their score: 
i. 0 - 5 : No Depression 
ii. 6 - 7 : Mild Depression 
iii. 8 – 15 : Severe Depression 
2.4.3 Body mass index (BMI) 
Demi-span was measured in centimetres (cm) and height was calculated from this using the 
two standard formulae for males [height = 1.40 x demi-span + 57.8] and females [height = 
1.35 x demi-span +60.1]. The BMI was then derived by using the derived height converted to 
metres (m) variable and the participant’s weight in kilograms (kg) measured during one of the 
interview visits using the standard equation [BMI = height^2/weight]. A categorical BMI 
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variable was also derived based on the World Health Organisation (WHO) classification 
(World Health Organisation, 2006) reduced to five main categories: 
i. Underweight: up to 18.5 
ii. Normal weight: 18.5 – 25 
iii. Overweight: 25 – 30 
iv. Obese: 30 – 40 
v. Morbidly obese: 40+ 
2.4.4 Physical activity  
Physical activity was measured through a self-report questionnaire based on three questions 
on frequency of very energetic, moderately energetic and mildly energetic activities. 
Participants were given a score of between zero and three based on the frequency of their 
activity for each question. A final physical activity score was calculated based on the sum of 
all three scores with a coefficient of 3, 2 and 1 being used for very, moderately and mildly 
energetic activity scores respectively as demonstrated below (Innerd et al., 2015).  
A categorical variable for physical activity was derived from this score with three bandings: 
i. Low physical activity: 0 – 1 
ii. Medium physical activity: 2 – 6 
iii. High physical activity: 7 – 18 
There was strong agreement between the subjective (questionnaire) and objective 
(accelerometer) at 36 months (only time point for accelerometry) (Innerd et al., 2015).  
2.4.5 Auditory and visual function 
Participants were asked about everyday situations such as difficulty in following 
conversations in the background whilst wearing a hearing aid if they had one. The everyday 
situational questions asked about participant’s ability to recognise friends across the road 
(whilst wearing glasses or contact lenses if necessary) or reading a newspaper.     
2.4.6 Blood based biomarkers 
Blood was drawn from participants with 95% of samples received by the laboratory for 
processing within an hour with over 72 biomarkers being profiled (Martin-Ruiz et al., 2011). 
Three inflammatory markers which have previously been shown to be inversely associated 
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with lung function measures FEV1 and FVC (Ahmadi-Abhari et al., 2014) (Gimeno et al., 
2011) and a biomarker of ageing was included in respiratory analyses: 
i. Interleukin-6 (IL-6) 
ii. Tumour necrosis factor alpha (TNFα) 
iii. C-Reactive Protein (CRP) 
iv. Telomere length  
2.4.7 Multimorbidity 
Two separate disease burden measures were calculated, one based on a previously used 
disease count (Collerton et al., 2009), with most of the prevalence derived from GPRR and 
others from the functional and blood tests performed during the interview stage, and the 
second disease count based solely on GPRR with the exception of cognitive impairment 
which used the SMMSE  from the MDHA.  
The first disease count was based on 18 diseases: hypertension, ischaemic heart disease, 
cerebrovascular disease, peripheral vascular disease, heart failure, atrial fibrillation, diabetes 
mellitus, thyroid disease, arthritis, osteoporosis, cancer excluding non-melanoma skin cancer, 
eye disease, dementia, Parkinson’s disease, anaemia, renal impairment, COPD and other 
respiratory disease. A shortened version of this disease count was calculated, excluding 
COPD and other respiratory disease (maximum 16 diseases) (Collerton et al., 2009) (Fisher et 
al., 2016) 
The second disease count variable was originally a sum of eight disease groups and thus 
participants could score a maximum of 8 (Table 2.1) (Kingston et al., 2014). For this thesis, 
the respiratory disease group was removed and used separately for analysis and thus the 
maximum for this disease count was 7.  
It is worth mentioning that due to the second disease count being solely based on GPRR, there 
were fewer missing values on this variable in comparison to the first where only 86.3% 
(729/845) of participants had complete data.   
2.4.8 Spirometry  
Spirometry and peak flow measurements were performed by a trained research nurse using 
the MicroLab Spirometer and Spida software (Micro Medical Ltd, Rochester, UK) at the 
participant’s place of residence. Lung function measures were obtained at baseline, 18 and 36 
months. “The aim was to obtain three technically satisfactory maximal effort 'blows' to 
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generate reproducible forced expiratory volume in 1 second (FEV1), forced vital capacity 
(FVC), and peak flow measurement (PEF); blows were repeated until this was achieved or 
maximum effort reached” (Fisher et al., 2016). Built-in Spida algorithms were used to assess 
technical adequacy of the each blow. The spirometry curves were independently assessed by a 
respiratory clinical physiologist and participants with at least two adequate blows were 
included in the analysis. However if this necessary quality was not achieved, the participants 
were excluded from the respiratory analysis. Participant’s height was derived from demi-span 
measurements using standard equations as this has been found to be more accurate in those 
aged 65 and over (Hirani and Mindell, 2008).   
Age, gender and height were used to calculate predicted FEV1, FVC and peak flow values for 
each participants using the ERS 1993 (Quanjer et al., 1993) coefficients currently approved by 
the UK Department of Health (Department of Health, 2013). Spirometry classifications were 
based on the FEV1/FVC ratio and percentage predicted values for FEV1 and FVC. Participants 
classified with obstructive spirometry were subsequently categorised as mild, moderate, 
severe or very severe using the GOLD criteria (Global Initiative for Chronic Obstructive Lung 
Disease (GOLD), 2010) (Table 2.2)   Lung function can also be classified using the LLN 
method which takes standardised values (z-scores) for each participant and places them within 
three groups; below lower limit of normal, normal and above upper limit of normal. 
Furthermore, using the newer Global Lungs Initiative (GLI) prediction model equations 
(validated for ages 3 – 95 years) (Quanjer et al., 2012), additional predicted values for FEV1, 
FVC and PEF were calculated to enable comparison of methods and diagnosis of lung disease 
present in this cohort.   
2.5 Newcastle 85+ population 
2.5.1 Participant recruitment and retention 
The study invited 1459 people and managed to make contact with 97% (1409/1459) of whom 
74% (1042/1409) gave written informed consent to participate in the study (Davies et al., 
2010). In total 851 consented to both MDHA and GPRR, 188 to GPRR only and 3 to health 
assessment with the remaining 358 declining any participation.  
Participant retention has been fully documented and a study of participant retention and the 
effectiveness of strategies employed around this was investigated (Davies et al., 2014). In 
brief of the 854 participants at baseline 74% were retained for phase 2 (631/854) with 61% 
(135/223) of the attrition being due to death. 57% (484/854) were retained for phase 3 of the 
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study with an attrition rate of 17% (147/854) with 65% (95/147) being due to death. For phase 
4, 40% (344/854) were retained. The attrition rate between phases 3 and 4 was 16% (141/854) 
of whom 81% (114/141) were death (Davies et al., 2014). Factors which led to good retention 
rates included marginal loss to follow-up which was 0.5% (5/854) of participants through 
maintaining good relationship with their GP and where relevant their care home staff 
members in addition to maintaining contact with participants throughout the study (Davies et 
al., 2014).  
Of the 851 who agreed to MDHA and GPRR, six participants withdrew during the lifetime of 
the study and requested their data to be removed, leaving a complete cohort of 845 (526 
women; 319 men) for the purpose of this thesis. 
2.5.2 Sociodemography 
Data from both the MDHA and GPRR was available for 845 participants, 58.2% (845/1453) 
of all those eligible, with a mean (standard deviation) age of 85.5 (0.4) years. Females 
accounted for 62.3% (526/845) of the participants and 99.6% (839/845) were of white ethnic 
group (Table 2.2). In terms of living arrangements, 77.0% (651/845) lived in standard 
housing, 12.8% (108/845) in sheltered accommodation and 10.2% (86/845) in institutional 
care. The proportion of males living in standard housing (83.4%, 266/319) was higher than 
that for women (73.2%, 385/526), lower for sheltered housing (men: 10.3%, 33/319; women: 
14.3%, 75/526) and institutional care (men: 6.3%, 20/319; women: 12.6%, 66/526) (p-value= 
0.002).  
2.5.3 Baseline health behaviours 
Examining the smoking history of the participants, 35.8% (301/845) reported themselves as 
never smokers with women (42.0%, 220/526) reporting a higher abstinence rate than men 
(25.6%, 81/316). Although almost three-quarters (74.4%, 235/316) of men and over half of 
women (58.0%, 304/524) had smoked in their lifetime, very few (men: 4.4%, 14/316; women: 
6.5%, 34/524) were current smokers (Table 2.2).  
Just over half of both men (51.5%, 151/293) and women (51.1, 218/427) were categorised as 
having normal weight with a normal BMI classification. The overweight BMI was the 
category with the second highest proportion of men (35.8%, 105/293) and women (30.7%, 
131/427). The underweight category was only 6.5% (47/720) of the whole population with the 
obese/morbidly obese at 9.5% (68/720). 
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Exploring baseline physical activity levels, just under a quarter of women (24.8%, 124/501) 
and 21% (65/311) of men had low levels of physical activity. The highest proportion of 
women (49.5%, 248/501) were scored as having medium levels of physical activity compared 
to just 32.5% (101/311) of men. In men 46.6% (145/311) were categorised as having high 
levels of physical activity in comparison to women with just over a quarter (25.8%, 129/501) 
falling in the same category.   
Over half (55.9%, 171/306) of men and almost a fifth (19.8%, 98/495) of women had 
occupational exposures which may have affected their respiratory health. This trend of higher 
occupational exposure prevalence was confirmed when detailing the different industries the 
participants were employed in (heavy industry: 41.2%, 126/306; coal mining: 11.4%, 35/307; 
chemical industry: 11.1%, 34/306; asbestos: 28.9%, 88/305), reflecting common historical 
occupations in this region of the UK (Table 2.2).  
2.5.4 Baseline health 
A higher proportion of men (31.6%, 100/317) had no disability at baseline compared to 
women (16.3%, 85/522). The majority of men (52.4%, 166/317) had a disability score 
between one and six, similar to that of women (57.5%, 300/522). Participants with the highest 
disability score (13 – 17) comprised of only 6.3% (53/839) of the whole population (men: 
4.4%, 14/317; women: 7.5%, 39/522) (Table 2.3).  
The majority (71.7%, 599/839) of the population had normal cognitive function (MMSE score 
of 26 – 30) at baseline with similar proportions between men (71.9%, 228/317) and women 
(71.1%, 371/522). Severe cognitive impairment was observed in 6.9% (58/839) of the 
population (men: 6.3%, 20/317; women: 7.3%, 38/522) (Table 2.3).  
In terms of disease count, there was no difference observed in the median number of disease 
groups between men (Median: 2, IQR: 1 – 3) and women (Median: 2, IQR: 2 – 3). However, 
with the number of chronic diseases (comprehensive) at baseline, a statistically significant 
difference was observed between men (4, IQR: 3 – 6) and women (5, IQR: 4 – 6), with 
women having on average a higher number of diseases (Table 2.3).  
With regard to gender differences in the systemic inflammatory biomarkers, men had a higher 
IL-6 (logarithmic mean, SD: 9.77, 0.89) compared to women (9.64, 0.90). A similar trend was 
observed for TNFα (men: 6.25, 1.19; women: 6.10, 1.22). Telomere length as a biomarker of 
ageing also presented a statistically significantly difference between men (8.28, 0.19) and 
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women (8.23, 0.19) (p<0.001) in line with previous findings (Table 2.3) (Gardner et al., 
2014).  
2.6 Summary 
This chapter described the design of the Newcastle 85+ study, and reported baseline 
prevalence of pertinent variables for subsequent chapters, The Newcastle 85+ Study was the 
first prospective longitudinal cohort study of 85 year olds conducted in the UK, with 
considerable success in recruiting and retaining participants over the period of three follow-up 
visits spanning 5 years. The study contained a quantitative component providing the study 
with vital information about the physical and mental well-being of the participants through 
health assessments and review of GP records. The study was found to be representative of the 
England and Wales population of this age group (Collerton et al., 2009). 
The main findings at baseline were: 
1. The main cohort moving forward in this thesis comprised of 845 participants with 
37.9% (323) men and 62.1% (529) women who agreed to both the health assessment 
and GPRR. 
2.  The retention rates were high between each phase and most of the attrition was due to 
death. 
3. This population lived mainly in standard housing (77.0%), with higher proportion of 
women living in sheltered (14.3%) or were in institutional care (12.6%) compared to 
men. 
4. Women had a higher proportion of never smokers (42.0%) and current smokers 
(6.5%) in comparison to men (25.6% and 4.4% respectively). 
5. More men (46.6%) had high levels of physical activity in comparison to women 
(33.7%). 
6. A higher proportion of men (55.9%) however worked in industries with respiratory 
related occupational exposures than women (19.8%). 
7. Higher proportion of men (31.6%) reported no disability in comparison to women 
(22.1%). 
8. On average, there was more chronic diseases observed in women (5, IQR: 4 – 6) than 
men (4, IQR: 3 – 6). 
The following chapter will investigate lung function within the study’s spirometric cohort, 
comparing different prediction formulae in assessing COPD. 
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Table 2.1: Disease groups and respective disease and conditions under each category 
Disease group Diseases and Conditions 
Arthritis* 
Generalised Osteoarthritis, Hand, Hip and Knee Osteoarthritis 
Rheumatoid, Degenerative, Poly, Gouty, Septic, Peri, Lumbar 
Spondylosis, Cervical Spondylosis, Ankylosing Spondylitis and 
Psoriatic Arthropathy 
Cancer* 
Any cancer diagnosis in past 5 years excluding non-melanoma skin 
cancer 
Cardiac disease* 
Heart Failure, Ischaemic heart disease (Angina, Myocardial Infarction, 
Coronary Artery Bypass Graft, Coronary Angioplasty/Stent) 
Cerebrovascular 
disease* 
Carotid Endarterectomy, Stroke, Transient Ischaemic Attack 
Diabetes 
mellitus* 
Type I, Type II and type unspecified 
Hypertension* Hypertension 
Respiratory 
disease* 
Bronchiectasis, Pulmonary Fibrosis, Fibrosing Alveolitis, Asbestosis, 
Pneumoconiosis, Asthma, Chronic Bronchitis, Emphysema, COPD 
Cognitive 
Impairment** 
Standardised Mini-Mental State Examination (sMMSE) score of ≤21 
* Data from GPRR; **  Calculated using MDHA 
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Table 2.2: Sociodemographic, respiratory and health behaviour characteristics of total 
Newcastle 85+ cohort and by gender 
 Men Women Overall  
p-value* 
% (N) (n=319) (n=526) (n=845) 
Ethnicity White  99.4 (316) 99.8 (523) 99.6 (839) 0.2721 
Living 
arrangements 
Standard housing  83.4 (266) 73.2 (385) 77.0 (651) 
0.0021 Sheltered housing 10.3 (33) 14.3 (75) 12.8 (108) 
Institutional care  6.3 (20) 12.6 (66) 10.2 (86) 
Education 9 Years 62.3 (195) 65.7 (339) 64.4 (534) 
0.5761 10 - 11 Years 24.6 (77) 21.7 (112) 22.8 (189) 
12+ Years 13.1 (41) 12.6 (65) 12.8 (106) 
Smoking Never  25.6 (81) 42.0 (220) 35.8 (301) 
<0.0011 Former  69.9 (221) 51.5 (270) 58.5 (491) 
Current  4.4 (14) 6.5 (34) 5.7 (48) 
BMI Underweight <18.5 4.4 (13) 8.0 (34) 6.5 (47) 
0.1612 
Normal Weight  
(18.5 - 25) 
51.5 (151) 51.1 (218) 51.3 (369) 
Overweight (25 - 30) 35.8 (105) 30.7 (131) 32.8 (236) 
Obese (30 - 40) 8.19 (24) 9.8 (42) 9.2 (66) 
Morbidly Obese 40+  0.0 (0) 0.5 (2) 0.3 (2) 
Physical 
Activity 
Low 20.9 (65) 24.8 (124) 23.3 (189) 
<0.0011 Medium 32.5 (101) 49.5 (248) 43.0 (349) 
High 46.6 (145) 25.8 (129) 33.7 (274) 
Occupational 
Exposures 
Any Respiratory 
Related occupations 
55.9 (171) 19.8 (98) 33.6 (269) <0.0011 
Heavy Industry 41.2 (126) 16.6 (83) 25.9 (209) <0.0011 
Coal mining 11.4 (35) 0.0 (0) 4.3 (35) <0.0012 
Chemical industry 11.1 (34) 4.0 (20) 6.7 (54) <0.0011 
Asbestos exposure 28.9 (88) 1.6 (8) 12.0 (96) <0.0011 
*comparison of men and women;  1 Chi-Square test; 2 Fisher’s exact test 
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Table 2.3: Health characteristics of total Newcastle 85+ cohort and by gender 
 Men Women Overall  
p-value* 
 (n=319) (n=526) (n=845) 
Disability 
 % (N) 
None 31.6 (100) 16.3 (85) 22.1 (185) 
<0.0011 
 1 - 6 52.4 (166) 57.5 (300) 55.5 (466) 
 7 - 12 11.7 (37) 18.8 (98) 16.1 (135) 
 13 - 17 4.4 (14) 7.5 (39) 6.3 (53) 
MMSE 
% (N) 
Normal (26-30) 71.9 (228) 71.1 (371) 71.4 (599) 
0.1111 
Mild (22-25) 18.3 (58) 14.8 (77) 16.1 (135) 
Moderate (18-21) 3.5 (11) 6.9 (36) 5.6 (47) 
Severe (0-17) 7.3 (38) 7.3 (38) 6.9 (58) 
Disease Count 
Median (IQR) 
GPRR 2 (1 - 3) 2 (2 - 3) 2 (1 - 3) 0.4633 
Comprehensive 4 (3 - 6) 5 (4 - 6) 5 (3 - 6) 0.0473 
Blood 
Biomarkers ** 
Mean (SD) 
CRP 1.09 (1.29) 0.97 (1.26) 1.02 (1.27) 0.1843 
IL-6  9.77 (0.89) 9.64 (0.90) 9.69 (0.89) 0.0263 
TNFα 6.25 (1.19) 6.10 (1.22) 6.16 (1.21) 0.0383 
Telomere Length 8.28 (0.19) 8.23 (0.19) 8.25 (0.19) <0.0013 
*comparison of men and women;  1 Chi-Square test; 2 Fisher’s exact test;  
3 Mann-Whitney U test; ** log-transformed 
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Chapter 3. Lung function at age 85 
3.1 Aims of the chapter 
This chapter aims to: 
1. Describe the respiratory health  of the study cohort 
2. Examine the difference between the spirometry cohort sub-group and those without 
3. Describe baseline lung function of the spirometry cohort and sub-groups using GOLD 
and GLI prediction methods 
a. Spirometry cohort as a whole 
b. COPD group 
c. Healthy Reference Group (HRG) 
4. Investigate the difference between GP diagnosed COPD and obstructive spirometry as 
determined using the  GOLD and GLI formulae 
3.2 Background 
The lung function of very old individuals is affected by  the accumulation of exposures 
throughout life and physiological changes with ageing such as loss of lung elasticity and 
reduced thoracic cage movement which has an effect on the objective lung function measures 
(Vaz Fragoso and Lee, 2012). This means that the risk of developing respiratory impairment 
increases in the older population, resulting in higher chronic respiratory disease prevalence and 
severity. Therefore it is expected that this population will present many respiratory symptoms 
such as dyspnoea, which has a prevalence of over 40% (Tessier et al., 2001), leading to older 
people frequently seeking healthcare.   
Objective lung function measures are used to classify and diagnose patients with respiratory 
conditions. The two main pulmonary function tests carried out for diagnosis of loss of lung 
function are: spirometry which measures Forced Expiratory Volume in 1 second (FEV1) and 
Forced Vital Capacity (FVC); and Peak Expiratory Flow (PEF) which measures the highest 
forced expiratory flow measured using a peak flow meter.  The current UK and international 
guidelines on Chronic Obstructive Pulmonary Disease (COPD) management use the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (as FEV1/FVC < 0.7 and FEV1 
< 80% predicted) to define obstructive spirometry (Global Initiative for Chronic Obstructive 
Lung Disease (GOLD), 2010) and inform physicians on the use of specific respiratory 
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treatments. The predicted values used in the GOLD guidelines were derived from the 1993 
European Respiratory Society (ERS) reference regression values (Quanjer et al., 1993). The 
accuracy of GOLD lung function criteria in diagnosing airflow obstruction or restrictive lung 
disease in the very old has since been debated due to the physiological changes that occur in 
this group as part of normal ageing (Vaz Fragoso and Gill, 2012; Marcus et al., 2015; Karrasch 
et al., 2016).   
Previously studies examining lung function in the older population defined this population as 
those aged 65 years and older (National Health Service, 2011; Guder et al., 2012). The use of 
such an age cut off meant adequate sample size for answering the authors’ research question. 
However, no meaningful inferences could be made about the lung function of the very old. This 
area of research, as previously discussed, lacks large cohort studies to extend our knowledge of 
respiratory health, and the prevalence of lung disease with ageing. Through investigation of 
lung function in the very old, this chapter will examine whether perceived norms of lung 
function measures using these prediction formulae corresponds with observed data.  
Research in this area is further justified by findings from other studies  that have suggested the 
likelihood of misdiagnosis and missed diagnosis in COPD (Guder et al., 2012; Scholes et al., 
2014; Miller and Levy, 2015; Roberts et al., 2015; Karrasch et al., 2016). In those aged 65 
years and over the use of GOLD diagnostic criteria led to over-diagnosis whilst Lower Limit of 
Normal (LLN) definitions resulted in the under-diagnosis of COPD (Guder et al., 2012).  
Another study reported prevalence of airflow obstruction in those aged 40 – 95 years as 22.2% 
using GOLD and 13.1% when applying LLN definition (Scholes et al., 2014). More recently, it 
was found that use of the GOLD criteria was responsible for increases in COPD prevalence 
(Karrasch et al., 2016). In a younger population, from the Health Survey of  England, GOLD 
criteria suggested airflow obstruction in 11.8% of participants leading to a third of this sample 
being false positives for COPD  (Miller and Levy, 2015). In all these studies the very old (85+) 
numbered under 100 people.  
The aim of this chapter is to address the lack of knowledge surrounding objective lung function 
measures, prevalence of respiratory symptoms and disease in the very old by examining their 
interrelationship in the N85+ study. My focus throughout this chapter will be on physician-
diagnosed lung disease (available from the GPRR), in particular COPD, assessing its accuracy 
using the baseline spirometry data and comparing the COPD diagnosis with that obtained from  
the GOLD and LLN prediction formulae. I will investigate risk factors for respiratory ill health 
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and the appropriateness of prescribed respiratory medication. I will also identify a healthy 
reference group within this cohort in order to evaluate the application of the three standard 
methods of interpreting lung function measurements as normal or abnormal. 
3.3 Methods 
Details of the N85+ study have been comprehensively discussed in the previous chapter and 
publications (Collerton et al., 2007; Collerton et al., 2009). This study included baseline 
measures followed by three follow-ups at 18, 36 and 60 months. In this chapter I will 
concentrate on the baseline measures of FEV1, FVC (including predicted values) and PEF. 
In addition to the three observed measurements, spirometric ventilatory status, z-scores and 
LLN/ULN were derived using both GOLD and GLI prediction formulae Table 3.1. Agreement 
between the three different diagnosis methods (GP, GOLD and GLI) of COPD was also 
investigated. 
3.3.1 Existing diagnoses of respiratory symptoms, disease, medications and environmental 
risk factors  
A predetermined checklist was used to identify participants’ current and past respiratory 
diagnoses from their GP records, including: asbestosis, asthma, bronchiectasis, COPD, 
pneumoconiosis, pulmonary fibrosis/fibrosing alveolitis and tuberculosis (TB). The data 
derived included date of diagnosis and medication use but not dosage. Respiratory medications 
included: inhaled short or long acting beta-2 adrenoreceptor agonists, inhaled short or long 
acting muscarinic antagonists, inhaled corticosteroids either as single agent or as part of a 
combination with long acting beta-2 adrenoreceptor agonists, oral corticosteroids, oral 
leukotriene receptor antagonists, oral theophylline and supplemental oxygen. Breathlessness, 
cough, wheeze and sputum production were the respiratory symptoms, which were identified as 
part of the health assessment interview conducted by the research nurse using a structured 
questionnaire. Medical Research Council (MRC) dyspnoea scores (range 1 – 5) were assigned 
to each participant based on their responses about the limitations they faced in carrying out day 
to day activities due to breathlessness ( Appendix B: MRC Dyspnoea Questionnaire) (Fletcher 
et al., 1959).  
Relevant environmental exposures of each participant were obtained including: complete 
smoking history, relevant occupational exposures (including heavy industry, chemical industry, 
asbestos and coal mining). 
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3.3.2 Analytical methods  
Participants with a GP diagnosis of COPD prior to the study were identified. A Healthy 
Reference Group of participants was identified who had none of the following; respiratory 
symptoms, respiratory disease diagnoses, respiratory medication use and respiratory related 
diagnoses which may influence their lung function such as Parkinson’s disease, ankylosing 
spondylitis, heart failure and kyphoscoliosis. A sensitivity analysis was conducted to explore 
the need to exclude those with a BMI of over 30 from this group.  
Gender differences in socio-demographic and health characteristics were explored by X2 tests 
(ethnicity, living arrangements, smoking status, occupational exposures, respiratory diagnoses, 
medications), Kruskal Wallis tests (MRC dyspnoea scores) and Mann-Whitney U tests (total 
disease count and the disease count excluding respiratory). The disease count variable used in 
this section was the composite count derived from MDHA and GPRR. 
Gender differences in lung functions measures (observed and predicted), spirometry 
classification, standardised FEV1 and FVC z-scores and oxygen saturation were investigated 
within the whole sample, the COPD group and the HRG using X2 and Fisher’s exact tests for 
categorical measures, and Kruskal-Wallis tests for ordered categorical measures. Pearson 
correlation coefficients were used to investigate the relationship between FEV1 and PEF scores. 
Sensitivity analyses were carried out to examine the effect of including participants with a Body 
Mass Index (BMI) score of 30 and over in the HRG, and the differences between those with and 
without spirometry measures and MRC dyspnoea scores within the total cohort.  
The level of agreement between the three different COPD diagnosis methods (GP diagnosis, 
GOLD and GLI) was assessed by McNemar’s and Cohen’s Kappa test (Fleiss, 1981).  All 
analyses were conducted using Stata 12.0 (StataCorp; College Station, TX).    
3.4 Results 
3.4.1 Respiratory symptomatology, diagnoses and medication use  
Chronic cough was self-reported in 26.7% (217/812) and wheeze in 22.0% (179/812) of 
participants. Regular sputum production was more common in men (men: 40.7%, 127/312; 
women: 28.0%, 140/500; p<0.001). The MRC dyspnoea scores could be calculated for 70.8% 
(598/845) of participants, those without a score having their activity limited by other non-
respiratory conditions. In men, 50.2% (123/245) and in women 40.5% (143/353) had an MRC 
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dyspnoea score of 1 and thus had no limitations to their daily activities due to breathlessness. At 
the other end of the spectrum, only 4.7% (28/598) of participants reported a score of 5 and were 
classed as too breathless to leave the house, or breathless when dressing/undressing (Table 3.2).  
COPD was the most common respiratory diagnosis in the GPRR with a prevalence of 16.6% 
(140/845), with no significant difference (p-value=0.43) observed between men (17.9%, 
57/319) and women (15.8%, 83/526). Asthma was the second most prevalent respiratory 
diagnosis at 10.5% (89/845), with men (6.9%, 22/319) reporting significantly lower prevalence 
than women (12.7%, 67/526) (p-value=0.007). Other respiratory conditions included 
bronchiectasis (1.9%, 16/845), pulmonary fibrosis (0.1%, 1/845), asbestosis (0.6%, 5/845), 
pneumoconiosis (0.5%, 4/845) and tuberculosis (4.7%, 40/845). Asbestosis and 
pneumoconiosis were only observed in male participants and the only pulmonary fibrosis 
diagnosis was seen in a female participant (Table 3.2).  
The most frequently prescribed respiratory medications were inhaled short acting beta-2 
adrenoreceptor agonists (10.5%, 89/845 of participants) followed by inhaled corticosteroids 
(6.9%, 58/845). Only 2.0% (17/845) were taking a combination inhaler containing 
corticosteroid and a long acting beta-2 adrenoreceptor agonist (Table 3.2). 
3.4.2 Lung function measurements  
Spirometry was performed by 93.0% (786/845) of participants of whom 98.2% (772/786) 
provided at least two adequate blows conforming to American Thoracic Society (ATS) and 
ERS guidelines. A further 14 participants did not have technically satisfactory blows for at least 
one of the spirometry measures and were excluded. Participants without adequate demispan 
measures (35/772) were also excluded with the remaining 87.2% (737/845) of the overall 
cohort forming the spirometry group (Figure 3.1). Sensitivity analysis was performed to 
compare the spirometry group against participants excluded (108/845) due to 
missing/inadequate spirometry and/or missing demispan. It was observed that those excluded 
were more likely to be females, living in an institution and previously exposed to the chemical 
industry but no significant differences were found in smoking history, respiratory symptoms, 
diagnoses or medications and dyspnoea scores (Table 3.2).  
 In the whole spirometry group, 31.1% (229/737) had a normal FEV1 /FVC ratio and 15.2% 
(112/737) presented with a restrictive pattern. Obstructive spirometry was the commonest 
finding (men: 58.7%, 172/293; women: 50.5%, 224/444) with 85.9% presenting with mild or 
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moderate levels of severity. No gender difference was observed in the spread of severity (Table 
3.4). Measured values of FEV1 and FVC in the spirometry group were normally distributed and 
had much wider range of values in comparison to the GOLD/ERS  predicted values (Quanjer et 
al., 1993) (Figure 3.2). The PEF median (IQR) was significantly higher in men (441 (323 - 604) 
litres/min) compared to that in women (283 (196 - 362) litres/min) but was highly correlated 
with measured FEV1 in both sexes (Figure 3.3).  
Scatter plots comparing the observed and predicted values of FEV1
 and FVC revealed more 
participants with measured values below the predicted values than above, with lung function 
being worse than expected according to the reference values (Figure 3.4 and Figure 3.5). The 
spread of FEV1 and FVC measurements around the predicted values was much wider in men 
than women (Figure 3.4 and Figure 3.5 respectively). A higher proportion of women had 
normal or above Upper Limits of Normal (ULN) measurements (Table 3.4).  
Predicted values using GLI prediction models were derived for the whole spirometry group to 
enable comparison with the GOLD criteria currently used within the National Health Service 
(NHS) (Table 3.4). More than half (52.7%, 388/737) of the cohort were deemed to have normal 
spirometry based on the GLI reference values (men: 52.9%, 155/293; women: 52.5%, 233/444) 
and under a quarter with restrictive (23.3%) or obstructive (24.0%) patterns. Based on z-scores 
for FEV1, 59.7% (175/293) of men and 57.4% (255/444) women fell within the normal 
spirometric range (Table 3.4).   
3.4.3 Prevalence and accuracy of physician-diagnosed COPD  
Of the spirometry group, 16.7% (123/737) had a physician-diagnosed COPD (COPD group) of 
whom 57.7% (71/123) were female and 23.8% (29/123) reported as ‘never smokers’ (Table 
3.5). Just over half (51.7%) of the non-smokers did not have any relevant occupational 
exposures.  
Respiratory symptoms were common but not universal in this group with 50.4% (62/123) 
reporting cough and 58.2% (71/123) sputum production.  Nevertheless 26.8% (11/52) of men 
and 12.5% (7/71) of women with a COPD diagnosis had only minimal breathlessness (MRC 
Dyspnoea score=1). In terms of co-morbid respiratory diagnosis, 39.0 % (48/123) were 
diagnosed with asthma, with other diagnoses including bronchiectasis (4.9%), asbestosis 
(3.3%), pneumoconiosis (1.6%) and TB (8.1%) (Table 3.6).   
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Based on the GOLD criteria, 75.6% (93/123) of the COPD group had obstructive spirometry 
(Table 3.6). A breakdown of obstructive severity showed that only 63.4% (78/123) of the 
COPD group fulfilled UK NICE guidelines definition of moderate, severe or very severe 
disease by spirometry. Classification of FEV1 based on the z-score and LLN approach revealed 
that 48.1% (25/52) of men and 33.8% (24/71) of women from the COPD group fell below LLN, 
suggesting that a considerable proportion (60.2%, 74/123) of those with physician-diagnosed 
COPD had an FEV1 within the normal range and/or no airflow obstruction on spirometric 
measurement (Table 3.6). These proportions were even higher when looking at those who were 
classed as having normal FVC (72.4 %, 89/123) with a gender difference observed for both set 
of measurements. The GLI prediction formulae were applied to the COPD group and 
obstructive spirometry criteria were satisfied in 48.1% (25/52) of men and 50.7% (36/71) of 
women (Table 3.7).   
3.4.4 Agreement of classification methods for obstructive lung function  
Agreement between the three methods was tested using the McNemar and Cohen’s Kappa test 
(Fleiss, 1981). Varying levels of agreement were found between all three methods. The highest 
level of disagreement was between the GOLD and physician diagnosed COPD  (Kappa 
agreement: good, 54.8%), with physician diagnosis only identifying 23.5% of those classed as 
GOLD obstructive with COPD.  The highest level of agreement was found  between the 
physician diagnosed and  the GLI method (Kappa agreement: excellent, 75.9%).  Although 
there was still a significant level of disagreement, all participants classed as obstructive by GLI 
were also recognised as such by the GOLD criteria. The GOLD method also recognised 38.9% 
of those with no GLI obstruction as having obstructive lung function (Kappa agreement: fair, 
70.3%) (Table 3.8) (Fleiss, 1981).  
3.4.5 Lung function of the healthy reference group (HRG)  
Figure 3.1 shows the derivation of the HRG which comprised 20.5% (151/737) of the whole 
spirometry cohort. Measured values of FEV1 and FVC in the HRG were normally distributed 
and had much wider range of values in comparison to the GOLD/ERS predicted values (Figure 
3.6). In the HRG, just under half of men (49.1%, 28/57) and women (42.6%, 40/94) presented 
with airflow obstruction by GOLD criteria (Table 3.9). However they did not fulfil the 
requirements for a diagnosis of COPD through lack of symptoms, although 19.2% (29/151) 
fulfilled the spirometry definition of at least moderate COPD using National Institute for 
Clinical Excellence (NICE) criteria (obstructive spirometry and an FEV1 <80% predicted).  
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The measured PEF median (IQR) of this group was 367 (263 – 515) litres/min, significantly 
higher in men (515 (340 – 647) litres/min) than in women (329.5 (243 – 417) litres/min) 
(p<0.001), and highly correlated with FEV1 (men: r=0.82; women: r=0.74) (Figure 3.7).  
Comparison of observed spirometric values and equation derived predicted values based on 
gender and height in the HRG were made using the three accepted methods: percent-predicted 
value, LLN and Z scores (Table 3.9). There was no difference observed in median (IQR) 
percent-predicted FEV1 between men (90.1% (67.6-103.8%)) and women (93.8% (78.6-
106.0%)) in the HRG. In total, 11.3% (17/151) had FEV1 levels below LLN with a significant 
gender difference (men: 21.1%, 12/57; women: 5.3%, 5/94; p=0.008). A similar trend was also 
observed in measured FVC and the proportion of participants falling below the LLN (men: 
29.8%, 17/57; women: 6.4%, 6/94; p<0.001).  
GLI prediction models were used to calculate the spirometric percent predicted values and z-
scores. Based on FEV1 z-scores, 24.5% (37/151) had measured FEV1 below LLN with no sex 
differences observed. These results were comparable to those based on FVC with 23.2% 
(35/151) of the HRG having below LLN values with again no sex differences found (Table 
3.10).  
3.5 Summary 
This study showed that a high success rate of spirometry testing (87.2%, 737/845) with at least 
two adequate blows could be achieved even at an advanced age of 85 years. In this population, 
a quarter of participants (214/845) had at least one diagnosed respiratory condition in their GP 
records, with a similar proportion in the spirometry subset (186/737). However, the level of 
prescribed respiratory medication was much lower than diagnosis levels at 13.6% (115/845). 
The availability of the lung function measures allowed for a thorough examination of different 
prediction formulae in conjunction with the GP diagnosed COPD in this age group. The main 
findings of the baseline lung function were: 
1. The expected spirometric differences between males and females, with larger lung and 
higher spirometric values in males across all three measures;  
2. GOLD method identifying 53.7% (396/737) of the spirometry population with 
obstructive spirometry in comparison to 24.0% (177/737)  for GLI;  
3. Using FEV1 the GOLD method over estimated normal lung function (80.9%, 596/737) 
in comparison to GLI (58.3%, 430/737) and the LLN. 
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4. Considerable differences between GP COPD diagnosis and the spirometric levels of that 
group using GLI and GOLD prediction formulae 
i. The GOLD method identified 75.6% (93/123) of this group as having 
obstructive spirometry with  63.4% (78/123) labelled as moderate, severe or very 
severe 
ii. The GLI  identifying only 49.6% (61/123) of participants with obstructive 
spirometry 
iii. Based on FEV1, GOLD estimated 60.2% (74/123) within normal range whilst 
GLI showed only 27.6% (34/123) falling within this boundary 
iv. Statistically significant (p<0.001) levels of disagreement between all three 
methods (GLI vs GOLD, GLI vs physician and GOLD vs physician).  
v. The highest level of agreement was found  between the physician diagnosed and  
the GLI method (Kappa agreement: excellent, 75.9%) 
vi. Physician diagnosed COPD may be more useful as more information is available 
when making diagnosis. 
vii. There is a need for a more unified formula that accounts for additional 
information to reduce possible misdiagnosis. 
This chapter has described in detail the respiratory function of people aged 85. Whilst this 
chapter has revealed the burden of respiratory symptom and disease in the very old, the next 
chapter will investigate whether lung function is still predictive of mortality in this age group. 
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Table 3.1: Formulae used for calculation of spirometric ventilatory status based on GOLD 
criteria and ERS predicted values 
Spirometry Definition 
Normal   FEV1/FVC > 0.7  FEV1 ≥ 80% predicted 
Restrictive   FEV1/FVC > 0.7  FEV1 ≤ 80% predicted 
Obstructive   FEV1/FVC < 0.7    
      
Obstructive Spirometry Grading Definition 
Mild   FEV1/FVC < 0.7  FEV1≥ 80% predicted 
Moderate   FEV1/FVC < 0.7 50% ≤ FEV1 < 80% predicted 
Severe   FEV1/FVC < 0.7  30% ≤ FEV1 < 50% predicted 
Very Severe   FEV1/FVC < 0.7 FEV1 < 30% predicted 
  
Limits of Normal*  FEV1 FVC 
Men FEV1Pred +/- (0.51*1.645) FVCPred +/- (0.61*1.645) 
Women FEV1 Pred +/- (0.38*1.645) FVCPred +/- (0.43*1.645) 
   
Z-Score FEV1 FVC 
Men (FEV1Pred - FEV1 Actual)/0.51 (FVCPred - FVCActual)/0.61 
Women (FEV1Pred - FEV1 Actual)/0.38 (FVCPred - FVCActual)/0.43 
Range Upper Limit of Normal > 1.645 Lower Limit of Normal < -1.645 
*Use + for Upper Limit of Normal (ULN) and - for Lower Limit of Normal (LLN)  
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Table 3.2: Respiratory health characteristics of the total Newcastle 85+ cohort (n=845) and by 
gender 
 Men 
(n=319) 
Women 
(n=526) 
Overall  
(n=845) 
p-value* 
Respiratory 
symptoms  
% (N) 
Cough 
Wheeze 
Sputum production  
28.3 (88) 
25.0 (78) 
40.7 (127) 
25.8 (129) 
20.2 (101) 
28.0 (140) 
26.7 (217) 
22.0 (179) 
32.9 (267) 
0.4252 
0.1092 
<0.001 
MRC 
Dyspnoea 
Score 
% (N) 
1 
2 
3 
4 
5 
50.2 (123) 
11.4 (28) 
20.4 (50) 
15.1 (37) 
2.9 (7) 
40.5 (143) 
19.0 (67) 
17.6 (62) 
17.0 (60) 
6.0 (21) 
44.5 (266) 
15.9 (95) 
18.7 (112) 
16.2 (97) 
4.7 (28) 
0.0481 
Respiratory 
diagnoses 
% (N) 
COPD 17.9 (57) 15.8 (83) 16.6 (140) 0.4292 
Asthma 6.9 (22) 12.7 (67) 10.5 (89) 0.0072 
Bronchiectasis 2.5 (8) 1.5 (8) 1.9 (16) 0.3082 
Pulmonary Fibrosis 0.0 (0) 0.2 (1) 0.1 (1) 1.000 3 
Asbestosis 1.6 (5) 0.0 (0) 0.6 (5) 0.008 3 
Pneumoconiosis 1.3 (4) 0.0 (0) 0.5 (4) 0.020 3 
Tuberculosis 4.4 (14) 4.9 (26) 4.7 (40) 0.7132 
     
Respiratory Medications - % (N)     
Inhaled short acting β-2 
adrenoreceptor agonists 
9.1 (29) 11.4 (60) 10.5 (89) 0.2882 
Inhaled muscarinic antagonists 3.8 (12) 3.8 (20) 3.8 (32) 0.9762 
Oral Theophylline 0.3 (1) 0.5 (3) 0.5 (4) 0.598 3 
Combination short acting 
bronchodilators 
0.6 (2) 0.0 (0) 0.2 (2) 0.142 3 
Inhaled Corticosteroids 5.3 (17) 7.8 (41) 6.9 (58) 0.1692 
Combination inhaled Corticosteroids 
and long acting β-2 adrenoreceptor 
agonists 
1.9 (6) 2.1 (11) 2.0 (17) 0.8332 
Oral leukotriene receptor antagonists 0.0 (0) 0.4 (2) 0.2 (2) 0.529 3 
Oral mucolytics 0.6 (2) 0.2 (1) 0.4 (3) 0.560 3 
At least one respiratory medication 
% (N) 
12.2 (39) 14.5 (76) 13.6 (115) 0.3612 
     
Disease count - Median (IQR) 4 (3 - 6) 5 (4 - 6) 5 (3 - 6) 0.0741 
Co-morbid Disease Count 
Median (IQR) 
4 (3 - 6) 5 (4 - 6) 5 (3 - 6) 0.0471 
*comparison of men and women;  ** Denominators vary due to missing values;  
1 Mann-Whitney test; 2 Chi-square test 
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Table 3.3: Comparison of the groups included and excluded in the spirometry cohort 
 Non-spirometry 
(n=108) 
Spirometry 
(n=737) 
p-value* 
Sex  Female   75.9 (82) 60.2 (444) 0.0022 
Ethnicity White   98.1 (104) 99.9 (735) 0.0432 
Living 
arrangements 
% (N) 
Standard housing   
Sheltered housing 
Institutional care 
46.3 (50) 
13.0 (14) 
40.7 (44) 
81.6 (601) 
12.8 (94) 
5.7 (42) 
<0.0012 
Smoking 
% (N) 
Never   
Former   
Current   
41.9 (44) 
53.3 (56) 
4.8 (5) 
35.0 (257) 
59.2 (435) 
5.9 (43) 
0.3752 
Occupational 
Exposures 
% (N) 
Heavy Industry 
Coal mining   
Chemical industry 
Asbestos  exposure 
18.1 (13) 
2.7 (2) 
12.7 (9) 
5.7 (4) 
26.7 (196) 
4.5 (33) 
6.1 (45) 
12.6 (92) 
0.1112 
0.7633 
0.0352 
0.1213 
Respiratory 
symptoms 
% (N) 
Cough   
Wheeze   
Sputum production   
26.9 (21) 
20.8 (16) 
26.0 (20) 
26.7 (196) 
22.2 (163) 
33.6 (247) 
0.9612 
0.7832 
0.1772 
MRC 
Dyspnoea 
Score 
% (N) 
1 
2 
3 
4 
5 
40.5 (15) 
13.5 (5) 
13.5 (5) 
21.6 (8) 
10.8 (4) 
44.8 (251) 
16.0 (90) 
19.1 (107) 
15.9 (89) 
4.3 (24) 
0.2571 
Respiratory 
diagnoses 
% (N) 
COPD   15.7 (17) 16.7 (123) 0.8042 
Asthma   7.4 (8) 4.1 (30) 0.1182 
Bronchiectasis   0.9 (1) 2.0 (15) 0.7083 
Pulmonary Fibrosis 0.9 (1) 0.0 (0) 0.1283 
Asbestosis   0.0 (0) 0.7 (5) 1.0003 
Pneumoconiosis   0.0 (0) 0.5 (4) 1.0003 
Tuberculosis   2.8 (3) 5.0 (37) 0.4653 
    
Respiratory Medications - % (N)    
Inhaled short acting β-2 adrenoreceptor 
agonists 
11.1 (12) 10.5 (77) 0.8342 
Inhaled muscarinic antagonists 3.7 (4) 3.8 (28) 1.0003 
Oral Theophylline 0.0 (0) 0.5 (4) 1.0003 
Combination short acting bronchodilators 0.0 (0) 0.3 (2) 1.0003 
Inhaled Corticosteroids 4.6 (5) 7.2 (53) 0.3252 
Combination inhaled Corticosteroids and 
long acting β-2 adrenoreceptor agonists 0.9 (1) 2.2 (16) 0.712
3 
Oral leukotriene receptor antagonists 0.0 (0) 0.3 (2) 1.0003 
Oral mucolytics 0.0 (0) 0.4 (3) 1.0003 
At least 1 Respiratory Medication - % (N) 12.0 (13) 13.8 (102) 0.6102 
    
Disease count - Median (IQR) 5 (4 - 6) 4 (3 - 6) 0.1781 
* Comparison of Men and Women; ** Denominators may vary due to missing values;  
1 Mann-Whitney test; 2 Chi-square test; 3 Fisher-exact test 
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Table 3.4: Results of Spirometry in the cohort completing spirometry with adequate reproducible blows and demi-span available for calculation 
of predicted blows (n=737)  
Men (n=293) Women (n=444) All (n=737) p-value* 
Observed 
Median (IQR) 
FEV1 (l) 
FVC  (l) 
FEV1/FVC 
PEFR (l/m) 
1.8 (1.4 - 2.2) 
2.7 (2.2 - 3.2) 
0.7 (0.6 - 0.8) 
441 (323 - 604) 
1.2 (1.0 - 1.5) 
1.8 (1.4 - 2.1) 
0.7 (0.6 - 0.8) 
283 (196 - 362) 
1.4 (1.1 - 1.8) 
2.0 (1.6 - 2.6) 
0.7 (0.6 - 0.8) 
328 (233 - 450) 
<0.0011 
<0.0011 
0.0061 
<0.0011 
% predicted  
Median (IQR)  
FEV1   
FVC   
78.8 (62.4 - 94.3) 
83.4 (70.3 - 99.6) 
83.4 (68.1 - 98.8) 
96.6 (79.1 - 113.7) 
81.5 (65.6 - 97.1) 
90.8 (74.1 - 108.4) 
0.0081 
<0.0011 
Spirometry 
% (N) 
Normal   
Restrictive   
Obstructive   
27.7 (81) 
13.7 (40) 
58.7 (172) 
33.3 (148) 
16.2 (72) 
50.5 (224) 
31.1 (229) 
15.2 (112) 
53.7 (396) 
0.0892 
Grading of obstructive 
spirometryα 
% (N) 
Mild   
Moderate   
Severe   
Very Severe   
36.1 (62) 
46.5 (80) 
14.5 (25) 
2.9 (5) 
43.3 (97) 
45.1 (101) 
9.8 (22) 
1.8 (4) 
40.2 (159) 
45.7 (181) 
11.9 (47) 
2.3 (9) 
0.2984 
FEV1 
% (N) 
Below LLN 
Normal range    
Above ULN  
25.9 (76) 
73.7 (216) 
0.3 (1) 
13.3 (59) 
85.6 (380) 
1.1 (5) 
18.3 (135) 
80.9 (596) 
0.8 (6) 
<0.0013 
FEV1 Z-Score Median (IQR) 1.0 (0.2 - 1.7) 0.6 (0.0 - 1.2) 0.8 (0.1 - 1.4) <0.001
1 
FVC 
% (N) 
Below LLN 
Normal range   
Above ULN  
25.6 (75) 
73.4 (215) 
1.0 (3) 
14.2 (63) 
84.0 (373) 
1.8 (8) 
18.7 (138) 
79.8 (588) 
1.5 (11) 
<0.0012 
FVC Z-Score Median (IQR) 1.1 (0.2 - 1.7) 0.5 (-0.3 – 1.3) 0.7 (-0.1 - 1.4) <0.0011 
Oxygen Saturation Median (IQR)  97 (96 - 98) 97 (96 - 98) 97 (96 - 98) 0.5131 
* Comparison of Men and Women; 1 Mann-Whitney test; 2 Chi-square test; 3 Fisher-exact test; α This is based on the 396 participant subsample 
with obstructive spirometry 
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Table 3.5: Results of Spirometry in the cohort completing spirometry with adequate reproducible blows and demi-span available for calculation 
of predicted blows using GLI prediction models (n=737)  
 Men (n=293) Women (n=444) All (n=737) p-value* 
Observed  
Spirometry 
Median (IQR) 
FEV1 
FVC 
FEV1/FVC 
PEFR 
1.8 (1.4 - 2.2) 
2.7 (2.2 - 3.2) 
0.7 (0.6 - 0.8) 
441 (323 - 604) 
1.2 (1.0 - 1.5) 
1.8 (1.4 - 2.1) 
0.7 (0.6 - 0.8) 
283 (196 - 362) 
1.4 (1.1 - 1.8) 
2.0 (1.6 - 2.6) 
0.7 (0.6 - 0.8) 
328 (233 - 450) 
<0.0011 
<0.0011 
0.0061 
<0.0011 
% predicted 
Median (IQR) 
FEV1 
FVC 
74.3 (58.7 - 88.6) 
80.8 (67.2 - 95.9) 
72.4 (59.4 - 87.2) 
80.4 (64.9 - 94.0) 
73.2 (58.9 - 87.7) 
80.6 (66.1 - 94.7) 
0.4571 
0.1621 
Spirometry 
% (N) 
Normal 
Restrictive 
Obstructive 
52.9 (155) 
22.2 (65) 
24.9 (73) 
52.5 (233) 
24.1 (107) 
23.4 (104) 
52.7 (388) 
23.3 (172) 
24.0 (177) 
0.8002 
FEV1 
% (N) 
Below LLN 
Normal range 
Above ULN 
39.9 (117) 
59.7 (175) 
0.3 (1) 
42.1 (187) 
57.4 (255) 
0.5 (2) 
41.3 (304) 
58.3 (430) 
0.4 (3) 
0.8123 
FEV1 Z-Score Median (IQR) -1.3 (-2.1 - -0.6) -1.4 (-2.1 - -0.7) -1.4 (-2.1 - -0.6) 0.248
1 
FVC 
%(N) 
Below LLN 
Normal range 
Above ULN 
31.4 (92) 
67.6 (198) 
1.0 (3) 
31.5 (140) 
68.2 (303) 
0.2 (1) 
31.5 (232) 
68.0 (501) 
0.5 (4) 
0.3523 
FVC Z-Score Median (IQR) -1.1 (-1.9 - -0.2) -1.0 (-1.8 - -0.3) -1.1 (-1.8 - -0.3) 0.7271 
Oxygen Saturation Median (IQR) 97 (96 - 98) 97 (96 - 98) 97 (96 - 98) 0.5131 
* Comparison of Men and Women; 1 Mann-Whitney test; 2 Chi-square test; 3 Fisher-exact test; 
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Table 3.6: Descriptive characteristics of subset with physician-diagnosed COPD in GP records 
 Men 
(n=52) 
Women 
(n=71) 
All 
(n=123) 
p-value* 
Smoking 
% (N) 
Never   
Former   
Current   
21.2 (11) 
67.3 (35) 
11.5 (6) 
25.7 (18) 
67.1 (47) 
7.1 (5) 
23.8 (29) 
67.2 (82) 
9.0 (11) 
0.637 2 
Occupational 
Exposure  
% (N) 
 
Heavy Industry 
Coal Mining 
Chemical 
Asbestos 
49.0 (25) 
17.7 (9) 
13.7 (7) 
33.3 (17) 
19.7 (14) 
0.0 (0) 
2.8 (2) 
7.1 (5) 
32.0 (39) 
7.4 (9) 
7.4 (9) 
18.2 (22) 
0.001 2 
<0.0013 
0.0343 
<0.0012 
Non-Smokers with no Occupational 
Exposures % (N) 
3.9 (2) 18.3 (13) 12.2 (15) 0.023 2 
Respiratory 
symptoms  
% (N) 
Cough 
Wheeze 
Sputum production   
46.2 (24) 
53.9 (28) 
63.5 (33) 
53.5 (38) 
56.3 (40) 
54.3 (38) 
50.4 (62) 
55.3 (68) 
58.2 (71) 
0.419 2 
0.7842 
0.3102 
MRC 
Dyspnoea 
Score 
% (N) 
1 
2 
3 
4 
5 
26.8 (11) 
9.8 (4) 
34.2 (14) 
22.0 (9) 
7.3 (3) 
12.5 (7) 
16.1 (9) 
19.6 (11) 
33.9 (19) 
17.9 (10) 
18.6 (18) 
13.4 (13) 
25.8 (25) 
28.9 (28) 
13.4 (13) 
0.0351 
Co-morbid  
respiratory 
diagnoses  
% (N) 
Asthma  25.0 (13) 49.3 (35) 39.0 (48) 0.006 2 
Bronchiectasis  7.7 (4) 2.8 (2) 4.9 (6) 0.240 3 
Asbestosis  7.7 (4) 0.0 (0) 3.3 (4) 0.030 3 
Pulmonary Fibrosis 0.0 (0) 0.0 (0) 0.0 (0) - 
Pneumoconiosis  3.9 (2) 0.0 (0) 1.6 (2) 0.177 3 
Tuberculosis  5.8 (3) 9.9 (7) 8.1 (10) 0.516 3 
Respiratory Medications - % (N)     
Inhaled short acting β-2 adrenoreceptor 
agonists 
36.5 (19) 52.1 (37) 45.5 (56) 0.087 2 
Inhaled muscarinic antagonists 17.3 (9) 22.5 (16) 20.3 (25) 0.4772 
Oral Theophylline 1.9 (1) 4.2 (3) 3.3 (4) 0.637 3 
Combination short acting bronchodilators 1.9 (1) 0.0 (0) 0.8 (1) 0.423 3 
Inhaled Corticosteroids  17.3 (9) 38.0 (27) 29.3 (36) 0.0132 
Combination inhaled Corticosteroids and 
long acting β-2 adrenoreceptor agonists 
11.5 (6) 12.7 (9) 12.2 (15) 0.8492 
Oral leukotriene receptor antagonists 0.0 (0) 1.4 (1) 0.8 (1) 1.000 3 
Oral mucolytics 1.9 (1) 1.4 (1) 1.6 (2) 1.000 3 
Oral glucocorticoid therapy  5.8 (3) 4.2 (3) 4.9 (6) 0.697 3 
At least 1 Respiratory Medication - % (N) 46.2 (24) 66.2 (47) 57.7 (71) 0.026 2 
     
Disease count - Median (IQR) 5 (4 - 7) 6 (5 - 7) 6 (4 - 7) 0.1561 
Non-respiratory Disease Count  
Median (IQR) 
5 (4 - 6) 6 (5 - 7) 6 (4 - 7) 0.0641 
*comparison of men and women;  ** Denominators vary due to missing values; 
 1 Mann-Whitney test; 2 Chi-square test; 3 Fisher’s exact test 
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Table 3.7: Results of Spirometry in the COPD completing spirometry with adequate reproducible blows and demi-span available for calculation 
of predicted blows (n=123) 
 
Men (n=52) Women (n=71) All (n=123) p-value* 
Observed 
Median (IQR) 
FEV1 
FVC 
FEV1/FVC 
PEFR 
1.4 (1.1 - 1.8) 
2.4 (2.0 - 3.1) 
0.6 (0.5 - 0.7) 
382.5 (243 - 519) 
1.0 (0.7 - 1.1) 
1.6 (1.3 - 1.9) 
0.6 (0.5 - 0.7) 
218 (144 - 290) 
1.1 (0.8 - 1.4) 
1.9 (1.5 - 2.3) 
0.6 (0.5 - 0.7) 
259 (191 - 380) 
<0.0011 
<0.0011 
0.5911 
<0.0011 
% predicted  
Median (IQR)  
FEV1 
FVC 
63.5 (50.9 - 73.4) 
77.4 (64.2 - 94.1) 
64.2 (51.7 - 79.9) 
87.6 (70.4 - 101.0) 
64.2 (51.3 - 76.4) 
82.8 (68.2 - 99.8) 
0.6091 
0.0401 
Spirometry 
% (N) 
Normal 
Restrictive 
Obstructive 
7.7 (4) 
15.4 (8) 
76.9 (40) 
8.5 (6) 
16.9 (12) 
74.7 (53) 
8.1 (10) 
16.3 (20) 
75.6 (93) 
0.9592 
Obstructive spirometry α 
% (N) 
Mild   
Moderate   
Severe   
Very Severe   
10.0 (4) 
60.0 (24) 
27.5 (11) 
2.5 (1) 
20.8 (11) 
56.6 (30) 
20.8 (11) 
1.9 (1) 
16.1 (15) 
58.1 (54) 
23.7 (22) 
2.2 (2) 
0.5404 
FEV1 
% (N) 
Below LLN 
Normal range    
Above ULN  
48.1 (25) 
51.9 (27) 
0.0 (0) 
33.8 (24) 
66.2 (47) 
0.0 (0) 
39.8 (49) 
60.2 (74) 
0.0 (0) 
0.1103 
FEV1 Z-Score Median (IQR) 1.6 (1.2 - 2.2) 1.3 (0.7 - 2.0) 1.5 (0.9 - 2.0) 0.039
1 
FVC 
%(N) 
Below LLN 
Normal range   
Above ULN  
38.5 (20) 
61.5 (32) 
0.0 (0) 
19.7 (14) 
80.3 (57) 
0.0 (0) 
27.6 (34) 
72.4 (89) 
0.0 (0) 
0.0223 
FVC Z-Score Median (IQR) 1.3 (0.5 - 1.9) 0.9 (0.3 - 1.5) 1.1 (0.3 - 1.8) 0.0601 
Oxygen Saturation Median (IQR)  97 (96 - 98) 97 (95 - 98) 97 (95 - 98) 0.5211 
* Comparison of Men and Women; 1 Mann-Whitney test; 2 Chi-square test; 3 Fisher’s exact test; 4 Kruskal-Wallis test; αThis is based on the 93 
participant subsample with obstructive spirometry; 
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Table 3.8: Results of Spirometry in the COPD completing spirometry with adequate reproducible blows and demi-span available for calculation 
of predicted blows using GLI prediction models (n=123)  
 
Men (n=52) Women (n=71) All (n=123) p-value* 
Observed 
Median (IQR) 
FEV1 
FVC 
FEV1/FVC 
PEFR 
1.4 (1.1 - 1.8) 
2.4 (2.0 - 3.1) 
0.6 (0.5 - 0.7) 
382.5 (243 - 519) 
1.0 (0.7 - 1.1) 
1.6 (1.3 - 1.9) 
0.6 (0.5 - 0.7) 
218 (144 - 290) 
1.1 (0.8 - 1.4) 
1.9 (1.5 - 2.3) 
0.6 (0.5 - 0.7) 
259 (191 - 380) 
<0.0011 
<0.0011 
0.5911 
<0.0011 
% predicted  
Median (IQR)  
FEV1 
FVC   
60.7 (48.8 - 69.1) 
73.8 (62.0 - 91.1) 
56.5 (43.4 - 68.9) 
71.8 (59.5 - 85.0) 
58.6 (44.8 - 69.0) 
73.2 (60.3 - 86.8) 
0.3131 
0.2211 
Spirometry 
% (N) 
Normal 
Restrictive 
Obstructive 
26.9 (14) 
25.0 (13) 
48.1 (25) 
23.9 (17) 
25.4 (18) 
50.7 (36) 
25.2 (31) 
25.2 (31) 
49.6 (61) 
0.9282 
FEV1 
% (N) 
Below LLN 
Normal range    
Above ULN  
69.2 (36) 
30.8 (16) 
0.0 (0) 
74.7 (53) 
25.4 (18) 
0.0 (0) 
72.4 (89) 
27.6 (34) 
0.0 (0) 
0.5073 
FEV1 Z-Score Median (IQR)  -2.0 (-2.5 - -1.6)  -2.3 (-2.9 - -1.6)  -2.1 (-2.8 - -1.6) 0.128
1 
FVC 
%(N) 
Below LLN 
Normal range   
Above ULN  
46.2 (24) 
53.9 (28) 
0.0 (0) 
45.1 (32) 
54.9 (39) 
0.0 (0) 
45.5 (56) 
54.5 (67) 
0.0 (0) 
0.9053 
FVC Z-Score Median (IQR)  -1.5 (-2.2 - -0.5)  -1.5 (-2.1 - -0.8)  -1.5 (-2.2 - -0.7) 0.5601 
Oxygen Saturation Median (IQR)  97 (96 - 98) 97 (95 - 98) 97 (95 - 98) 0.5211 
* Comparison of Men and Women; 1 Mann-Whitney test; 2 Chi-square test; 3 Fisher-exact test; 
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Table 3.9:  Level of agreement between the three methods of obstructive lung function 
classification. 
 
Physician Diagnosed COPD 
GOLD Obstructive  
 
No Yes 
No 91.2 (312) 8.8 (30) 
Yes 76.5 (302) 23.5 (93) 
Total 83.3 (614) 16.7 (123) 
McNemar test 
 
 p<0.001 
Kappa agreement = 54.8% Expected agreement = 47.5% Kappa = 0.139  
 Physician Diagnosed COPD 
GLI Obstructive 
 
No Yes 
No 88.9 (498) 11.1 (62) 
Yes 65.5 (116) 34.5 (61) 
Total 83.3 (614) 16.7 (123) 
McNemar test 
 
 p<0.001 
Kappa agreement = 75.9% Expected agreement = 67.3% Kappa = 0.261  
 GOLD COPD 
GLI Obstructive 
 
No Yes 
No 61.1 (342) 38.9 (218) 
Yes 0.0 (0) 100.0 (177) 
Total 46.4 (342) 53.6 (395) 
McNemar test 
 
 p<0.001 
Kappa agreement = 70.3% Expected agreement = 48.1% Kappa = 0.428  
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Table 3.10: Results of Spirometry in the HRG completing spirometry with adequate reproducible blows and demi-span available for calculation 
of predicted blows (n=151)   
Men (n=57) Women (n=94) All (n=151) p-value* 
Observed 
Median (IQR) 
FEV1 
FVC 
FEV1/FVC 
PEFR 
2.0 (1.7 - 2.4) 
2.9 (2.4 - 3.5) 
0.7 (0.6 - 0.8) 
515 (340 - 647) 
1.4 (1.2  - 1.6) 
1.9 (1.6 - 2.2) 
0.7 (0.7 - 0.8) 
329.5 (243 - 417) 
1.5 (1.2 - 2.0) 
2.1 (1.8 - 2.8) 
0.7 (0.6 - 0.8) 
367 (263 - 515) 
<0.0011 
<0.0011 
0.2441 
<0.0011 
% predicted  
Median (IQR)  
FEV1 
FVC   
90.1 (67.6 - 103.8) 
92.3 (72.0 - 107.7) 
93.8 (78.6 - 106.0) 
101.2 (85.2 - 121.7) 
91.6 (76.0 - 106.0) 
97.5 (80.6 - 115.2) 
0.1541 
0.0061 
Spirometry 
% (N) 
Normal 
Restrictive 
Obstructive 
36.8 (21) 
14.0 (8) 
49.1 (28) 
44.7 (42) 
12.8 (12) 
42.6 (40) 
41.7 (63) 
13.3 (20) 
45.0 (68) 
0.6362 
Obstructive 
spirometry α  
% (N) 
Mild   
Moderate   
Severe   
Very Severe   
50.0 (14) 
32.1 (9) 
10.7 (3) 
7.1 (2) 
62.5 (25) 
32.5 (13) 
5.0 (2) 
0.0 (0) 
57.4 (39) 
32.4 (22) 
7.4 (5) 
2.9 (2) 
0.2574 
FEV1 
% (N) 
Below LLN 
Normal range    
Above ULN  
21.1 (12) 
77.2 (44) 
1.8 (1) 
5.3 (5) 
93.6 (88) 
1.1 (1) 
11.3 (17) 
87.4 (132) 
1.3 (2) 
0.0113 
FEV1 Z-Score Median (IQR) 0.5 (-0.2 - 1.6) 0.3 (-0.2 - 0.9) 0.3 (-0.2 - 1.0) 0.071
1 
FVC 
%(N) 
Below LLN 
Normal range   
Above ULN  
29.8 (17) 
70.2 (40) 
0.0 (0) 
6.4 (6) 
91.5 (86) 
2.1 (2) 
15.2 (23) 
83.4 (126) 
1.3 (2) 
<0.0013 
FVC Z-Score Median (IQR) 0.6 (-0.2 - 1.7)  0.3 (-0.6 - 0.9) 0.4 (-0.4 – 1.2) 0.0401 
Oxygen Saturation Median (IQR)  98 (96 - 98) 98 (97 - 98) 98 (96 - 98) 0.9701 
* Comparison of Men and Women; 1 Mann-Whitney test; 2 Chi-square test; 3 Fisher-exact test; α This is based on the 68 participant subsample 
with obstructive spirometry 
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Table 3.11: Results of Spirometry in the HRG completing spirometry with adequate reproducible blows and demi-span available for calculation 
of predicted blows using GLI prediction models (n=151) 
 
Men (n=57) Women (n=94) All (n=151) p-value* 
Observed 
Median (IQR) 
FEV1 
FVC 
FEV1/FVC 
PEFR 
2.0 (1.7 - 2.4) 
2.9 (2.4 - 3.5) 
0.7 (0.6 - 0.8) 
515 (340 - 647) 
1.4 (1.2  - 1.6) 
1.9 (1.6 - 2.2) 
0.7 (0.7 - 0.8) 
329.5 (243 - 417) 
1.5 (1.2 - 2.0) 
2.1 (1.8 - 2.8) 
0.7 (0.6 - 0.8) 
367 (263 - 515) 
<0.0011 
<0.0011 
0.2441 
<0.0011 
% predicted  
Median (IQR)  
FEV1 
FVC   
83.9 (65.7 - 97.5) 
90.3 (70.5 - 104.2) 
84.0 (69.7 - 93.3) 
85.0 (72.4 - 99.3) 
83.9 (69.0 - 94.2) 
86.4 (70.9 - 102.8) 
0.9971 
0.6021 
Spirometry 
% (N) 
Normal 
Restrictive 
Obstructive 
63.2 (36) 
19.3 (11) 
17.5 (10) 
67.0 (63) 
17.0 (16) 
16.0 (15) 
65.6 (99) 
17.9 (27) 
16.6 (25) 
0.8882 
FEV1 
% (N) 
Below LLN 
Normal range    
Above ULN  
26.3 (15) 
71.9 (41) 
1.8 (1) 
23.4 (22) 
75.5 (71) 
1.1 (1) 
24.5 (37) 
74.2 (112) 
1.3 (2) 
0.8553 
FEV1 Z-Score Median (IQR)  -0.9 (-1.7  -0.1)  -0.9 (-1.6 - -0.4)  -0.9 (-1.6 - -0.3) 0.918
1 
FVC 
%(N) 
Below LLN 
Normal range   
Above ULN  
26.3 (15) 
73.7 (42) 
0.0 (0) 
21.3 (20) 
78.7 (74) 
0.0 (0) 
23.2 (35) 
76.8 (116) 
0.0 (0) 
0.4773 
FVC Z-Score Median (IQR)  -0.5 (-1.7 - 0.2)  -0.8 (-1.4 - 0.0)  -0.7 (-1.6 - 0.1) 0.8451 
Oxygen Saturation Median (IQR)  98 (96 - 98) 98 (97 - 98) 98 (96 - 98) 0.9701 
* Comparison of Men and Women; 1 Mann-Whitney test; 2 Chi-square test; 3 Fisher’s exact test; 4 Kruskal-Wallis test;  
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Figure 3.1: Flow chart illustrating how the total cohort of Newcastle 85+ Study participants 
was sub-divided in the respiratory study sample, demonstrating why different numbers of 
participants are included in the analyses. 
Participants with data available 
on Cough, Sputum & Wheeze  
N = 809 – All 
Males – 311, Female – 498 
Participants with both Health 
Assessment & review of general 
practice records 
N = 845 – All 
 Males – 319, Female – 526 
Participants with unreliable 
cough, sputum, wheeze data 
N = 1 – All, Males – 0, Female – 1 
Participants with adequate 
spirometry performed 
N = 772 – All 
Males – 302, Female – 470 
Participants with spirometry 
performed 
N = 786 – All 
Males – 304, Female – 482 
Participants with adequate 
spirometry and demi-span 
N = 737 – All 
Males – 294, Female – 443 
Participants with available MRC 
Dyspnoea scores 
N = 598 – All 
Males – 245, Female – 353 
 
Participants without MRC 
Dyspnoea Score 
N = 247 – All 
Males – 74, Female – 173 
Healthy reference group without 
any respiratory exclusion criteria 
N = 170 – All 
Males – 62, Female – 108 
Healthy reference group without any 
respiratory or other exclusion criteria 
N = 151 – All, Males – 57, Female – 94 
Participants with at least one 
exclusion criterion of non-
respiratory conditions 
N = 19 – All 
Males – 5, Female – 14 
Parkinson’s disease – 3 
Kyphosis/ Kyphoscoliosis – 9 
Heart Failure – 7 
Ankylosing Spondylitis – 1 
Participants without complete 
cough, wheeze & sputum data 
N = 35 – All 
Males – 8, Female – 27 
Unwell – 2  
Too Busy – 1  
Withdrew from study before 
respiratory assessment -28 
Missing data on all 3 measures – 4 
Participants without 
spirometry 
N = 59 – All 
Males – 15, Female – 44 
Reasons: - 
Technical Problems – 1 
Frail/Fatigue/Unwell – 11 
Distress – 3 
Too Busy – 1 
Interviewer Safety – 1 
Refused (No Reason) – 6  
Cognitive Impairment – 3 
Could not comprehend – 3 
Tracheostomy – 1 
Too much saliva – 1 
Withdrew from study before 
respiratory assessment-28 
Participants without adequate 
spirometry 
N = 14 – All 
 Males – 2, Female – 12 
No technically satisfactory blows 
for at least 1 of 3 spirometry 
measures (FEV1, FVC, PEF) 
missing 
Participants without adequate 
demispan  
(Required for calculation of 
predicted blows) 
N = 35 – All 
Males – 9, Female – 26 
Participants with at least one 
exclusion criterion for 
Respiratory reasons 
N = 567 – All 
Males – 232, Female – 335 
Pulmonary Fibrosis – 0 
Asbestosis – 5 
Asthma – 30 
Bronchiectasis – 15 
COPD – 123 
Pneumoconiosis – 4 
Tuberculosis – 37 
MRC Dyspnoea Score > 1 – 310 
Cough/Wheeze/Sputum – 365 
Participants using at least one 
respiratory related medication – 
102  
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Figure 3.2: Distribution Curves of FEV1 and FVC in all participants in spirometry cohort, 
measured (blue) and predicted (green) 
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Figure 3.3: Scatter plot of measured PEF against FEV1 showing the correlation between the 
two measures in whole spirometry cohort by sex 
 
Figure 3.4: Scatter-plots of predicted and observed FEV1 values by sex. The dots above the red 
line shows participants with lower than predicted FEV1 and dots below the blue line suggest 
higher measured FEV1 than expected. 
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Figure 3.5: Scatter-plots of predicted and observed FVC values by sex. The dots above the red 
line shows participants with lower than predicted FVC and dots below the blue line suggest 
higher measured FVC than expected. 
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Figure 3.6: Distribution Curves of FEV1 and FVC in HRG participants in spirometry cohort, 
measured (blue) and predicted (green) 
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Figure 3.7 Scatter plot of measured PEF against FEV1 showing the correlation between the two 
measures in HRG by sex. 
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Chapter 4. Lung function as a predictor of mortality in the very old 
4.1 Aims of the chapter 
This chapter aims to: 
1. Investigate the relationship between both observed and percent predicted lung function 
measures at age 85 and subsequent mortality 
2. Examine whether the inclusion of subsequent changes in lung function from baseline 
improves mortality prediction 
3. Examine whether lung function predicts mortality in a healthy respiratory group 
4.2 Background 
Globally, respiratory disease is considered as one of the leading causes of years of life lost with 
lower respiratory infections being ranked 2nd, Chronic Pulmonary Obstructive Disease (COPD) 
ranked 12th, lung cancer ranked 15th and asthma ranked 32nd (Mortality and Causes of Death, 
2014). In 2006, respiratory disease was reported as the second most common cause of hospital 
admissions accounting for 20% of all death in the UK (Hubbard, 2006). Age-standardised 
mortality of men aged 85 and in 2009 was 15 times higher than those aged 50 – 54 years 
(Sweet, 2011).  
Mechanical properties of the lung and thoracic cage decline with age so that functional residual 
capacity and residual volume increase, with a resulting decrease in vital capacity (VC) (Pride, 
2005). Since this population has a high disease burden, including respiratory disease,  and the 
highest expenditure per capita on health care (Summerfield and Babb, 2004), it is important to 
understand how the level of lung function influences survival in this age group. However, for 
this age group there is little data on how lung function changes or whether measures that predict 
mortality at younger ages still do so in the very old.  
Only one study has captured the predictive value of lung function measures on survival in the 
very old, the  Danish 1905 cohort study, where participants had their FEV1 recorded in 1998 at 
age 93 years, and were followed-up for 13 years until 2011 (Miller et al., 2014). Applying 
prediction equations for survival from six different studies, they found those in the lowest 
quartile of FEV1 had a 60% increased risk of mortality (Miller et al., 2014).  
The ability of lung function to predict mortality has been investigated in other studies in 
younger age groups (Hsu and Pwu, 2004; Lyyra et al., 2005; van den Borst et al., 2012). In  
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Finnish 75 year olds born in 1914 (Lyyra et al., 2005), the lowest tertile of VC had an increased 
risk of mortality when compared to the highest tertile, but this was no longer significant after 
adjustment for other sensory and motor functions.  
Another study of a younger population (mean age of 73) compared the effects of abdominal 
visceral fat on inflammatory pathways and mortality between those with and without 
obstructive lung disease defined by LLN cut-offs (van den Borst et al., 2012). After adjustment 
for sociodemographic and health behaviour covariates, inflammatory marker (IL-6) and 
adiponectin they found that those with obstructive lung disease had a 52% higher risk of all-
cause mortality (van den Borst et al., 2012).  
The Whitehall II study in particular made an in depth investigation of the relationship between 
FEV1 and mortality in a population of civil servants with mean age of 60.8 years (SD, 5.9) and  
a mean follow-up period of 6.4 (SD, 5.9) years (Sabia et al., 2010). Sociodemographic factors 
(age, sex and employment grade), health behaviours (smoking and alcohol consumption) and 
health characteristics (diseases, symptoms and blood biomarkers) were included as covariates in 
the cox regression models. After adjustment by all covariates, those in the lowest tertile of 
FEV1/height
2 had a 52% increased risk of mortality compared to the other two tertiles (Sabia et 
al., 2010).   
Given the dearth of very old participants in previous studies, the aim of this chapter is to 
investigate whether lung function still predicts mortality at an advanced age, in particular using 
the same methods of the Whitehall II study. Previous studies will be extended by examining a 
fuller range of lung function measures (observed and predicted) collected at multiple time 
points, as well as examining a greater range of confounders that may affect this relationship. In 
addition, I will investigate whether lung function predicts mortality in a healthy respiratory 
group.  
4.3 Analytical methods    
4.3.1 Lung function measures 
As discussed in previous chapters, FEV1, FVC and PEF were collected and percent predicted 
values for FEV1 and FVC calculated using both the GOLD and GLI methodology. Standardised 
z-scores for FEV1, FVC and PEF were calculated, by subtracting the mean  from the observed 
value and dividing the result by the standard deviation, within sex and sample (i.e. whole 
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spirometry cohort or the Healthy Reference Group). All ten measures were available at 
baseline, 18 months and 36 months follow-up.         
4.3.2 Confounders 
From a literature search, factors associated with lung function or mortality were identified 
(Veale et al., 2000; Hsu and Pwu, 2004; Lyyra et al., 2005; Sabia et al., 2010) for inclusion in 
the analysis. These were: age; sex; smoking status (categorised as never, former and current 
smokers); years of education (categorised as 0-9 years, 10 – 11 years, 12+ years); occupational 
exposure; respiratory conditions; chronic disease count; and cognitive impairment. 
Occupational exposure was defined as having worked in any of heavy industry, coal mining, 
chemical works or asbestos related occupations. Respiratory disease was based on respiratory 
diagnoses from the GPRR. Disease count was the sum of 7 disease categories: arthritis, cancer, 
cardiac disease, cerebrovascular disease, diabetes, hypertension and cognitive impairment, all 
based on GPRR diagnoses with the exception of cognitive function which was ascertained from 
the MMSE in the MDHA. MMSE scores were categorised as normal (26-30), mild (22-25), 
moderate (18-21) and severe (0-17). Three serum biomarkers of inflammation were included: 
Interleukin 6 (IL-6), tumour necrosis factor alpha (TNFα), C-reactive protein (CRP), in addition 
to telomere length which has been identified as a biomarker for ageing (Gardner et al., 2014) 
and associated with increased risk of mortality (Cawthon et al., 2003).   
4.3.3 Survival analysis 
To assess the relationship between lung function measures and survival/mortality, Cox 
Proportional Hazards regression models were fitted for each of the lung function measures, 
updating the lung function measures at each assessment and thus treating them as time-varying. 
All confounders previously mentioned were also updated at each subsequent time point (18 and 
36 months) apart from sex, smoking status, years of education and occupational exposures as 
these were fixed or considered to be fixed. PEF was transformed by dividing by 600 to allow 
for better interpretation and model convergence. Stepwise modelling was used with the Akaike 
Information Criterion (AIC) to identify the best fitting model. For observed measures, hazard 
ratios were reported for every 1 litre increase in FEV1 and FVC, and every 10 decilitre/second 
increase in PEF Furthermore, hazard ratios were reported for every 10% increase in lung 
function for the percent predicted measures. 
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Survival models were fitted separately for men and women as there is a difference in lung 
function levels reported in previous chapters. The first model (unadjusted) had only the lung 
function measures as a predictor to inform of the univariate effects of these measures on 
survival. In model 2, smoking was added as it widely reported that smoking has an effect on 
lung function (Beck et al., 1981; Anthonisen et al., 2002). All further models were compared to 
Model 2 to replicate the analysis of the Whitehall II study (Sabia et al., 2010) and to investigate 
whether the same factors act as confounders (e.g. socio-economic status) or mediators (e.g. 
physical activity) to the relationship between lung function and mortality at both younger ages 
and an advanced age. Model 3, added education and occupational history to model 2 since both 
are associated with mortality and lung function and may therefore be confounders. Model 4 
adjusted for model 2 factors, physical activity and BMI investigating the effects of lung 
function on survival whilst adjusting for modifiable lifestyle characteristics. Model 5, adjusted 
for model 2 factors, respiratory disease, GP disease count and MMSE investigating effects of 
disease and cognitive ageing on lung function ability to predict mortality. Model 6, adjusted for 
model 2 factors and IL-6, TNFα, CRP and telomere length which were the inflammatory and 
ageing biomarkers which may be used as early indicators for disease onset. The final model, 
Model 7, contained all the covariates used in Models 2 – 6 adjusting for all possible 
confounders/mediators. Mortality data was available to 31st July 2014. The analysis was 
undertaken for men and women separately, on all participants and then repeated for the HRG 
group. The proportional hazards assumption of all Cox models was checked using Schoenfeld 
residuals.  
One assumption of the Cox models previously described is that the relationship between lung 
function measures and mortality is linear. A sensitivity analysis was undertaken to test this 
assumption  by fitting restricted cubic splines (Durrleman and Simon, 1989) in SAS version 9.3 
(SAS Institute Inc., Cary, NC, USA). The only significant non-linear relationship between 
mortality and FEV1 was observed in HRG women (p=0.028) ( Figure 4.2). All other lung 
function measures were found to have a linear relationship with mortality for both sexes 
regardless of whether in the whole spirometry cohort or HRG (Figures 4.1 – 4.14). All other 
analyses were undertaken in Stata 12.0 (StataCorp; College Station, TX, USA).  
4.4 Effects of lung function on mortality  
Participants were followed for a median survival time of 5.4 years. Whilst all baseline observed 
and percent predicted lung function measures (adjusted for all confounders) were predictive of 
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survival in women (Figures 4.1 – 4.14), only FVC percent predicted (GOLD and GLI) were 
predictive of survival in men (p= 0.014 and p=0.021 respectively) (Figure 4.11 and Figure 
4.13). FEV1 percent predicted (GLI) for women was the only measure to predict survival in the 
HRG (p=0.026) ( Figure 4.10).  
In the complete spirometry sample (Table 4.1), FEV1 was not predictive of survival for men 
(Models 1 -7). In women however, FEV1 did predict survival with a 63% reduced risk of 
mortality (Model 1) for every litre increase. FVC and PEF were predictive of survival for men 
and women (Model 1) and remained so after adjustment for smoking status, education and 
occupational exposure (Model 3). At this stage, based on FVC, men had a 25% (HR: 0.75, 95% 
CI: 0.59 – 0.96) lower risk of mortality per litre increase in their FVC, whereas for women this 
was 54% (HR: 0.46, 95% CI: 0.31 – 0.67). For PEF, men showed a 67% (HR: 0.33, 95% CI: 
0.18 – 0.62) reduced risk of mortality in comparison to women who had an 88% (HR: 0.12, 
95% CI: 0.04 – 0.32) reduced risk of mortality (Model 3). In men, neither FVC nor PEF were 
predictive of survival once the models were fully adjusted (Model 7), most likely due to 
biomarkers, disease and physical activity attenuating the effect of lung function on survival. In 
women however, FEV1 showed a 48% (HR: 0.52, 95% CI: 0.32 – 0.86) and FVC a 43% (HR: 
0.57, 95% CI: 0.39 – 0.82) reduced risk of mortality for every one litre increase in each 
respective measure. For PEF a 76% (HR: 0.24, 95% CI: 0.09 – 0.70) reduced risk of mortality 
was also observed in women (Table 4.1).  
Percent predicted FEV1 for both the GOLD and GLI method were predictive of survival in the 
univariate models and when further adjusted for smoking and socioeconomic status (models 1 -
3); however these effects no longer held for men when models included physical activity and 
biomarkers (models 4 and 6) (Table 4.2). For the percent predicted FEV1 and FVC (Table 4.2) 
none of the fully adjusted models (Model 7) were found to be predictive of survival in men, 
partly attributable to physical activity attenuating such effects for GOLD percent predicted 
values as lung function was predictive of survival in all other models. This was in contrast to 
the results for women where for every 10% increase in percent predicted FEV1 (GOLD and 
GLI) there was an 11% (HR: 0.89, 95% CI: 0.83 – 0.96) reduced risk of mortality, indicating 
that both prediction method are similar in their ability to predict mortality in women. A similar 
trend was observed for FVC percent predicted measures in women (Table 4.2).  
Results from the standardised values of the complete spirometry cohort (Table 4.3) were similar 
to those of the unstandardised values as they are derived from the same measures. However, the 
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standardised values allow comparison of the 3 measures on the same metric. Examining the 
fully adjusted models (Model 7) for women, all three measures were predictive of survival with 
similar hazard ratios (95% confidence interval) for FEV1:0.79 (0.66 – 0.94), FVC: 0.76 (0.64 – 
0.90) and PEF: 0.78 (0.65 – 0.95) (all p<0.05).  
When analysis was restricted to the HRG (Table 4.4), none of the measures were predictive of 
survival in men. However, in women, although FEV1 did not evidence of being predictive of 
survival, FVC and PEF were predictive of survival in unadjusted models (Model 1) and after 
adjusting for smoking, education and occupational history (Model 3). For a one litre increase in 
FVC at this point a 66% (HR: 0.34, 95% CI 0.13 – 0.88) reduced risk of mortality was observed 
(Model 3) in comparison to PEF which had a 96% (95% CI: 0 – 47) reduced risk of mortality 
for the same percentage increase. Nevertheless, when the models were fully adjusted for 
covariates (Model 7) neither FVC nor PEF remained predictive of survival in women in the 
HRG.     
For the GOLD and GLI percent-predicted values in HRG women, only FVC measures were 
predictive of survival in unadjusted models (Model 1) and this effect was lost after complete 
adjustment for confounders (Model 7) (Table 4.5). Findings were similar for the standardised 
models (Table 4.6).  
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4.5 Summary 
This chapter has confirmed that lung function still predicts survival as people reach an 
advanced age, albeit in women only. The effect of FVC and PEF on survival for men was 
mostly attenuated once the models adjusted for physical activity and biomarkers, which may be 
used as indicators of adverse health. Such findings could mean that some of the factors adjusted 
for in the models may act as mediators and not confounders. However, in a healthy group of the 
very old, with no previous respiratory symptoms, respiratory disease or respiratory related 
conditions, there was no evidence of the predictive ability of lung function for survival.  The 
main findings of the chapter were: 
1. FVC and PEF were predictive of survival before and after adjustment for sex and 
smoking. 
2. FEV1, FVC and PEF were predictive of survival women even after further adjustments 
for socioeconomic status, lifestyle behaviours, disease and biomarkers. 
3. FEV1, FVC and PEF did not predict survival in men after adjustment for all 
confounding factors regardless of whether or not they were healthy (i.e. had no 
respiratory related symptoms, disease or conditions) at baseline.  
4. A litre increase in FEV1 and FVC was associated with a 48% and 43% lower risk of 
mortality in women respectively.  
5. FEV1 and FVC percent predicted results were similar regardless of the calculation 
method (GOLD and GLI). 
Whilst this chapter has revealed the relationship between lung function and mortality in the 
very old, the next chapter will investigate changes in lung function over time and the 
contributing factors (sociodemographic, health and lifestyle) to this.
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Table 4.1: Effect of observed lung function measures on survival, Hazard Ratios (HR), 95% confidence interval for HR, p-value, whole 
spirometry cohort 
Males FEV1 FVC PEF 
Model* HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
1 0.74 (0.53 - 1.02) 0.064 0.75 (0.58 - 0.95) 0.019 0.35 (0.19 - 0.64) 0.001 
2 0.76 (0.55 - 1.06) 0.109 0.76 (0.60 - 0.98) 0.031 0.36 (0.20 - 0.68) 0.001 
3 0.73 (0.53 - 1.02) 0.067 0.75 (0.59 - 0.96) 0.021 0.33 (0.18 - 0.62) 0.001 
4 0.95 (0.67 - 1.35) 0.781 0.86 (0.66 - 1.10) 0.230 0.60 (0.31 - 1.15) 0.124 
5 0.78 (0.55 - 1.11) 0.168 0.79 (0.61 - 1.01) 0.057 0.40 (0.21 - 0.75) 0.005 
6 0.91 (0.64 - 1.29) 0.583 0.86 (0.67 - 1.12) 0.268 0.45 (0.23 - 0.86) 0.015 
7 1.06 (0.73 - 1.56) 0.749 0.96 (0.73 - 1.26) 0.769 0.63 (0.31 - 1.29) 0.210 
Females FEV1 FVC PEF 
Model* HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
1 0.37 (0.22 - 0.60) <0.001 0.46 (0.31 - 0.67) <0.001 0.11 (0.04 - 0.29) <0.001 
2 0.37 (0.22 - 0.60) <0.001 0.46 (0.32 - 0.68) <0.001 0.11 (0.04 - 0.31) <0.001 
3 0.36 (0.22 - 0.60) <0.001 0.46 (0.31 - 0.67) <0.001 0.12 (0.04 - 0.32) <0.001 
4 0.50 (0.31 - 0.80) 0.004 0.56 (0.39 - 0.81) 0.002 0.22 (0.08 - 0.59) 0.003 
5 0.39 (0.24 - 0.65) <0.001 0.50 (0.34 - 0.73) <0.001 0.13 (0.05 - 0.36) <0.001 
6 0.39 (0.24 - 0.65) <0.001 0.48 (0.33 - 0.71) <0.001 0.12 (0.04 - 0.32) <0.001 
7 0.52 (0.32 - 0.86) 0.010 0.57 (0.39 - 0.82) 0.003 0.24 (0.09 - 0.70) 0.008 
*Model 1 unadjusted. Model 2 adjusted for smoking status. Model 3 adjusted for model 2, education, and occupational exposure. Model 4 
adjusted for model 2, physical activity and BMI. Model 5 adjusted for model 2, COPD, other respiratory disease, disease count excluding 
respiratory conditions and MMSE. Model 6 adjusted for model 2, IL-6, TNFα, CRP and Telomere length. Model 7 adjusted to include all 
parameters from models 2 to 6. Italic values indicate unmet proportional hazard assumptions in the modelling process. 
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Table 4.2: Effect of lung function on survival using percent predicted values, Hazard Ratios (HR), 95% confidence interval for HR, p-value, 
whole spirometry cohort 
Males FEV1 % Predicted (GOLD) FEV1 % Predicted (GLI) FVC % Predicted (GOLD) FVC % Predicted (GLI) 
Model* HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
1 0.92 (0.86 - 0.99) 0.033 0.90 (0.84 - 0.97) 0.005 0.89 (0.82 - 0.96) 0.004 0.88 (0.82 - 0.95) 0.001 
2 0.93 (0.86 - 1.00) 0.062 0.91 (0.85 - 0.98) 0.010 0.90 (0.83 - 0.97) 0.008 0.88 (0.82 - 0.95) 0.001 
3 0.92 (0.86 - 1.00) 0.041 0.91 (0.84 - 0.97) 0.006 0.89 (0.83 - 0.97) 0.006 0.88 (0.82 - 0.95) 0.001 
4 0.97 (0.90 - 1.05) 0.432 0.95 (0.88 - 1.02) 0.150 0.92 (0.85 - 1.00) 0.055 0.91 (0.84 - 0.98) 0.011 
5 0.93 (0.86 - 1.01) 0.870 0.91 (0.84 - 0.98 0.014 0.90 (0.83 - 0.98) 0.015 0.89 (0.83 - 0.96) 0.002 
6 0.96 (0.89 - 1.05) 0.374 0.94 (0.87 - 1.01) 0.111 0.93 (0.85 - 1.01) 0.091 0.91 (0.84 - 0.99) 0.020 
7 0.99 (0.91 - 1.08) 0.845 0.96 (0.88 - 1.04) 0.332 0.96 (0.88 - 1.04) 0.306 0.93 (0.86 - 1.01) 0.085 
Females FEV1 % Predicted (GOLD) FEV1 % Predicted (GLI) FVC % Predicted (GOLD) FVC % Predicted (GLI) 
Model* HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
1 0.84 (0.79 - 0.91) <0.001 0.84 (0.78 - 0.91) <0.001 0.85 (0.79 - 0.91) <0.001 0.84 (0.78 - 0.90) <0.001 
2 0.84 (0.79 - 0.91) <0.001 0.84 (0.78 - 0.91) <0.001 0.85 (0.79 - 0.91) <0.001 0.84 (0.78 - 0.90) <0.001 
3 0.84 (0.79 - 0.91) <0.001 0.84 (0.78 - 0.91) <0.001 0.85 (0.79 - 0.91) <0.001 0.84 (0.78 - 0.90) <0.001 
4 0.89 (0.83 - 0.95) 0.001 0.88 (0.82 - 0.95) 0.001 0.88 (0.83 - 0.94) <0.001 0.87 (0.82 - 0.94) <0.001 
5 0.85 (0.79 - 0.91) <0.001 0.85 (0.78 - 0.91) <0.001 0.85 (0.79 - 0.92) <0.001 0.85 (0.78 - 0.91) <0.001 
6 0.85 (0.79 - 0.92) <0.001 0.85 (0.79 - 0.92) <0.001 0.85 (0.80 - 0.92) <0.001 0.85 (0.79 - 0.91) <0.001 
7 0.89 (0.83 - 0.96) 0.002 0.89 (0.83 - 0.96) 0.002 0.88 (0.82 - 0.95) 0.001 0.88 (0.81 - 0.94) 0.001 
*Model 1 unadjusted. Model 2 adjusted for smoking status. Model 3 adjusted for model 2, education, and occupational exposure. Model 4 
adjusted for model 2, physical activity and BMI. Model 5 adjusted for model 2, COPD, other respiratory disease, disease count excluding 
respiratory conditions and MMSE. Model 6 adjusted for model 2, IL-6, TNFα, CRP and Telomere length. Model 7 adjusted to include all 
parameters from models 2 to 6. Italic values indicate unmet proportional hazard assumptions in the modelling process. HR Change for every 
10% increase.  
63 
 
Table 4.3: Effect of standardised lung function measures on survival, Hazard Ratios (HR), 95% confidence interval for HR, p-value, whole 
spirometry cohort 
Males FEV1 (Standardised) FVC (Standardised) PEF (Standardised) 
Model* HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
1 0.85 (0.72 - 1.01) 0.072 0.80 (0.68 - 0.95) 0.012 0.75 (0.63 - 0.90) 0.002 
2 0.87 (0.73 - 1.04) 0.122 0.81 (0.68 - 0.97) 0.019 0.76 (0.64 - 0.91) 0.004 
3 0.85 (0.72 - 1.02) 0.075 0.80 (0.67 - 0.95) 0.013 0.74 (0.62 - 0.89) 0.001 
4 0.98 (0.81 - 1.18) 0.826 0.88 (0.73 - 1.05) 0.163 0.89 (0.73 - 1.07) 0.218 
5 0.88 (0.73 - 1.06) 0.184 0.83 (0.70 - 0.99) 0.037 0.78 (0.65 - 0.95) 0.011 
6 0.95 (0.79 - 1.15) 0.623 0.89 (0.74 - 1.06) 0.194 0.81 (0.67 - 0.98) 0.033 
7 1.04 (0.85 - 1.27) 0.716 0.95 (0.79 - 1.15) 0.614 0.90 (0.73 - 1.12) 0.347 
Females FEV1 (Standardised) FVC (Standardised) PEF (Standardised) 
Model* HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
1 0.70 (0.58 - 0.83) <0.001 0.69 (0.58 - 0.82) <0.001 0.68 (0.57 - 0.81) <0.001 
2 0.70 (0.58 - 0.83) <0.001 0.69 (0.58 - 0.82) <0.001 0.68 (0.57 - 0.82) <0.001 
3 0.69 (0.58 - 0.83) <0.001 0.69 (0.58 - 0.82) <0.001 0.69 (0.57 - 0.82) <0.001 
4 0.78 (0.65 - 0.92) 0.004 0.76 (0.64 - 0.89) 0.001 0.77 (0.64 - 0.92) 0.005 
5 0.71 (0.59 - 0.86) <0.001 0.71 (0.59 - 0.85) <0.001 0.70 (0.58 - 0.85) <0.001 
6 0.72 (0.60 - 0.86) <0.001 0.71 (0.59 - 0.85) <0.001 0.68 (0.57 - 0.83) <0.001 
7 0.79 (0.66 - 0.94) 0.009 0.76 (0.64 - 0.90) 0.002 0.78 (0.65 - 0.95) 0.013 
*Model 1 unadjusted. Model 2 adjusted for smoking status. Model 3 adjusted for model 2, education, and occupational exposure. Model 4 
adjusted for model 2, physical activity and BMI. Model 5 adjusted for model 2, COPD, other respiratory disease, disease count excluding 
respiratory conditions and MMSE. Model 6 adjusted for model 2, IL-6, TNFα, CRP and Telomere length. Model 7 adjusted to include all 
parameters from models 2 to 6. Italic values indicate unmet proportional hazard assumptions in the modelling process. 
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Table 4.4: Effect of observed lung function measures on survival, Hazard Ratios (HR), 95% confidence interval for HR, p-value, HRG 
Males FEV1 FVC PEF 
Model* HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
1 1.12 (0.44 - 2.84) 0.811 1.08 (0.56 - 2.10) 0.819 0.61 (0.12 - 3.22) 0.562 
2 1.13 (0.44 - 2.88) 0.799 1.09 (0.56 - 2.12) 0.802 0.61 (0.12 - 3.28) 0.568 
3 1.02 (0.37- 2.82) 0.967 1.00 (0.49 - 2.05) 0.992 0.55 (0.10 - 3.08) 0.497 
4 0.85 (0.30 - 2.41) 0.762 0.93 (0.46 - 1.90) 0.845 0.68 (0.10- 4.73) 0.694 
5 1.23 (0.46 - 3.30) 0.682 1.26 (0.62 - 2.55) 0.523 0.64 (0.10 - 3.98) 0.633 
6 1.84 (0.55 - 6.13) 0.320 1.41 (0.61 - 3.26) 0.423 1.04 (0.15 - 7.31) 0.972 
7 1.44 (0.35 - 5.94) 0.612 1.32 (0.53 - 3.32) 0.555 1.38 (0.07 - 27.26) 0.832 
Females FEV1 FVC PEF 
Model* HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
1 0.37 (0.11 - 1.20) 0.098 0.37 (0.15 - 0.90) 0.028 0.05 (0.00- 0.60) 0.018 
2 0.35 (0.11 - 1.14) 0.082 0.36 (0.15 - 0.89) 0.026 0.05 (0.00 - 0.51) 0.012 
3 0.34 (0.10 - 1.15) 0.084 0.34 (0.13 - 0.88) 0.025 0.04 (0.00 - 0.47) 0.011 
4 0.45 (0.14 - 1.41) 0.168 0.45 (0.18 - 1.14) 0.093 0.07 (0.00 - 1.02) 0.052 
5 0.22 (0.06 - 0.81) 0.023 0.34 (0.13 - 0.88) 0.026 0.03 (0.00 - 0.38) 0.007 
6 0.40 (0.13 - 1.29 0.126 0.38 (0.15 - 0.95) 0.039 0.07 (0.01 - 0.77) 0.030 
7 0.67 (0.14 - 3.15) 0.613 0.67 (0.20 - 2.23) 0.510 0.41 (0.02 - 10.4) 0.591 
*Model 1 unadjusted. Model 2 adjusted for smoking status. Model 3 adjusted for model 2, education, and occupational exposure. Model 4 
adjusted for model 2, physical activity and BMI. Model 5 adjusted for model 2, COPD, other respiratory disease, disease count excluding 
respiratory conditions and MMSE. Model 6 adjusted for model 2, IL-6, TNFα, CRP and Telomere length. Model 7 adjusted to include all 
parameters from models 2 to 6.  
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Table 4.5: Effect of lung function on survival using percent predicted values, Hazard Ratios (HR), 95% confidence interval for HR, p-value, 
HRG 
Males FEV1 % Predicted (GOLD) FEV1 % Predicted (GLI) FVC % Predicted (GOLD) FVC % Predicted (GLI) 
Model* HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
1 0.94 (0.75 - 1.17) 0.570 0.94 (0.77 - 1.15) 0.550 0.94 (0.76 - 1.17) 0.576 0.94 (0.78 - 1.14) 0.543 
2 0.94 (0.75 - 1.17) 0.571 0.94 (0.77 - 1.15) 0.552 0.94 (0.76 - 1.17) 0.582 0.94 (0.78 - 1.14) 0.550 
3 0.89 (0.68 - 1.16) 0.397 0.90 (0.72 - 1.14) 0.390 0.90 (0.71 - 1.15) 0.411 0.91 (0.73 - 1.13) 0.379 
4 0.91 (0.72 - 1.14) 0.408 0.91 (0.73 - 1.12) 0.363 0.92 (0.74 - 1.15) 0.476 0.92 (0.75 - 1.13) 0.432 
5 0.95 (0.75 - 1.21) 0.700 0.95 (0.77 - 1.18) 0.636 0.99 (0.78 - 1.24) 0.902 0.98 (0.80 - 1.20) 0.821 
6 0.99 (0.74 - 1.31) 0.928 0.99 (0.77 - 1.27) 0.920 0.96 (0.73 - 1.26) 0.783 0.96 (0.75 - 1.23) 0.768 
7 1.00 (0.72 - 1.41) 0.980 0.98 (0.73 - 1.32) 0.894 1.02 (0.75 - 1.40) 0.876 1.00 (0.77 - 1.31) 0.990 
Females FEV1 % Predicted (GOLD) FEV1 % Predicted (GLI) FVC % Predicted (GOLD) FVC % Predicted (GLI) 
Model* HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
1 0.83 (0.69 - 1.00) 0.050 0.86 (0.71 - 1.03) 0.096 0.80 (0.68 - 0.96) 0.015 0.81 (0.68 - 0.97) 0.022 
2 0.83 (0.69 - 0.99) 0.043 0.85 (0.71 - 1.02) 0.080 0.81 (0.68 - 0.96) 0.015 0.81 (0.68 - 0.97) 0.022 
3 0.83 (0.69 - 1.00) 0.045 0.85 (0.70 - 1.02) 0.081 0.79 (0.66 - 0.96) 0.015 0.80 (0.66 - 0.97) 0.020 
4 0.88 (0.73 - 1.04) 0.141 0.89 (0.75 - 1.06) 0.191 0.86 (0.72 - 1.02) 0.090 0.86 (0.72 - 1.03) 0.105 
5 0.78 (0.63 - 0.96) 0.018 0.80 (0.65 - 0.98) 0.028 0.80 (0.67 - 0.97) 0.021 0.80 (0.66 - 0.98) 0.027 
6 0.84 (0.70 - 1.01) 0.067 0.87 (0.73 - 1.04) 0.137 0.81 (0.68 - 0.97) 0.023 0.82 (0.68 - 0.99) 0.036 
7 0.90 (0.70 - 1.17) 0.433 0.95 (0.74 - 1.21) 0.666 0.90 (0.71 - 1.15) 0.406 0.92 (0.72 - 1.19) 0.541 
*Model 1 unadjusted. Model 2 adjusted for smoking status. Model 3 adjusted for model 2, education, and occupational exposure. Model 4 
adjusted for model 2, physical activity and BMI. Model 5 adjusted for model 2, COPD, other respiratory disease, disease count excluding 
respiratory conditions and MMSE. Model 6 adjusted for model 2, IL-6, TNFα, CRP and Telomere length. Model 7 adjusted to include all 
parameters from models 2 to 6. HR Change for every 10% increase. 
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Table 4.6: Effect of standardised lung function measures on survival, Hazard Ratios (HR), 95% confidence interval for HR, p-value, HRG 
Males FEV1 (Standardised) FVC (Standardised) PEF (Standardised) 
Model* HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
1 1.04 (0.63 - 1.73) 0.868 1.05 (0.65 - 1.69) 0.857 0.85 (0.52 - 1.41) 0.540 
2 1.05 (0.63 - 1.74) 0.857 1.05 (0.65 - 1.70) 0.840 0.86 (0.52 - 1.42) 0.547 
3 0.99 (0.57 - 1.72) 0.974 0.99 (0.59 - 1.66) 0.964 0.83 (0.49 - 1.40) 0.480 
4 0.89 (0.51 - 1.57) 0.689 0.94 (0.56 - 1.58) 0.815 0.87 (0.49 - 1.56) 0.642 
5 1.10 (0.64 - 1.87) 0.730 1.16 (0.70 - 1.93) 0.563 0.88 (0.51 - 1.52) 0.639 
6 1.35 (0.70 - 2.60) 0.362 1.26 (0.69 - 2.32) 0.453 1.00 (0.55 - 1.81) 0.994 
7 1.18 (0.56 - 2.51) 0.666 1.20 (0.62 - 2.34) 0.586 1.08 (0.44 - 2.65) 0.860 
Females FEV1 (Standardised) FVC (Standardised) PEF (Standardised) 
Model* HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
1 0.68 (0.43 - 1.06) 0.087 0.62 (0.41 - 0.95) 0.026 0.61 (0.39 - 0.94) 0.024 
2 0.66 (0.42 - 1.03) 0.070 0.62 (0.41 - 0.94) 0.025 0.59 (0.39 - 0.91) 0.017 
3 0.66 (0.41 - 1.04) 0.072 0.60 (0.39 - 0.93) 0.024 0.57 (0.36 - 0.90) 0.016 
4 0.73 (0.47 - 1.12) 0.153 0.69 (0.45 - 1.06) 0.090 0.64 (0.40 - 1.04) 0.073 
5 0.55 (0.34 - 0.91) 0.019 0.60 (0.39 - 0.94) 0.025 0.54 (0.34 - 0.87) 0.011 
6 0.70 (0.45 - 1.09) 0.115 0.64 (0.42 - 0.98) 0.040 0.64 (0.42 - 0.98) 0.041 
7 0.85 (0.48 - 1.53) 0.595 0.83 (0.48 - 1.46) 0.526 0.90 (0.51 - 1.60) 0.723 
*Model 1 unadjusted. Model 2 adjusted for smoking status. Model 3 adjusted for model 2, education, and occupational exposure. Model 4 
adjusted for model 2, physical activity and BMI. Model 5 adjusted for model 2, COPD, other respiratory disease, disease count excluding 
respiratory conditions and MMSE. Model 6 adjusted for model 2, IL-6, TNFα, CRP and Telomere length. Model 7 adjusted to include all 
parameters from models 2 to 6.  
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Figure 4.1: Restricted cubic spline curves of baseline FEV1 (litres) levels and mortality in men and women in the whole spirometry cohort 
adjusted for smoking status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count excluding respiratory 
conditions, MMSE, IL-6, TNFα, CRP and Telomere length 
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Figure 4.2: Restricted cubic spline curves of baseline FEV1 (litres) levels and mortality in men and women in the HRG adjusted for smoking 
status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count excluding respiratory conditions, MMSE, 
IL-6, TNFα, CRP and Telomere length 
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Figure 4.3: Restricted cubic spline curves of baseline FVC (litres) levels and mortality in men and women in the whole spirometry cohort 
adjusted for smoking status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count excluding respiratory 
conditions, MMSE, IL-6, TNFα, CRP and Telomere length 
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Figure 4.4: Restricted cubic spline curves of baseline FVC (litres) levels and mortality in men and women in the HRG adjusted for smoking 
status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count excluding respiratory conditions, MMSE, 
IL-6, TNFα, CRP and Telomere length 
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Figure 4.5: Restricted cubic spline curves of baseline PEF (litres) levels and mortality in men and women in the whole spirometry cohort 
adjusted for smoking status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count excluding respiratory 
conditions, MMSE, IL-6, TNFα, CRP and Telomere length 
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Figure 4.6: Restricted cubic spline curves of baseline PEF (litres) levels and mortality in men and women in the HRG adjusted for smoking 
status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count excluding respiratory conditions, MMSE, 
IL-6, TNFα, CRP and Telomere length 
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Figure 4.7: Restricted cubic spline curves of baseline GOLD FEV1 Percent Predicted (%) levels and mortality in men and women in the whole 
spirometry cohort adjusted for smoking status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count 
excluding respiratory conditions, MMSE, IL-6, TNFα, CRP and Telomere length.  
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Figure 4.8: Restricted cubic spline curves of baseline GOLD FEV1 Percent Predicted (%) levels and mortality in men and women in the HRG 
adjusted for smoking status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count excluding respiratory 
conditions, MMSE, IL-6, TNFα, CRP and Telomere length.
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Figure 4.9: Restricted cubic spline curves of baseline GLI FEV1 Percent Predicted (%) levels and mortality in men and women in the whole 
spirometry cohort adjusted for smoking status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count 
excluding respiratory conditions, MMSE, IL-6, TNFα, CRP and Telomere length. 
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Figure 4.10: Restricted cubic spline curves of baseline GLI FEV1 Percent Predicted (%) levels and mortality in men and women in the HRG 
adjusted for smoking status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count excluding respiratory 
conditions, MMSE, IL-6, TNFα, CRP and Telomere length.
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Figure 4.11: Restricted cubic spline curves of baseline GOLD FVC Percent Predicted (%) levels and mortality in men and women in the whole 
spirometry cohort adjusted for smoking status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count 
excluding respiratory conditions, MMSE, IL-6, TNFα, CRP and Telomere length.
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Figure 4.12: Restricted cubic spline curves of baseline GOLD FVC Percent Predicted (%) levels and mortality in men and women in the HRG 
adjusted for smoking status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count excluding respiratory 
conditions, MMSE, IL-6, TNFα, CRP and Telomere length.
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Figure 4.13: Restricted cubic spline curves of baseline GLI FVC Percent Predicted (%) levels and mortality in men and women in the whole 
spirometry cohort adjusted for smoking status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count 
excluding respiratory conditions, MMSE, IL-6, TNFα, CRP and Telomere length.
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Figure 4.14: Restricted cubic spline curves of baseline GLI FVC Percent Predicted (%) levels and mortality in men and women in the HRG 
adjusted for smoking status, education, occupational exposure, physical activity, BMI, Respiratory disease, disease count excluding respiratory 
conditions, MMSE, IL-6, TNFα, CRP and Telomere length.
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Chapter 5. Trajectories of lung function from age 85 
In the previous chapter, the repeated measures of lung function obtained in the N85+ study 
were utilised to position the lung function measure closer to the event of death so that the effect 
of lung function on mortality could be estimated more precisely. This chapter will explore the 
pattern of change in lung function in 85 year olds as they age.  
5.1 Aims of the chapter 
Specifically this chapter will:  
1. Describe lung function measures at baseline, 18 and 36 months 
2. Quantify the extent of new cases of respiratory disease at 18 and 36 months 
3. Investigate the lung function trajectories of change and their determinants within the 
a. Whole spirometry cohort 
b. HRG  
c. Survivor Group 
4. Explore the relationship of inflammatory blood biomarkers to lung function over the 36 
months period 
5.2 Background 
As discussed in the previous chapter, various studies have found reduced lung function to be a 
predictor of increased mortality in both younger and older populations (Lyyra et al., 2005; 
Sabia et al., 2010; Miller et al., 2014). The N85+ study also confirmed that better lung function 
predicted lower risk of mortality but only in women in a general population. Earlier chapters 
have discussed that the ageing lung sees its function decrease over time (Pride, 2005; Vaz 
Fragoso and Lee, 2012). However, there have been few studies investigating lung function 
changes over time and specifically exploring the determinants and consequences of changes in 
lung function in the very old.  
The literature review in Chapter 1 described the studies in older populations that have explored 
longitudinal changes in lung function. Findings from these included that decrease in fat free 
mass (FFM) decrease and increase in sagittal abdominal diameter were associated with  decline 
in  pulmonary function over a 7 year period (Rossi et al., 2008); better pulmonary function 
resulting in slower cognitive decline (Weuve et al., 2011; Emery et al., 2012; Vidal et al., 
2013); and worse pulmonary function resulting in decline in cognitive function (Emery et al., 
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2012). However, most longitudinal studies of lung function are in younger populations. In this 
age group  socio-economic status (SES) at birth was found to be  inversely associated with lung 
function during adolescence (Menezes et al., 2011). As previously discussed, the longitudinal 
effect of inflammatory markers such as IL-6, TNFα and CRP on lung function has been 
extensively researched (Shaaban et al., 2006; Gimeno et al., 2011; Ahmadi-Abhari et al., 2014; 
Hancox et al., 2016).  
In the Whitehall II study, an increase of 10 percent in baseline CRP was associated with a 4.7 
ml decrease in FVC and 3.0 ml decrease in FEV1 over a period of approximately 12 years.  IL-6 
followed a similar trend, but with a ten percent increase resulting in 12.6 ml decrease in FVC 
and 7.3 ml decrease in FEV1 after adjusting for all covariates (Gimeno et al., 2011). Analysis of 
the effect of CRP on both FEV1 and FVC over a 13 year follow-up revealed an inverse 
association; however, CRP at baseline was not found to be predictive of lung function rate of 
change (Ahmadi-Abhari et al., 2014). Another study of the association between CRP and FEV1 
over an 8.5 year follow-up period found a decline in lung function based on increasing tertiles 
of CRP after adjusting for sociodemographic (age and sex), life style (smoking habits and BMI) 
and health characteristics such as cholesterol levels, atopy and asthma (Shaaban et al., 2006). 
This brief review of  longitudinal studies of lung function measures  has revealed a gap which 
this chapter will address using   the different lung function measures available in the N85+ 
study at two follow-ups  covering  a period of 36 months from age  85. Specifically, these 
analyses will explore the association between sociodemographic, health and lifestyle 
characteristics as well as blood biomarkers and changes in lung function measures.  
5.3 Analytical methods       
5.3.1 Lung function measures  
The lung function measures collected remain the same throughout the study, however for the 
purpose of the analysis in this section, only observed measures will be investigated, specifically 
FEV1, FVC, PEF and FEV1/VC which were available at baseline, 18 months and 36 months 
follow-up.           
5.3.2 Confounders   
As previously mentioned in chapter 4, a series of factors were identified from the literature 
search for inclusion in the mortality analyses that were also relevant to trajectories of change. 
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These were: age; age2; sex; smoking status (categorised as never, former and current smokers); 
years of education (categorised as 0-9 years, 10 – 11 years, 12+ years); BMI (categorised as 
underweight <18.5, normal 18.5 – 25, overweight 25 – 30, obese and morbidly obese 30+); 
physical activity (categorised as low, medium, high); occupational exposure; respiratory 
conditions; chronic disease count; and cognitive impairment. Occupational exposure was 
defined as having worked in any of heavy industry, coal mining, chemical works or asbestos 
related occupations. Respiratory disease was based on respiratory diagnoses from the GPRR. 
Disease count was the sum of 7 disease categories: arthritis, cancer, cardiac disease, 
cerebrovascular disease, diabetes, hypertension and cognitive impairment, also based GPRR 
diagnoses with the exception of cognitive impairment which was ascertained at interview. 
MMSE scores were categorised as normal (26-30), mild (22-25), moderate (18-21) and severe 
(0-17). Also included were three serum biomarkers of inflammation which had been explored in 
previous studies: Interleukin 6 (IL-6) , tumour necrosis factor alpha (TNFα), C-reactive protein 
(CRP), in addition to telomere length which has been identified as a biomarker for ageing 
(Shaaban et al., 2006; Gimeno et al., 2011; Ahmadi-Abhari et al., 2014; Gardner et al., 2014; 
Hancox et al., 2016).        
5.3.3 Longitudinal analysis  
To model the trajectory of each lung function measure over the 36 months follow-up, multilevel 
random effects models were fitted with age as the time scale and including polynomial 
functions of age. The effect of key socio-demographic and health factors and biomarkers 
individually were assessed in subsequent models: sex; socio-economic status (education), 
occupational exposure, physical activity, BMI, respiratory diagnoses; chronic disease count; 
cognitive function (MMSE), IL-6, TNFα, CRP and telomere length. Due to skewed distribution, 
the biomarkers were log-transformed. Apart from education and smoking status, all other 
variables were updated. The analysis was performed for the whole spirometry cohort, HRG and 
the HRG survivor group (defined as those from the HRG who survived all 3 time points of the 
study and did not have a respiratory disease diagnoses at any point). A sensitivity analysis was 
performed using only survivors of all three times points to investigate the presence of survival 
bias affecting the findings. All analyses used Stata 12.0 (StataCorp; College Station, TX, USA). 
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5.4 Lung function trajectories of change        
5.4.1 Respiratory disease diagnoses 
From the respiratory diagnoses in the GPRR at 18 months in the whole spirometry cohort, 5 
new cases of COPD were found, along with 2 cases of asthma, pulmonary fibrosis, asbestosis 
and one case of bronchiectasis and TB each (Table 5.1). A further 7 cases of COPD were found 
by 36 months in addition to 3 bronchiectasis and 1 pulmonary fibrosis diagnoses. Overall, there 
were 24 new diagnoses of respiratory disease over the 36 months follow-up period. This was in 
contrast to the number of cases diagnosed in the HRG with only 1 case of bronchiectasis and 1 
of pulmonary fibrosis over the same period (Table 5.1). The incidence rate for COPD in this 
cohort was 7.8 cases per 1000 persons per year.   
5.4.2 Changes in lung function measures over time  
In the spirometry cohort, mean FEV1 for men was 1.80 litres at baseline, 1.85 litres at 18 
months and 1.80 litres at 36 months.In women mean FEV1 was 1.22 litres at baseline, 1.21 
litres at 18 months and 1.20 litres at 36 months (Table 5.2). For FVC, both men and women saw 
an overall decline with overall mean of 2.14 (SD: 0.75) decreasing to 2.02 (SD: 0.74) over the 
36 months follow-up (Table 5.2). Mean PEF increased over the 36 months period for both men 
(461, SD: 188 to 488, SD: 171) and women (287, SD: 117 to 309, SD: 106) and the FEV1/FVC 
ratio had a similar trend to that of FEV1 for both men and women (Table 5.2). Similar trends 
were observed for the HRG lung function in both men and women (Table 5.2).   
In the HRG survivor group a gradual decrease was observed in both FEV1 and FVC. It is worth 
noting that PEF did actually decrease overall between baseline (423, SD: 169) and 36 months 
(411, SD: 165) though this was mostly between 18 and 36 months (Table 5.3). The average 
FEV1/FVC ratio did not change for men between baseline and 36 months though a slight but 
non-significant increase was observed for women for the same period (Table 5.3). 
5.4.3 Lung function trajectories of change 
The FEV1 trajectories of change are shown graphically in Figure 5.1. For the whole spirometry 
cohort. In men, there was a significant effect of time suggesting a non-linear trajectory whilst 
current smoking, cognitive impairment and higher CRP were associated with lower FEV1 
trajectories and higher education with higher FEV1 trajectories (Table 5.4). In contrast, 
women’s FEV1 did not change significantly over time, although current smoking, respiratory 
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disease and cognitive impairment resulted in significantly lower FEV1 (Table 5.4). Sensitivity 
analysis was performed based on the spirometry cohort participants who survived all three time 
points to investigate the possibility of survival bias (Table 5.5). Similar conclusions were drawn  
for the majority of variables with the exception of smoking status (no longer associated), TNF 
alpha (men)  and CRP  (women) (Table 5.5).  
In the HRG men, higher education levels and lower disease count resulted in significantly 
higher FEV1 whereas in women, medium physical activity, BMI of over 30, respiratory disease 
and higher disease count resulted in lower FEV1 (Table 5.6). In the HRG survivor group, mild 
and moderate cognitive impairment and raised TNFα resulted in lower FEV1 and in women 
medium physical activity and increased disease count resulted in lower FEV1 (Table 5.7). 
The FVC trajectories for the whole spirometry cohort are shown graphically in Figure 5.2. FVC 
did not change significantly over time in men or women (Table 5.8). However, men with 
greater cognitive impairment, higher CRP and longer telomere length had significantly lower 
FVC whilst higher BMI, the presence of respiratory disease and higher CRP in women resulted 
in significantly lower FVC (Table 5.8). In the HRG, none of the covariates impacted  men’s 
FVC trajectory in contrast to women where lower physical activity and higher BMI were 
associated with lower FVC (Table 5.9). In the HRG survivor group, physical activity in women 
was the only covariate found to impact FVC (Table 5.10). 
PEF trajectories are shown graphically for the whole spirometry cohort in Figure 5.3. PEF in 
men showed a non-linear relationship with time (β:-1.02, SE: 0.50) (Table 5.11). Current 
smokers (β:-0.25, SE: 0.08) compared to never smokers, medium (β:-0.10, SE: 0.03) and low 
(β:-0.06, SE: 0.02) physical activity compared to high levels and being underweight (β:-0.12, 
SE: 0.05) were all associated with lower PEF (Table 5.11). Lower cognitive function and higher 
CRP levels were also associated with lower PEF in men (Table 5.11). In women current 
smoking, lower physical activity, being underweight, respiratory disease, cognitive impairment 
and longer telomere length all resulted in lower PEF (Table 5.11). In the HRG, no associations 
were found between the covariates and PEF for men, though in women medium physical 
activity (β:-0.14, SE: 0.04) compared to high levels and IL-6 (β:-0.03, SE: 0.01) were inversely 
associated with PEF (Table 5.12). In the HRG survivor group, only physical activity and BMI 
impacted PEF trajectories in women (Table 5.13).  
The FEV1/FVC ratio trajectories (Figure 5.4) for whole spirometry cohort (Table 5.14), the 
HRG (Table 5.15) and HRG survivor group (Table 5.16) presented similar findings to that of 
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FEV1 and PEF trajectories.  
5.4.4 Lung function and biomarkers of inflammation 
This section will consolidate all significant findings for biomarkers of inflammation on all lung 
function measures. IL-6, TNFα and CRP were the three biomarkers of systemic inflammation 
investigated against the lung function trajectories. Increased IL-6 level was associated with 
lower PEF levels in HRG women (β:-0.04, SE: 0.02) and women in the HRG survivor group 
(β:-0.04, SE: 0.02) (Table 5.12, Table 5.13, Figure 5.6). Higher levels of TNFα (β:-0.05, SE: 
0.02) were associated with lower FEV1 levels of men in the HRG survivor groups (Figure 5.7, 
Table 5.7). In the whole spirometry group, increases in CRP (β:-0.05, SE: 0.01) had was 
associated with lower FEV1 in men of the whole spirometry cohort (Table 5.4, Figure 5.8). 
Increased CRP was associated with lower FVC levels in both men (β:-0.05, SE: 0.02) and 
women (β:-0.03, SE: 0.01) of the whole spirometry group (Table 5.8, Figure 5.8). Similar 
results were found in PEF for men in the whole spirometry group (Table 5.11, Figure 5.8) and 
the HRG survivor group (Table 5.13, Figure 5.8). 
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5.5 Summary 
This chapter explored lung function trajectories over time and investigated lifestyle and health 
characteristics which may influence them. There were similarities in FEV1, PEF and FEV1/FVC 
trajectories of men in whole spirometry group where change was non-linear over the 36 months 
period. However, in contrast, women’s lung function showed little evidence of change over 
time. Sensitivity analysis revealed minor differences between the whole spirometry cohort and 
its survivors. The effect of health characteristics were more pronounced in the whole spirometry 
groups and such effects were diminished when investigated in the HRG or the HRG survivor 
group indicating a survivor effect.     
The main findings of a longitudinal survival analysis were: 
1. There were 24 new cases of lung disease over the 36 month follow-up, and COPD 
accounted for 50% of all new lung disease diagnoses. 
2.  The incidence rate of COPD in this cohort was 7.8 cases per 1000 per year. 
3. FEV1 for the whole spirometry group was lower for current smokers and the cognitively 
impaired in both men and women. 
4. Smoking was no longer associated with FEV1 in whole spirometry cohort survivors. 
5. Cognitive impairment had an adverse effect on FEV1 levels for men in both the whole 
spirometry group and the HRG survivor group. 
6. BMI and physical activity had the most influence on lung function levels in women in 
the HRG and HRG survivor groups.  
7. Lower physical activity was associated with lower FEV1, FVC and PEF in women of 
the HRG survivor group.  
8. Increased IL-6 was associated with lower PEF levels in the HRG and HRG survivor 
group but only for women.  
9. Higher TNFα was associated with lower FEV1 in men in the HRG survivor group. 
10. Higher CRP was associated with lower FEV1, FVC and PEF for men in the whole 
spirometry group.  
Whilst this chapter has explored lung function trajectories between the ages of 85 and 88 and 
factors influencing them, the next chapter will investigate causal pathways between lung 
function and disability between ages 85 and 90.  
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Table 5.1: New cases of respiratory disease GP diagnoses at each time point by sex, whole spirometry cohort and HRG 
Spirometry 
Cohort Baseline  18 Months 36 Months 
Disease 
Male 
(293) 
Female 
(444) 
All 
(737) 
Male 
(214) 
Female 
(337) 
All  
(551) 
Male 
(157) 
Female 
(255) 
All  
(412) 
COPD 17.8 (52) 16.0 (71) 16.7 (123) 0.6 (1) 1.4 (4) 1.0 (5) 1.6 (2) 2.3 (5) 2.0 (7) 
Asthma 6.8 (20) 13.1 (58) 10.6 (78) 0.0 (0) 0.7 (2) 0.4 (2) 0.0 (0) 0.0 (0) 0.0 (0) 
Bronchiectasis 2.4 (7) 1.8 (8) 2.0 (15) 0.0 (0) 0.3 (1) 0.2 (1) 0.7 (1) 0.8 (2) 0.7 (3) 
Pulmonary Fibrosis 0.0 (0) 0.0 (0) 0.0 (0) 0.5 (1) 0.3 (1) 0.4 (2) 0.0 (0) 0.4 (1) 0.2 (1) 
Asbestosis 1.7 (5) 0.0 (0) 0.7 (5) 1.0 (2) 0.0 (0) 0.4 (2) 0.0 (0) 0.0 (0) 0.0 (0) 
Pneumoconiosis 1.4 (4) 0.0 (0) 0.5 (4) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 
Tuberculosis 4.4 (13) 5.4 (24) 5.0 (37) 0.0 (0) 0.3 (1) 0.2 (1) 0.0 (0) 0.0 (0) 0.0 (0) 
          
HRG Baseline  18 Months 36 Months 
Disease 
Male 
(57) 
Female 
(94) 
All 
(151) 
Male 
(46) 
Female 
(80) 
All 
(126) 
Male 
(39) 
Female 
(68) 
All 
(107) 
COPD 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 
Asthma 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 
Bronchiectasis 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 2.6 (1) 0.0 (0) 0.9 (1) 
Pulmonary Fibrosis 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 1.5 (1) 0.9 (1) 
Asbestosis 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 
Pneumoconiosis 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 
Tuberculosis 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 
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Table 5.2: Summary statistics of lung function measures over time by sex, whole spirometry 
cohort and HRG 
Whole Spirometry Group Male Female All 
 
Mean (SD) N Mean (SD) N Mean (SD) N 
FEV1        
Baseline 1.80 (0.56) 293 1.22 (0.38) 444 1.45 (0.54) 737 
18 Months 1.85 (0.52) 214 1.21 (0.37) 337 1.45 (0.53) 551 
36 Months 1.80 (0.52) 157 1.20 (0.36) 255 1.43 (0.52) 412 
FVC       
Baseline 2.72 (0.71) 293 1.76 (0.48) 444 2.14 (0.75) 737 
18 Months 2.67 (0.66) 214 1.67 (0.46) 337 2.05 (0.73) 551 
36 Months 2.62 (0.71) 157 1.65 (0.46) 255 2.02 (0.74) 412 
PEF       
Baseline 461 (188) 293 287 (117) 444 356 (172) 737 
18 Months 487 (178) 214 303 (115) 337 374 (168) 551 
36 Months 488 (171) 152 309 (106) 238 379 (161) 390 
FEV1/FVC       
Baseline 0.67 (0.13) 293 0.70 (0.13) 444 0.69 (0.13) 737 
18 Months 0.70 (0.11) 214 0.73 (0.12) 337 0.71 (0.12) 551 
36 Months 0.69 (0.11) 157 0.73 (0.12) 255 0.72 (0.12) 412 
       
HRG Male Female All 
 
Mean (SD) N Mean (SD) N Mean (SD) N 
FEV1       
Baseline 1.98 (0.63) 57 1.40 (0.35) 94 1.62 (0.55) 151 
18 Months 2.06 (0.51) 46 1.35 (0.37) 80 1.61 (0.55) 126 
36 Months 2.00 (0.53) 39 1.32 (0.38) 68 1.57 (0.55) 107 
FVC       
Baseline 2.90 (0.72) 57 1.94 (0.44) 94 2.30 (0.73) 151 
18 Months 2.86 (0.68) 46 1.78 (0.43) 80 2.17 (0.74) 126 
36 Months 2.79 (0.72) 39 1.77 (0.46) 68 2.14 (0.75) 107 
PEF       
Baseline 493 (204) 57 332 (129) 94 393 (179) 151 
18 Months 507 (195) 46 337 (119) 80 399 (172) 126 
36 Months 536 (174) 38 335 (104) 63 411 (166) 101 
FEV1/FVC       
Baseline 0.69 (0.15) 57 0.73 (0.12) 94 0.71 (0.13) 151 
18 Months 0.73 (0.09) 46 0.76 (0.11) 80 0.74 (0.10) 126 
36 Months 0.72 (0.07) 39 0.75 (0.11) 68 0.74 (0.10) 107 
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Table 5.3: Summary statistics of lung function measures over time by sex, survivor group 
Survivor Group Male Female All 
 
Mean (SD) N Mean (SD) N Mean (SD) N 
FEV1       
Baseline 2.15 (0.57) 36 1.45 (0.31) 62 1.71 (0.54) 98 
18 Months 2.12 (0.50) 36 1.40 (0.34) 62 1.66 (0.53) 98 
36 Months 2.00 (0.55) 36 1.32 (0.39) 62 1.57 (0.56) 98 
FVC       
Baseline 3.00 (0.73) 36 2.01 (0.44) 62 2.37 (0.73) 98 
18 Months 2.92 (0.68) 36 1.86 (0.39) 62 2.25 (0.72) 98 
36 Months 2.79 (0.75) 36 1.78 (0.47) 62 2.15 (0.76) 98 
PEF       
Baseline 538 (182) 36 356 (119) 62 423 (169) 98 
18 Months 539 (184) 36 350 (107) 62 419 (167) 98 
36 Months 527 (179) 35 340 (106) 57 411 (165) 92 
FEV1/FVC       
Baseline 0.72 (0.10) 36 0.73 (0.12) 62 0.73 (0.11) 98 
18 Months 0.73 (0.08) 36 0.75 (0.11) 62 0.74 (0.10) 98 
36 Months 0.72 (0.07) 36 0.74 (0.12) 62 0.74 (0.10) 98 
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Table 5.4: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of FEV1 adjusted for all covariates by sex, whole spirometry cohort 
Whole spirometry group Male   Female   
FEV1 Coeff SE p-value Coeff SE p-value 
Intercept -127.79 48.72 0.009 -7.06 31.80 0.824 
Age/10 30.18 11.25 0.007 2.17 7.33 0.767 
(Age/10)2 -1.75 0.65 0.007 -0.14 0.42 0.744 
Smoking Status   0.013   0.011 
Never 0 (Ref)   0 (Ref) 
  
Former  -0.11 0.06 0.075 -0.10 0.04 0.007 
Current -0.44 0.16 0.005 -0.15 0.07 0.031 
Education   0.029   0.580 
0 - 9 Years 0 (Ref)   0 (Ref)   
10 - 11 Years 0.01 0.07 0.837 0.00 0.04 0.928 
12+ Years 0.19 0.09 0.032 0.05 0.05 0.323 
       
Occupational Exposure -0.02 0.06 0.713 -0.02 0.04 0.662 
       
Physical Activity   0.109   0.355 
High 0 (Ref)   0 (Ref)   
Medium -0.01 0.04 0.800 -0.03 0.03 0.296 
Low -0.04 0.03 0.135 0.00 0.02 0.924 
BMI   0.567   0.173 
Normal (18.5 - 25) 0 (Ref)   0 (Ref)   
Underweight (<18.5) -0.05 0.08 0.530 -0.04 0.03 0.218 
Overweight (25 - 30) 0.03 0.04 0.524 -0.03 0.03 0.247 
Obese  (30+) -0.02 0.07 0.798 -0.08 0.04 0.055 
Respiratory Disease -0.11 0.06 0.053 -0.14 0.03 <0.001 
Disease Count  0.02 0.02 0.434 0.00 0.01 0.787 
       
Categorised MMSE   <0.001   0.001 
Normal (26-30) 0 (Ref)   0 (Ref)   
Mild (22-25) -0.02 0.04 0.559 -0.04 0.03 0.182 
Moderate (18-21) -0.25 0.08 0.001 -0.15 0.05 0.002 
Severe (0-17) -0.39 0.12 0.001 -0.24 0.07 <0.001 
IL-6*  0.01 0.02 0.706 0.01 0.01 0.324 
TNFα * -0.03 0.01 0.059 0.00 0.01 0.878 
CRP* -0.05 0.01 <0.001 -0.01 0.01 0.145 
Telomere Length* -0.01 0.05 0.816 -0.02 0.03 0.477 
* log-transformed       
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Table 5.5: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of FEV1 adjusted for all covariates by sex, whole spirometry cohort survivors 
Whole Spirometry Cohort Survivors Male   Female   
FEV1 Coeff SE p-value Coeff SE 
p-
value 
Intercept 
-
119.32 
49.47 0.016 -34.83 32.68 0.287 
Age/10 28.45 11.41 0.013 8.50 7.53 0.259 
(Age/10)2 -1.66 0.66 0.011 -0.50 0.43 0.247 
Smoking Status   0.148   0.498 
Never Ref   Ref 
  
Former  -0.05 0.09 0.555 -0.04 0.04 0.293 
Current -0.51 0.23 0.027 0.00 0.09 0.978 
Education   0.033   0.965 
0 - 9 Years Ref   Ref   
10 - 11 Years 0.17 0.10 0.086 -0.01 0.05 0.805 
12+ Years 0.14 0.11 0.203 -0.03 0.06 0.661 
Occupational Exposure -0.07 0.08 0.404 -0.07 0.05 0.207 
Physical Activity   0.927   0.892 
High Ref   Ref   
Medium 0.05 0.05 0.275 0.01 0.03 0.771 
Low 0.01 0.03 0.825 0.00 0.02 0.878 
BMI   0.266   0.348 
Normal (18.5 - 25) Ref   Ref   
Underweight (<18.5) 0.03 0.09 0.732 -0.02 0.03 0.492 
Overweight (25 - 30) -0.05 0.04 0.295 -0.03 0.03 0.318 
Obese and Morbidly Obese  (30+) -0.11 0.08 0.143 -0.06 0.05 0.205 
Respiratory Disease -0.06 0.07 0.370 -0.10 0.04 0.008 
Disease Count  0.03 0.02 0.239 0.02 0.02 0.314 
Categorised MMSE   <0.001   0.010 
Normal (26-30) Ref   Ref   
Mild (22-25) -0.05 0.04 0.209 -0.03 0.03 0.277 
Moderate (18-21) -0.25 0.08 0.001 -0.14 0.05 0.008 
Severe (0-17) -0.40 0.14 0.005 -0.23 0.08 0.003 
IL6 (log-transformed) 0.01 0.02 0.557 0.02 0.01 0.122 
TNF Alpha (log-transformed) -0.04 0.01 0.012 0.00 0.01 0.646 
CRP (log-transformed) -0.02 0.01 0.134 -0.02 0.01 0.047 
Telomere Length (log-transformed) -0.04 0.05 0.445 0.01 0.04 0.829 
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Table 5.6: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of FEV1 adjusted for all covariates by sex, HRG 
HRG Male   Female   
FEV1 Coeff SE p-value Coeff SE p-value 
Intercept -120.55 104.12 0.247 -7.86 53.66 0.884 
Age/10 28.41 24.07 0.238 2.55 12.38 0.837 
(Age/10)2 -1.64 1.39 0.236 -0.17 0.71 0.808 
Smoking Status   0.996   0.097 
Never 0 (Ref) 
  
0 (Ref)   
Former  0.00 0.15 0.996 -0.12 0.07 0.075 
Current - - - -0.51 0.24 0.036 
Education   0.011   0.546 
0 - 9 Years 0 (Ref)   0 (Ref)   
10 - 11 Years 0.42 0.17 0.013 -0.08 0.09 0.353 
12+ Years 0.49 0.21 0.020 -0.08 0.10 0.416 
       
Occupational Exposure 0.18 0.14 0.193 0.06 0.09 0.523 
       
Physical Activity   0.398   <0.001 
High 0 (Ref)   0 (Ref)   
Medium -0.16 0.12 0.181 -0.21 0.05 <0.001 
Low -0.05 0.06 0.442 0.01 0.03 0.767 
BMI   0.553   0.002 
Normal (18.5 - 25) 0 (Ref)   0 (Ref)   
Underweight (<18.5) -0.01 0.11 0.931 0.02 0.05 0.727 
Overweight (25 - 30) 0.06 0.10 0.556 0.06 0.05 0.294 
Obese  (30+) -0.49 0.37 0.186 -0.39 0.12 0.001 
Respiratory Disease 0.21 0.25 0.401 -0.06 0.16 0.714 
Disease Count  0.12 0.05 0.008 0.07 0.03 0.012 
       
Categorised MMSE   0.088   0.125 
Normal (26-30) 0 (Ref)   0 (Ref)   
Mild (22-25) -0.11 0.07 0.146 -0.09 0.05 0.067 
Moderate (18-21) -0.52 0.29 0.072 -0.01 0.09 0.873 
Severe (0-17) -0.84 0.37 0.023 0.15 0.14 0.268 
IL-6*  -0.01 0.03 0.783 -0.01 0.02 0.682 
TNFα * -0.05 0.03 0.054 0.02 0.02 0.231 
CRP* -0.04 0.03 0.147 -0.02 0.02 0.154 
Telomere Length* -0.03 0.11 0.792 0.01 0.06 0.869 
* log-transformed       
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Table 5.7: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of FEV1 adjusted for all covariates by sex, survivor group 
Survivor Group Male   Female   
FEV1 Coeff SE p-value Coeff SE p-value 
Intercept -64.93 92.95 0.485 -4.11 56.81 0.942 
Age/10 15.98 21.48 0.457 1.81 13.11 0.890 
(Age/10)2 -0.94 1.24 0.448 -0.14 0.76 0.857 
Smoking Status   0.576   0.371 
Never 0 (Ref) 
  
0 (Ref)   
Former  -0.12 0.21 0.576 -0.11 0.09 0.190 
Current - - - -0.24 0.34 0.475 
Education   0.081   0.960 
0 - 9 Years 0 (Ref)   0 (Ref)   
10 - 11 Years 0.50 0.22 0.021 -0.06 0.11 0.586 
12+ Years 0.11 0.28 0.699 -0.02 0.11 0.833 
Occupational Exposure 0.16 0.16 0.342 0.02 0.11 0.873 
       
Physical Activity 
  
0.910   0.002 
High 0 (Ref)   0 (Ref)   
Medium -0.05 0.11 0.633 -0.16 0.06 0.003 
Low -0.04 0.05 0.482 0.02 0.03 0.527 
BMI   0.916   0.048 
Normal (18.5 - 25) 0 (Ref)   0 (Ref)   
Underweight (<18.5) 0.04 0.11 0.731 0.02 0.05 0.668 
Overweight (25 - 30) -0.02 0.10 0.821 0.06 0.06 0.381 
Obese  (30+) - - - -0.39 0.17 0.021 
Disease Count  0.05 0.06 0.400 0.08 0.03 0.013 
       
Categorised MMSE   0.043   0.142 
Normal (26-30) 0 (Ref)   0 (Ref)   
Mild (22-25) -0.13 0.06 0.044 -0.10 0.05 0.070 
Moderate (18-21) -0.56 0.25 0.025 -0.02 0.10 0.803 
Severe (0-17) - - - 0.14 0.14 0.306 
IL-6*  0.01 0.03 0.723 -0.01 0.02 0.715 
TNFα * -0.05 0.02 0.022 0.02 0.02 0.413 
CRP* 0.00 0.03 0.893 -0.03 0.02 0.146 
Telomere Length* -0.11 0.09 0.229 -0.01 0.06 0.935 
* log-transformed       
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Table 5.8: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of FVC adjusted for all covariates by sex, whole spirometry cohort 
Whole spirometry group Male   Female   
FVC Coeff SE p-value Coeff SE p-value 
Intercept -22.73 77.04 0.768 19.32 44.78 0.666 
Age/10 6.92 17.79 0.697 -3.38 10.33 0.744 
(Age/10)2 -0.44 1.02 0.670 0.16 0.59 0.788 
Smoking Status   0.695   0.277 
Never 0 (Ref) 
  
0 (Ref)   
Former  0.01 0.08 0.952 0.00 0.04 0.985 
Current -0.17 0.21 0.424 -0.13 0.09 0.124 
Education   0.203   0.911 
0 - 9 Years 0 (Ref)   0 (Ref)   
10 - 11 Years -0.03 0.09 0.781 0.02 0.05 0.669 
12+ Years 0.19 0.12 0.106 0.00 0.07 0.962 
Occupational Exposure -0.04 0.08 0.647 -0.02 0.05 0.764 
       
Physical Activity   0.258   0.362 
High 0 (Ref)   0 (Ref)   
Medium -0.07 0.07 0.311 -0.03 0.04 0.384 
Low -0.08 0.05 0.092 0.01 0.03 0.746 
BMI   0.713   0.016 
Normal (18.5 - 25) 0 (Ref)   0 (Ref)   
Underweight (<18.5) -0.08 0.12 0.506 -0.07 0.04 0.119 
Overweight (25 - 30) -0.02 0.06 0.731 -0.09 0.03 0.009 
Obese  (30+) -0.10 0.10 0.319 -0.14 0.06 0.017 
Respiratory Disease -0.01 0.08 0.876 -0.18 0.04 <0.001 
Disease Count  -0.04 0.03 0.152 -0.01 0.02 0.672 
       
Categorised MMSE   0.019   0.121 
Normal (26-30) 0 (Ref)   0 (Ref)   
Mild (22-25) -0.04 0.06 0.444 -0.03 0.04 0.438 
Moderate (18-21) -0.31 0.12 0.008 -0.11 0.06 0.085 
Severe (0-17) -0.37 0.17 0.032 -0.20 0.09 0.030 
IL-6*  0.01 0.03 0.748 0.01 0.02 0.467 
TNFα * -0.04 0.02 0.069 0.01 0.01 0.306 
CRP* -0.05 0.02 0.008 -0.03 0.01 0.025 
Telomere Length* -0.17 0.08 0.036 -0.04 0.05 0.348 
* log-transformed       
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Table 5.9: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of FVC adjusted for all covariates by sex, HRG 
HRG Male   Female   
FVC Coeff SE p-value Coeff SE p-value 
Intercept -25.72 162.50 0.874 65.35 84.59 0.440 
Age/10 7.83 37.56 0.835 -13.72 19.52 0.482 
(Age/10)2 -0.49 2.16 0.823 0.74 1.12 0.510 
Smoking Status   0.889   0.746 
Never 0 (Ref) 
  
0 (Ref)   
Former  0.03 0.19 0.889 -0.01 0.08 0.938 
Current - - - -0.23 0.30 0.443 
Education   0.072   0.466 
0 - 9 Years 0 (Ref)   0 (Ref)   
10 - 11 Years 0.46 0.22 0.036 -0.11 0.10 0.279 
12+ Years 0.40 0.27 0.139 -0.11 0.12 0.390 
       
Occupational Exposure 0.13 0.17 0.445 0.08 0.11 0.435 
       
Physical Activity   0.479   0.002 
High 0 (Ref)   0 (Ref)   
Medium -0.12 0.18 0.486 -0.28 0.08 <0.001 
Low -0.11 0.10 0.236 -0.03 0.05 0.494 
BMI   0.799   0.035 
Normal (18.5 - 25) 0 (Ref)   0 (Ref)   
Underweight (<18.5) 0.11 0.17 0.514 0.08 0.08 0.280 
Overweight (25 - 30) 0.00 0.14 0.984 -0.10 0.08 0.207 
Obese  (30+) -0.36 0.47 0.444 -0.46 0.17 0.007 
Respiratory Disease 0.69 0.39 0.078 -0.28 0.26 0.274 
Disease Count  -0.04 0.06 0.538 0.07 0.04 0.067 
       
Categorised MMSE   0.089   0.791 
Normal (26-30) 0 (Ref)   0 (Ref)   
Mild (22-25) -0.17 0.11 0.117 0.03 0.07 0.666 
Moderate (18-21) -0.79 0.45 0.077 0.14 0.14 0.304 
Severe (0-17) -0.87 0.49 0.079 0.09 0.20 0.673 
IL-6*  -0.05 0.05 0.343 0.01 0.03 0.836 
TNFα * -0.03 0.04 0.528 0.04 0.03 0.196 
CRP* -0.03 0.04 0.436 -0.03 0.02 0.166 
Telomere Length* -0.27 0.16 0.098 -0.06 0.09 0.480 
* log-transformed  
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Table 5.10: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of FVC adjusted for all covariates by sex, survivor group 
Survivor Group Male   Female   
FVC Coeff SE p-value Coeff SE p-value 
Intercept -31.27 167.27 0.852 68.26 91.12 0.454 
Age/10 9.15 38.65 0.813 -14.34 21.02 0.495 
(Age/10)2 -0.57 2.23 0.800 0.77 1.21 0.522 
Smoking Status   0.545   0.968 
Never 0 (Ref) 
  
0 (Ref)   
Former  -0.16 0.27 0.545 0.00 0.10 0.976 
Current - - - -0.01 0.42 0.976 
Education   0.058   0.910 
0 - 9 Years 0 (Ref)   0 (Ref)   
10 - 11 Years 0.69 0.28 0.013 -0.06 0.13 0.674 
12+ Years 0.05 0.36 0.898 -0.03 0.14 0.840 
Occupational Exposure 0.11 0.21 0.584 0.03 0.13 0.795 
       
Physical Activity   0.639   0.005 
       
High 0 (Ref)   0 (Ref)   
Medium -0.01 0.19 0.952 -0.25 0.09 0.005 
Low -0.09 0.10 0.368 -0.03 0.05 0.542 
BMI   0.857   0.478 
Normal (18.5 - 25) 0 (Ref)   0 (Ref)   
Underweight (<18.5) 0.10 0.20 0.621 0.09 0.08 0.268 
Overweight (25 - 30) -0.03 0.16 0.831 -0.02 0.09 0.823 
Obese  (30+) - - - -0.11 0.25 0.666 
Disease Count  -0.04 0.09 0.667 0.07 0.04 0.093 
       
Categorised MMSE   0.113   0.609 
Normal (26-30) 0 (Ref)   0 (Ref)   
Mild (22-25) -0.17 0.11 0.126 0.04 0.08 0.632 
Moderate (18-21) -0.85 0.44 0.053 0.15 0.15 0.313 
Severe (0-17) - - - 0.10 0.22 0.647 
IL-6*  -0.03 0.05 0.492 -0.01 0.04 0.749 
TNFα * -0.04 0.04 0.370 0.03 0.03 0.364 
CRP* -0.01 0.05 0.898 -0.04 0.03 0.127 
Telomere Length* -0.25 0.16 0.126 -0.05 0.10 0.631 
* log-transformed       
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Table 5.11: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of PEF adjusted for all covariates by sex, whole spirometry cohort 
Whole spirometry group Male   Female   
PEF Coeff SE p-value Coeff SE p-value 
Intercept -76.86 37.57 0.041 -38.37 22.32 0.086 
Age/10 17.83 8.67 0.040 9.01 5.15 0.080 
(Age/10)2 -1.02 0.50 0.041 -0.52 0.30 0.082 
Smoking Status   0.002   0.004 
Never 0 (Ref) 
  
0 (Ref)   
Former  -0.04 0.03 0.257 -0.04 0.02 0.031 
Current -0.25 0.08 0.002 -0.10 0.03 0.002 
Education   0.090   0.070 
0 - 9 Years 0 (Ref)   0 (Ref)   
10 - 11 Years 0.04 0.04 0.285 0.02 0.02 0.412 
12+ Years 0.07 0.05 0.118 0.06 0.03 0.022 
       
Occupational Exposure 0.00 0.03 0.900 -0.01 0.02 0.776 
       
Physical Activity   <0.001   0.049 
High 0 (Ref)   0 (Ref)   
Medium -0.10 0.03 0.001 -0.04 0.02 0.018 
Low -0.06 0.02 0.004 -0.01 0.01 0.363 
BMI   0.015   0.023 
Normal (18.5 - 25) 0 (Ref)   0 (Ref)   
Underweight (<18.5) -0.12 0.05 0.020 -0.06 0.02 0.002 
Overweight (25 - 30) 0.04 0.03 0.137 -0.01 0.02 0.431 
Obese  (30+) 0.04 0.05 0.349 -0.01 0.03 0.644 
Respiratory Disease 0.00 0.03 0.883 -0.07 0.02 <0.001 
Disease Count  0.01 0.01 0.423 0.00 0.01 0.653 
       
Categorised MMSE   <0.001   0.007 
Normal (26-30) 0 (Ref)   0 (Ref)   
Mild (22-25) -0.05 0.03 0.064 -0.02 0.02 0.408 
Moderate (18-21) -0.20 0.05 <0.001 -0.08 0.03 0.005 
Severe (0-17) -0.26 0.08 0.002 -0.12 0.04 0.006 
IL-6*  0.00 0.01 0.902 0.00 0.01 0.897 
TNFα * -0.01 0.01 0.489 -0.01 0.01 0.421 
CRP* -0.03 0.01 <0.001 -0.01 0.01 0.189 
Telomere Length* 0.01 0.04 0.888 -0.05 0.02 0.029 
* log-transformed       
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Table 5.12: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of PEF adjusted for all covariates by sex, HRG 
HRG Male   Female   
PEF Coeff SE p-value Coeff SE p-value 
Intercept 54.55 85.80 0.525 21.38 43.26 0.621 
Age/10 -12.46 19.83 0.530 -4.58 9.98 0.646 
(Age/10)2 0.73 1.14 0.525 0.26 0.57 0.654 
Smoking Status   0.723   0.122 
Never 0 (Ref) 
  
0 (Ref)   
Former  0.03 0.08 0.721 -0.03 0.04 0.487 
Current - - - -0.21 0.14 0.142 
Education   0.774   0.465 
0 - 9 Years 0 (Ref)   0 (Ref)   
10 - 11 Years 0.07 0.09 0.425 -0.03 0.05 0.570 
12+ Years 0.10 0.11 0.390 0.02 0.05 0.761 
       
Occupational Exposure -0.02 0.07 0.786 0.04 0.05 0.418 
       
Physical Activity   0.056   <0.001 
High 0 (Ref)   0 (Ref)   
Medium -0.16 0.09 0.062 -0.14 0.04 0.001 
Low -0.10 0.05 0.035 -0.01 0.02 0.564 
BMI   0.328   0.087 
Normal (18.5 - 25) 0 (Ref)   0 (Ref)   
Underweight (<18.5) -0.07 0.08 0.414 -0.06 0.04 0.106 
Overweight (25 - 30) 0.13 0.07 0.048 0.06 0.04 0.089 
Obese  (30+) 0.06 0.20 0.747 -0.15 0.08 0.064 
Respiratory Disease 0.17 0.21 0.415 -0.06 0.13 0.654 
Disease Count  0.03 0.03 0.232 0.03 0.02 0.095 
       
Categorised MMSE   0.179   0.817 
Normal (26-30) 0 (Ref)   0 (Ref)   
Mild (22-25) -0.08 0.06 0.148 0.02 0.04 0.575 
Moderate (18-21) -0.05 0.23 0.841 0.02 0.07 0.734 
Severe (0-17) -0.40 0.22 0.067 0.05 0.13 0.685 
IL-6*  -0.03 0.03 0.206 -0.04 0.02 0.010 
TNFα * -0.02 0.02 0.350 0.03 0.02 0.057 
CRP* -0.04 0.02 0.050 -0.02 0.01 0.184 
Telomere Length* 0.02 0.09 0.850 -0.03 0.04 0.494 
* log-transformed       
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Table 5.13: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of PEF adjusted for all covariates by sex, survivor group 
Survivor Group Male   Female   
PEF Coeff SE p-value Coeff SE p-value 
Intercept 25.87 95.43 0.786 21.23 45.30 0.639 
Age/10 -5.70 22.05 0.796 -4.50 10.45 0.666 
(Age/10)2 0.33 1.27 0.794 0.25 0.60 0.678 
Smoking Status   0.272   0.510 
Never 0 (Ref) 
  
0 (Ref) 
  
Former  -0.11 0.10 0.272 -0.02 0.04 0.709 
Current - - - -0.19 0.16 0.251 
Education   0.172   0.422 
0 - 9 Years 0 (Ref)   0 (Ref)   
10 - 11 Years 0.15 0.11 0.162 -0.06 0.05 0.283 
12+ Years -0.16 0.14 0.264 0.03 0.05 0.617 
       
Occupational Exposure -0.03 0.08 0.697 0.02 0.05 0.623 
       
Physical Activity   0.178   0.019 
High 0 (Ref)   0 (Ref)   
Medium -0.05 0.10 0.621 -0.12 0.04 0.006 
Low -0.10 0.05 0.058 -0.01 0.02 0.736 
BMI   0.771   0.002 
Normal (18.5 - 25) 0 (Ref)   0 (Ref)   
Underweight (<18.5) -0.01 0.10 0.960 -0.06 0.04 0.143 
Overweight (25 - 30) 0.06 0.08 0.467 0.07 0.04 0.088 
Obese  (30+) - - - -0.29 0.11 0.009 
Disease Count  0.05 0.04 0.231 0.03 0.02 0.064 
       
Categorised MMSE   0.743   0.872 
Normal (26-30) 0 (Ref)   0 (Ref)   
Mild (22-25) -0.07 0.06 0.268 0.02 0.04 0.626 
Moderate (18-21) -0.04 0.24 0.872 0.06 0.08 0.459 
Severe (0-17) - - - 0.10 0.14 0.499 
IL-6*  -0.03 0.03 0.238 -0.04 0.02 0.016 
TNFα * -0.02 0.02 0.421 0.03 0.02 0.058 
CRP* -0.05 0.02 0.045 -0.01 0.01 0.425 
Telomere Length* 0.00 0.09 0.981 -0.03 0.05 0.594 
* log-transformed       
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Table 5.14: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of FEV1/FVC adjusted for all covariates by sex, whole spirometry cohort 
Whole spirometry group Male   Female   
FEV1/FVC Coeff SE p-value Coeff SE p-value 
Intercept -41.67 15.53 0.007 0.13 15.39 0.993 
Age/10 9.65 3.59 0.007 0.01 3.55 0.998 
(Age/10)2 -0.55 0.21 0.008 0.01 0.20 0.972 
Smoking Status   0.001   <0.001 
Never 0 (Ref) 
  
0 (Ref)   
Former  -0.04 0.01 0.008 -0.05 0.01 <0.001 
Current -0.12 0.04 0.002 -0.04 0.02 0.096 
Education   0.887   0.097 
0 - 9 Years 0 (Ref)   0 (Ref)   
10 - 11 Years 0.01 0.02 0.633 -0.01 0.01 0.250 
12+ Years 0.00 0.02 0.811 0.03 0.02 0.133 
       
Occupational Exposure 0.00 0.01 0.858 0.00 0.01 0.728 
       
Physical Activity   0.373   0.498 
High 0 (Ref)   0 (Ref)   
Medium 0.01 0.01 0.624 -0.01 0.01 0.294 
Low -0.01 0.01 0.368 -0.01 0.01 0.282 
BMI   0.086   0.048 
Normal (18.5 - 25) 0 (Ref)   0 (Ref)   
Underweight (<18.5) -0.02 0.02 0.454 -0.02 0.01 0.232 
Overweight (25 - 30) 0.02 0.01 0.066 0.02 0.01 0.028 
Obese  (30+) 0.04 0.02 0.035 0.02 0.02 0.145 
Respiratory Disease -0.05 0.01 <0.001 -0.02 0.01 0.045 
Disease Count  0.01 0.01 0.008 0.00 0.00 0.507 
       
Categorised MMSE   0.205   0.104 
Normal (26-30) 0 (Ref)   0 (Ref)   
Mild (22-25) 0.01 0.01 0.319 -0.01 0.01 0.253 
Moderate (18-21) -0.01 0.02 0.556 -0.04 0.02 0.054 
Severe (0-17) -0.05 0.03 0.092 -0.05 0.03 0.056 
IL-6*  0.00 0.01 0.950 0.00 0.01 0.787 
TNFα * 0.00 0.00 0.892 0.00 0.00 0.933 
CRP* -0.01 0.00 0.051 0.00 0.00 0.860 
Telomere Length* 0.02 0.02 0.146 0.00 0.02 0.921 
* log-transformed       
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Table 5.15: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of FEV1/FVC adjusted for all covariates by sex, HRG 
HRG Male   Female   
FEV1/FVC Coeff SE p-value Coeff SE p-value 
Intercept -40.80 40.67 0.316 -17.59 26.06 0.500 
Age/10 9.41 9.39 0.316 4.07 6.01 0.499 
(Age/10)2 -0.54 0.54 0.320 -0.23 0.35 0.510 
Smoking Status   0.382   0.001 
Never 0 (Ref) 
  
0 (Ref)   
Former  -0.02 0.03 0.378 -0.07 0.02 0.002 
Current - - - -0.23 0.08 0.003 
Education   0.616   0.868 
0 - 9 Years 0 (Ref)   0 (Ref)   
10 - 11 Years 0.02 0.03 0.537 -0.01 0.03 0.634 
12+ Years 0.03 0.04 0.372 -0.01 0.03 0.723 
       
Occupational Exposure 0.01 0.02 0.578 0.00 0.03 0.963 
       
Physical Activity   0.132   0.216 
High 0 (Ref)   0 (Ref)   
Medium -0.06 0.04 0.113 -0.03 0.02 0.243 
Low 0.02 0.02 0.482 0.01 0.01 0.459 
BMI   0.065   <0.001 
Normal (18.5 - 25) 0 (Ref)   0 (Ref)   
Underweight (<18.5) -0.02 0.03 0.477 -0.05 0.02 0.023 
Overweight (25 - 30) 0.06 0.02 0.016 0.07 0.02 0.001 
Obese  (30+) -0.05 0.06 0.430 -0.02 0.05 0.708 
Respiratory Disease -0.09 0.10 0.371 0.09 0.08 0.264 
Disease Count  0.03 0.01 0.003 0.00 0.01 0.744 
       
Categorised MMSE   0.259   0.003 
Normal (26-30) 0 (Ref)   0 (Ref)   
Mild (22-25) 0.02 0.02 0.329 -0.06 0.02 0.003 
Moderate (18-21) 0.08 0.10 0.448 -0.06 0.04 0.153 
Severe (0-17) -0.12 0.08 0.159 0.10 0.06 0.093 
IL-6*  0.00 0.01 0.711 0.00 0.01 0.685 
TNFα * 0.00 0.01 0.942 0.00 0.01 0.729 
CRP* -0.01 0.01 0.330 0.00 0.01 0.569 
Telomere Length* 0.04 0.04 0.279 0.04 0.03 0.171 
* log-transformed       
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Table 5.16: Association of socio-demographic, socio-economic, health and biomarkers on 
trajectories of FEV1/FVC adjusted for all covariates by sex, survivor group 
Survivor Group Male   Female   
FEV1/FVC Coeff SE p-value Coeff SE p-value 
Intercept -26.23 35.07 0.455 -16.55 24.75 0.504 
Age/10 6.09 8.10 0.452 3.86 5.71 0.499 
(Age/10)2 -0.35 0.47 0.456 -0.22 0.33 0.507 
Smoking Status   0.704   0.026 
Never 0 (Ref) 
  
0 (Ref)   
Former  -0.01 0.02 0.704 -0.07 0.03 0.009 
Current - - - -0.13 0.10 0.188 
Education   0.613   0.883 
0 - 9 Years 0 (Ref)   0 (Ref)   
10 - 11 Years -0.02 0.03 0.340 -0.02 0.03 0.618 
12+ Years 0.01 0.03 0.858 -0.01 0.03 0.867 
       
Occupational Exposure 0.01 0.02 0.648 0.00 0.03 0.938 
       
Physical Activity   0.311   0.316 
High 0 (Ref)   0 (Ref)   
Medium -0.03 0.04 0.387 0.00 0.02 0.956 
Low 0.02 0.02 0.348 0.02 0.01 0.172 
BMI   0.041   <0.001 
Normal (18.5 - 25) 0 (Ref)   0 (Ref)   
Underweight (<18.5) -0.03 0.03 0.373 -0.05 0.02 0.024 
Overweight (25 - 30) 0.05 0.02 0.017 0.06 0.02 0.020 
Obese  (30+) - - - -0.16 0.07 0.016 
Disease Count  0.00 0.01 0.919 0.00 0.01 0.775 
       
Categorised MMSE   0.979   <0.001 
Normal (26-30) 0 (Ref)   0 (Ref)   
Mild (22-25) 0.00 0.02 0.951 -0.07 0.02 0.001 
Moderate (18-21) 0.01 0.08 0.857 -0.06 0.04 0.154 
Severe (0-17) - - - 0.11 0.06 0.048 
IL-6*  0.01 0.01 0.588 0.00 0.01 0.828 
TNFα * 0.00 0.01 0.921 0.00 0.01 0.873 
CRP* 0.00 0.01 0.849 0.00 0.01 0.788 
Telomere Length* 0.03 0.03 0.378 0.03 0.03 0.201 
* log-transformed       
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Figure 5.1: FEV1 trajectory of change adjusted for smoking status, education, occupational 
exposure, respiratory disease, disease count, categorised MMSE, IL-6, TNFα, CRP and 
Telomere length 
 
Figure 5.2: FVC trajectory of change adjusted for smoking status, education, occupational 
exposure, respiratory disease, disease count, categorised MMSE, IL-6, TNFα, CRP and 
Telomere length. 
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Figure 5.3: PEF trajectory of change adjusted for smoking status, education, occupational 
exposure, respiratory disease, disease count, categorised MMSE, IL-6, TNFα, CRP and 
Telomere length. 
 
Figure 5.4: FEV1/FVC trajectory of change adjusted for smoking status, education, 
occupational exposure, respiratory disease, disease count, categorised MMSE, IL-6, TNFα, 
CRP and Telomere length. 
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Figure 5.5: Lung function measurements trajectory of change by sex, survivor group 
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Figure 5.6: Graphs showing effect of IL-6 on lung function measures over time by sex, survivor group 
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Figure 5.7: Graphs showing effect of TNF on lung function measures over time by sex, survivor group 
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Figure 5.8: Graphs showing effect of CRP on lung function measures over time by sex, survivor group
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Chapter 6. Relationship between lung function and disability 
The previous chapter investigated how lung function, its potential confounders and possible 
determinants changed between ages 85 and 88 years in the N85+ study.  This chapter will 
investigate the pathways between lung function and disability exploring potential mediators of 
the relationship. Disability is an important outcome for the very old, being a predictor of 
mortality as well as the need for social care. However, this chapter will not prejudge the causal 
link between lung function and disability but will use path models, a variant of structural 
equation modelling (SEM), to ascertain the direction of the relationship.   
6.1 Aims of the chapter 
Specifically this chapter will:  
1. Describe the disability measures used: 
a. Basic Activities of daily living (BADLs) 
b. Instrumental activities of daily living (IADLs) 
c. Mobility score 
2. Investigate the relationship between FEV1 and disability through SEM by: 
a. Exploring the pathways between FEV1 and each separate disability measures 
b. Exploring the effect of confounders whose effects may be mediated through this 
pathway 
6.2 Background 
Disability is an important indicator for independent living and a predictor of admissions to care 
home, hospitalisation and other health care services (Kingston et al., 2017). Disability is usually 
measured by BADLs (such as feeding oneself, washing face and hands and washing all over) 
and IADLs (e.g. laundry, light and heavy housework (Table 6.1). These have been shown by 
both cross-sectional and longitudinal studies to be lost in a particular order, broadly with IADLs 
first followed by BADLs (Dunlop et al., 1997; Ferrucci et al., 1998; Kingston et al., 2012). If 
both are available, as in the N85+ study, a severity scale for disability can be determined.  
The relationship between disability and cognitive impairment has been extensively researched 
in older people with studies finding a strong association between increased disability and 
decline in cognitive function including studies of the UK populations (N85+ cohort and CFAS) 
(Kingston et al., 2012) (Spiers et al., 2005; Seidel et al., 2009).   
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There have been few studies of the relationship between lung function and disability but all 
have hypothesised that lung function affects functional ability (Lahaije et al., 2010; Kingston et 
al., 2012; van Helvoort et al., 2016; Hegendorfer et al., 2017b). A case-control study of patients 
with early-stage COPD and its constraints on ADLs, found that patients “had greater ventilatory 
inefficiency and higher ventilatory requirements during ADL” and increased Dyspnoea scores 
(van Helvoort et al., 2016).  
In a longitudinal study of the very old, participants with excessive deterioration in their lung 
function (FEV1/height
3) had an increased risk (odds ratio: 2.02, 95% CI: 1.10 – 3.68) of decline 
in functional ability (ADL score) (Hegendorfer et al., 2017a). A further study used gait speed 
rather than self-reported ADL and found that increased pulmonary function predicted lower risk 
of disability, though the ability to predict disability was lost after adjusting for physical activity, 
BMI, vascular risk factors and diseases (Buchman et al., 2009).  
More studies have explored the link between lung function and cognitive function or dementia, 
predominantly, though not exclusively assuming lung function impacts cognitive function. A 
cross-sectional study found that those in the lowest group of lung function performance had 
more dementia compared to those with best lung function (Schaub et al., 2000). Better 
respiratory function has been found to reduce the risk of developing Alzheimer’s disease (Guo 
et al., 2007a), whilst a longitudinal study of African American adults showed that lung function 
was a significant predictor of cognitive status in older adults but not the younger population 
(Allaire et al., 2007). Other studies have reported similar findings (Weuve et al., 2011; Vidal et 
al., 2013). 
Only one previous study has explored the direction of the causal link  between lung function 
(FEV1 and FVC) and cognitive impairment (verbal ability; spatial ability; processing speed; and 
memory) using SEM (Emery et al., 2012), and found that decreases in lung function resulted in 
decline in cognitive functions including spatial performance, processing speeds and verbal 
ability (Emery et al., 2012).   
Despite previous studies, there is a lack of research investigating the direction of the 
relationship between lung function and disability in the very old. Moreover, given the increased 
risk of cognitive impairment in this age group and the known relationship between cognitive 
impairment and both lung function and disability, there is merit in investigating the role of 
cognitive impairment in modifying the lung function/disability relationship. To address this I 
shall use path models (a variant of SEM) to analyse the causal pathways between lung function, 
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cognitive function and disability to discern the direction of the causal pathway and explore 
possible mediators.  
6.3 Analytical methods 
6.3.1 Measures of functional status 
In the N85+ study, a 17 item ADL questionnaire was adapted based on the Groningen Activity 
Restriction Scale to calculate the participants’ disability, scoring 0 for performing each item 
without disability and 1 if there was any difficulty, with a maximum score of 15 (complete 
dependency) (Kempen et al., 1996) (Jagger et al., 2011). For the purposes of this thesis, three 
disability scores were derived from the 17 functional ability items: 8 items of basic activities of 
daily living (BADL), 6 instrumental activities of daily living (IADL) and 3 mobility items 
(Table 6.1) (Jagger et al., 2011). All three measures of functional status were calculated for 
baseline, 18 months, 36 months and 60 months follow-up.         
6.3.2 Statistical analysis  
Univariate regression models were fitted separately with each of the 3 measures of disability 
and FEV1 as dependent variables against these potential variables to explore quantitative 
associations. Models were fitted for baseline values and all 3 follow-up periods (except 60 
months for FEV1). Variables which could be part of the causal pathway were identified from 
the literature search,,results of analyses from previous chapters and the univariate models in 
investigating associations between different time points. Variables  included: sex; smoking 
status (categorised as never, former and current smokers); years of education (categorised as 0-
9 years, 10 – 11 years, 12+ years); BMI (categorised as underweight <18.5, normal 18.5 – 25, 
overweight 25 – 30, obese and morbidly obese 30+); physical activity (categorised as low, 
medium, high); occupational exposure; respiratory conditions; chronic disease count; and 
cognitive impairment. 
Path analysis, a version of SEM, is often used in the analysis of causal pathways where it 
explores the relationship between variables without imposing a direction for the relationship in 
the presence of intervening (mediating or confounding) variables. This analysis would therefore 
allow a life course epidemiological approach in investigating whether lung function had an 
effect on disability or vice versa answering the main research question of this thesis.  
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For path analysis, all possible variables were included in the model for all 4 time points, linking 
the factors to both the disability and FEV1 variables. The disability measure and FEV1 were 
also linked to each other at the subsequent time point (e.g. baseline FEV1 linked to 18 months 
BADL) and vice versa. Once the path diagram was constructed, the models were executed. 
Those factors which were no longer statistically significant were eliminated from the models in 
a stepwise manner to obtain the final model and odds ratios (OR) obtained. Three separate path 
models (diagrams) were constructed, one for each disability measure: BADL, IADL and 
mobility. This modelling method would allow better understanding of how poorer lung function 
could, for example, lead to difficulty for a person to do their shopping (IADL) or how cognitive 
impairment could result in a person’s inability to get dressed (BADL). The Akaike information 
criterion (AIC) and Bayesian information criterion (BIC) were used to assess model fit. All 
analyses were completed using Stata 14.0 (StataCorp; College Station, TX, USA).  
6.4 Results        
6.4.1 Path models  
All the disability scores increased significantly over time, after adjustment for age and sex 
(Table 6.2). At baseline (age 85) higher disability scores were evident for women, participants 
with respiratory disease and those with higher disease count (Table 6.3). Analysis of the impact 
of baseline (age 85) factors on disability scores at age 86.5 found that physical activity, 
respiratory disease, disease count and FEV1 affected all the three disability measures (Table 
6.4). Baseline cognitive impairment had an effect on all disability measures, though there was 
no difference found in mobility for those with mild cognitive impairment (Table 6.4). BMI only 
affected mobility and only for those underweight (β: 0.36, 95% CI: 0.00 – 0.72) and obese (β: 
0.72, 95% CI: 0.37 – 1.06) (Table 6.4).     
At age 86.5 years disability scores, physical activity, BMI, cognitive impairment, disease count 
and FEV1 were all predictive of disability scores at age 88 (Table 6.5). Similar patterns were 
also observed for factors at age 88 affecting disability at age 90 (Table 6.6).  
Once the path models were constructed and analysis performed, odds ratios were obtained for 
factors affecting both FEV1 and disability scores. Exploring the BADL path model at baseline, 
the effect of sex, education, smoking status and respiratory disease were mediated through 
FEV1 (Table 6.7, Figure 6.1). Those who never smoked were more likely to have better lung 
function compared to former smokers (OR: 0.90, 95% CI: 0.85 – 0.97) or current smokers (OR: 
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0.76, 95% CI: 0.66 – 0.88); participants with 0-9 years of education were more likely to have 
poorer lung function than those with 12+ years of education (OR: 1.15, 95% CI: 1.04 – 1.26) 
(Table 6.7, Figure 6.1). Disease count was the only factor which affected BADL directly with 
an increased risk of higher BADL score for each additional disease group diagnosis (OR: 1.37, 
95% CI: 1.25 – 1.50) (Table 6.7, Figure 6.1).  
Physical activity levels measured at baseline were predictive of both FEV1 and BADL score at 
18 months follow-up (Table 6.7, Figure 6.1). For the same time period severe cognitive 
impairment (MMSE<18) increased the risk of disability more than five fold (OR: 5.80, 95% CI: 
2.83 – 11.86) compared to those with normal cognition. Disease count also increased the risk of 
disability (OR: 1.24, 95% CI: 1.11 – 1.38) while increased FEV1 reduced the risk of disability 
(OR: 0.75, 95% CI: 0.60 – 0.95) (Table 6.7, Figure 6.1). BADL score at baseline was predictive 
of FEV1 with increased risk of lower FEV1 with every additional BADL item (OR: 0.96, 95% 
CI: 0.93 – 0.99) that participants had difficulty performing on their own (Table 6.7, Figure 6.1).  
Physical activity at age 86.5 was predictive of both FEV1 and BADL at age 88, whilst 
respiratory disease and BMI predictive of FEV1 only (Table 6.7, Figure 6.1). Higher FEV1 at 
ages 85 and 86.5 was predictive of a reduced risk for BADL both at age 86.5 (OR: 0.69, 95% 
CI: 0.53 – 90) and at age 88 (OR: 0.59, 95% CI: 0.43 – 82) respectively (Table 6.7, Figure 6.1). 
Worsening cognitive function and lower physical activity at age 88 predicted higher risk of 
BADL score at age 90 (Table 6.7, Figure 6.1).  
For IADL, patterns were similar to BADL, whereby FEV1 was predictive of IADL at every age 
but IADL only predicted FEV1 from 85 to 86.5 years (Table 6.8, Figure 6.2).  
Differences were observed in the mobility pathway (Table 6.9, Figure 6.3) compared to the 
BADL (Table 6.7, Figure 6.1) and IADL (Table 6.8, Figure 6.2) pathways. Cognitive 
impairment did not affect the mobility pathway (Table 6.9, Figure 6.3). However, being 
overweight or obese (compared to normal weight) at 85 and 88 years was predictive of higher 
mobility scores at subsequent follow-ups (Table 6.9, Figure 6.3). Increased disease count 
predicted higher mobility score whilst high physical activity predicted lower mobility scores in 
line with previous findings (Table 6.9, Figure 6.3). Better FEV1 at 85 years (OR: 0.75, 95% CI: 
0.64 - 0.89) and 86.5 (OR: 0.77, 95% CI: 0.65 - 0.91) was predictive of reduced risk of mobility 
problems (Table 6.9, Figure 6.3). Between ages 88 and 90, all the effects of FEV1 on mobility 
were mediated through physical activity, BMI and disease count (Table 6.9, Figure 6.3). 
115 
 
6.5 Summary 
This chapter has demonstrated the causal pathways between lung function and different 
measures of disability (BADL, IADL and mobility). The use of path analysis informed by 
univariate models investigating the association of potential confounders and mediators has 
provided novel findings about the disability and lung function causal pathway. The N85+ study 
has provided information that within the complete spirometric cohort, lung function and 
disability have a bidirectional cause and effect pathway and, depending on the type of activities, 
different factors act as mediators. Furthermore it has shown that only long term accumulation of 
disabilities are associated with lung function whereas even a short term decline of lung function 
has an adverse effect on disability. 
The major findings of this analysis were: 
1. Higher FEV1 at each time point was associated with lower BADL and IADL scores at 
subsequent follow-ups. 
2. All three disability measures at baseline (age 85) predicted an increased risk of lower 
FEV1 at age 86.5. 
3. Cognitive impairment significantly affects the BADL and IADL pathways but not 
mobility. 
4. Lower levels of physical activity at ages 85 and 86.5 predicted an increased risk of 
lower FEV1 at subsequent follow-up for all disability pathways. 
5. Higher BMI at age 86.5 was associated with an increased risk of lower FEV1 at age 88 
in all disability pathways. 
This chapter aimed to investigate and address one of the main aims of this thesis by 
investigating the relationship between lung function and disability. The next and final chapter 
discusses each of the sub-studies reported in Chapters 3-6 in relation to other literature and 
details the contribution of the work as a whole.  
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Table 6.1: Activities of Daily Living items in the Newcastle 85+ Study 
Activities of Daily Living (Newcastle 85+ Study) 
Basic Activities of Daily 
Living (BADL) 
Instrumental Activities of 
Daily Living (IADL) Mobility 
feeding self - including 
cutting up of food light housework getting around the house 
washing face and hands heavy housework 
going up and down 
stairs/steps 
washing all over 
preparing and cooking a hot 
meal walking at least 400 yards 
getting in and out of bed shopping for groceries  
getting on and off the toilet taking medication  
getting in and out of a chair managing money  
dressing and undressing   
cutting own toenails   
   
 
Table 6.2: Disability category scores over time, by sex 
 
Men Women All P-value* 
BADL Score 
    
85 Years 1.2 (1.5) 1.5 (1.6) 1.4 (1.6) 
<0.001 
86.5 Years 1.7 (1.7) 2.1 (1.8) 1.9 (1.8) 
88 Years  1.9 (1.9) 2.4 (1.8) 2.2 (1.8) 
90 Years  1.9 (1.9) 2.5 (1.8) 2.3 (1.9) 
IADL Score 
   
 
85 Years 1.2 (1.8) 1.8 (1.8) 1.6 (1.8) 
<0.001 
86.5 Years 1.8 (2.0) 2.7 (1.9) 2.3 (2.0) 
88 Years  2.4 (2.2) 2.9 (1.9) 2.7 (2.0) 
90 Years  2.3 (2.2) 3.0 (2.0) 2.8 (2.1) 
Mobility Score 
   
 
85 Years 0.9 (1.1) 1.2 (1.2) 1.1 (1.16) 
<0.001 
86.5 Years 1.2 (1.1) 1.6 (1.2) 1.4 (1.2) 
88 Years  1.5 (1.2) 1.8 (1.1) 1.7 (1.1) 
90 Years  1.5 (1.3) 1.8 (1.2) 1.7 (1.2) 
* trend over time adjusted for age and sex 
BADL: Basic activities of daily living 
IADL: Instrumental activities of daily living 
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Table 6.3: Univariate analysis of Disability outcomes at 85 years against sociodemographic, lifestyle and health characteristics in early life 
 
Age 85 - BADL Age 85 - IADL Age 85 - Mobility 
 
β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value 
Earlier Life 
      
Sex 0.28 (0.05 - 0.51) 0.015 0.65 (0.38 - 0.92) <0.001 0.30 (0.13 - 0.47) 0.001 
Smoking Status 
 
0.225 
 
0.067 
 
0.921 
Never 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Former   -0.13 (-0.37 - 0.11) 0.295  -0.17 (-0.46 - 0.11) 0.231 0.02 (-0.16 - 0.20) 0.812 
Current 0.25 (-0.25 - 0.76) 0.322 0.47 (-0.13 - 1.06) 0.124 0.07 (-0.30 - 0.45) 0.701 
Education 
 
0.666 
 
0.051 
 
0.666 
0 - 9 Years 1 (Ref) - 1 (Ref) - 1 (Ref) - 
10 - 11 Years  -0.11 (-0.38 - 1.65) 0.443  -0.17 (-0.49 - 0.15) 0.287  -0.13 (-0.33 - 0.08) 0.221 
12+ Years  -0.11 (-0.45 - 0.24) 0.534  -0.49 (-0.90 - -0.08) 0.018  -0.39 (-0.65 - -0.13) 0.003 
       
Occupational Exposure 0.12 (-0.12 - 0.36) 0.342  -0.10 (-0.39 - 0.18) 0.471 0.00(-0.17 - 0.18) 0.967 
Respiratory Disease 0.33 (0.08 - 0.59) 0.012 0.31(0.22 - 0.41) <0.001 0.39 (0.08 - 0.69) 0.014 
Disease Count 0.41 (0.30 - 0.52) <0.001 0.42 (0.22 - 0.61) <0.001 0.26 (0.19 - 0.33) <0.001 
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Table 6.4: Univariate analysis of Disability outcomes at 86.5 years against lifestyle and health characteristics in between ages 85 and 86.5 
 
Age 86.5 - BADL Age 86.5 - IADL Age 86.5 - Mobility 
Aged 85 years old β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value 
Physical Activity  <0.001  <0.001  <0.001 
High 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Low 2.14 (2.14 - 2.93) <0.001 3.27 (2.84 - 3.71) <0.001 1.61 (1.33 - 1.88) <0.001 
Medium 1.23 (0.97 - 1.49) <0.001 1.56 (1.27 - 1.85) <0.001 0.87 (0.69 - 1.06) <0.001 
       
BMI  0.067  0.069  <0.001 
Normal (18.5 - 25) 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Underweight (<18.5) -0.00 (-0.59 - 0.58) 0.989  0.51 (-0.18 - 1.20) 0.149  0.26 (-0.16 - 0.68) 0.217 
Overweight  (25 - 30) 0.20 (-0.11 - 0.50) 0.202 0.14 (-0.22 - 0.49) 0.452 0.34 (0.12 - 0.55) 0.002 
Obese (30+) 0.63 (0.15 - 1.11) 0.011 0.70 (0.13 - 1.27) 0.017 0.72 (0.37 - 1.06) <0.001 
       
Respiratory Disease 0.36 (0.03 - 0.69) 0.031 0.53 (0.15 - 0.90) 0.006 0.38 (0.16 - 0.61) 0.001 
Disease Count 0.40 (0.28 - 0.51) <0.001 0.39 (0.26 - 0.53) <0.001 0.29 (0.21 - 0.37) <0.001 
       
Categorised MMSE  <0.001  <0.001  <0.001 
Normal (26-30) 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Mild (22-25) 0.50 (0.10 - 0.91) 0.014 1.08 (0.64 - 1.52) <0.001 0.15 (-0.14 - 0.43) 0.315 
Moderate  (18-21) 1.08 (0.40 - 1.76) 0.002 2.66 (1.92 - 3.40) <0.001 0.61 (0.12 - 1.09) 0.014 
Severe  (0-17) 3.34 (2.37 - 4.31) <0.001 4.09 (3.04 - 5.15) <0.001 1.15 (0.46 - 1.84) 0.001 
FEV1  -0.66 (-0.92 - -0.40) <0.001  -1.00 (-1.29 - -0.70) <0.001  -0.51(-0.69 - -0.33) <0.001 
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Table 6.5: Univariate analysis of Disability outcomes at age 88 against lifestyle and health characteristics between ages 86.5 and 88 
 
Age 88 - BADL Age 88 - IADL Age 88 - Mobility 
Aged 86.5 years β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value 
Physical Activity 
 
<0.001 
 
<0.001 
 
<0.001 
High 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Low 2.91(2.53 - 3.30) <0.001 3.27(2.82 - 3.71) <0.001 1.72 (1.47 - 1.98) <0.001 
Medium 0.96 (0.66 - 1.26) <0.001 1.59 (1.24 - 1.93) <0.001 0.97 (0.77 - 1.17) <0.001 
 
      
BMI 
 
<0.001 
 
0.009 
 
0.001 
Normal (18.5 - 25) 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Underweight (<18.5)  0.40 (-0.12 - 0.93) 0.134  0.93 (0.30 - 1.56) 0.004  0.36 (0.00 - 0.72) 0.048 
Overweight (25 - 30) 0.35 (-0.00 - 0.70) 0.053 0.08 (-0.34 - 0.50) 0.711 0.12 (-0.12 - 0.36) 0.317 
Obese (30+) 1.33 (0.74 - 1.92) <0.001 0.74 (0.04 - 1.45) 0.039 0.77 (0.37 - 1.18) <0.001 
 
      
Respiratory Disease 0.17 (-0.55 - 0.55) 0.381 0.17 (-0.26 - 0.60) 0.436 0.19 (-0.05 - 0.43) 0.123 
Disease Group 0.46 (0.32 - 0.59) <0.001 0.52 (0.36 - 0.67) <0.001 0.28 (0.19 - 0.37) <0.001 
 
      
Categorised MMSE 
 
<0.001 
 
<0.001 
 
0.027 
Normal (26-30) 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Mild (22-25) 0.73 (0.26 - 1.19) 0.002 1.52 (1.01 - 2.03) <0.001 0.28 (-0.03 - 0.58) 0.073 
Moderate (18-21) 1.57 (0.66 - 2.49) 0.001 2.79 (1.79 - 3.80) <0.001 0.57 (-0.03 - 1.17) 0.063 
Severe (0-17) 3.57 (1.19 - 5.96) 0.003 3.65 (1.04 - 6.26) 0.006 1.43 (-0.14 - 2.99) 0.074 
       
FEV1  -0.84 (-1.15 - -0.54) <0.001  -1.04 (-1.38 - -0.69) <0.001  -0.58 (-0.77 - -0.39) <0.001 
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Table 6.6: Univariate analysis of Disability outcomes at age 90 against lifestyle and health characteristics between ages 88 and 90 
 
Age 90 - BADL Age 90 - IADL Age 90 - Mobility 
Aged 88 years β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value 
Physical Activity 
 
<0.001 
 
<0.001 
 
<0.001 
High 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Low 2.55 (2.06 - 3.03) <0.001 2.89 (2.34 - 3.44) <0.001 1.67 (1.35 - 1.99) <0.001 
Medium 0.92 (0.50 - 1.34) <0.001 1.30 (0.82 - 1.78) <0.001 0.81 (0.53 - 1.09) <0.001 
 
      
BMI 
 
<0.001 
 
<0.001 
 
0.007 
Normal (18.5 - 25) 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Underweight (<18.5)  0.54 (-0.09 - 1.17) 0.091  0.84 (0.10 - 1.58) 0.026  0.35 (-0.09 - 0.79) 0.120 
Overweight (25 - 30) 0.02 (-0.41 - 0.45) 0.925  -0.15 (-0.65 - 0.36) 0.570  -0.03 (-0.34 - 0.27) 0.834 
Obese (30+) 1.91 (1.14 - 2.68) <0.001 1.60 (0.70 - 2.51) 0.001 0.85 (0.31 - 1.39) 0.002 
 
      
Respiratory Disease  -0.02 (-0.49 - 0.44) 0.922 0.08 (-0.45 - 0.61) 0.764 0.06 (-0.24 - 0.37) 0.688 
Disease Group 0.47 (0.31 - 0.62) <0.001 0.51 (0.33 - 0.69) <0.001 0.26 (0.15 - 0.37) <0.001 
 
      
Categorised MMSE 
 
<0.001 
 
<0.001 
 
0.018 
Normal (26-30) 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Mild (22-25) 0.02 (-0.49 - 0.54) 0.926 1.13 (0.55 - 1.70) <0.001 0.08 (-0.28 - 0.45) 0.652 
Moderate (18-21) 1.55 (0.81 - 2.29) <0.001 2.48 (1.56 - 3.19) <0.001 0.59 (0.06 - 1.11) 0.028 
Severe (0-17) 3.63 (2.44 - 4.82) <0.001 3.79 (2.47 - 5.10) <0.001 1.03 (0.19 - 1.87) 0.016 
       
FEV1  -0.78 (-1.17 - -0.39) <0.001  -1.08 (-1.51 - -0.64) <0.001  -0.46 (-0.72 - -0.20) <0.001 
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Table 6.7: Path analysis of BADL score and FEV1 from ages 85 to 90 
 FEV1 BADL Score 
Earlier Life on age 85 OR (95% CI) P-Value OR (95% CI) P-Value 
Sex      
Female 0.56 (0.52 - 0.59) <0.001   
Education     
0 - 9 Years 1 (Ref)   
10 - 11 Years 1.02 (0.95 - 1.10) 0.568   
12+ Years 1.15 (1.04 - 1.26) 0.006   
Smoking Status     
Never 1 (Ref)   
Former Smoker 0.90 (0.85 - 0.97) 0.004   
Current Smoker 0.76 (0.66 - 0.88) <0.001   
Respiratory Disease 0.77 (0.71 - 0.83) <0.001   
GP Disease Count - - 1.37 (1.25 - 1.50) <0.001 
     
Age 85 on age 86.5     
FEV1   0.75 (0.60 - 0.95) <0.001 
BADL Score 0.96 (0.93 - 0.99) 0.005 - - 
Physical Activity     
High 1 (Ref) 1 (Ref) 
Medium  0.72 (0.65 - 0.87) <0.001 2.74 (2.10 - 3.58) <0.001 
Low 0.75 (0.65 - 0.78) <0.001 9.13 (6.13 - 13.59) <0.001 
MMSE Score     
Normal (26-30)   1 (Ref) 
Mild (22-25)   1.40 (0.99 - 1.98) 0.061 
Moderate (18-21)   1.28 (0.72 - 2.29) 0.403 
Severe (0-17)   5.80 (2.83 - 11.86) <0.001 
GP Disease Count   1.24 (1.11 - 1.38) <0.001 
Respiratory Disease 0.77 (0.70 - 0.85) <0.001 - - 
     
Age 86.5 on age 88     
FEV1   0.69 (0.53 - 0.90) 0.006 
Physical Activity     
High  1 (Ref) 1 (Ref) 
Medium 0.77 (0.69 - 0.86) <0.001 2.21 (1.63 - 3.00) <0.001 
Low 0.74 (0.63 - 0.86) <0.001 12.51 (8.27 - 18.90) <0.001 
GP Disease Count   1.26 (1.12 - 1.42) <0.001 
Respiratory Disease 0.76 (0.68 - 0.85) <0.001 - - 
BMI   - - 
Underweight (<18.5) 0.82 (0.70 - 0.97) 0.022   
Normal (18.5 - 25) 1 (Ref)   
Overweight (25 - 30) 1.05 (0.95 - 1.17) 0.324   
Obese (30+) 1.20 (1.00 - 1.43) 0.053   
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Age 88 on age 90     
FEV1   0.59 (0.43 - 0.82) 0.002 
Physical Activity     
High   1 (Ref) 
Medium   1.87 (1.25 - 2.80) 0.002 
Low   6.98 (4.32 - 11.27) <0.001 
MMSE Score     
Normal (26-30)   1 (Ref) 
Mild  (22-25)   0.71 (0.46 - 1.10) 0.128 
Moderate  (18-21)   2.02 (1.06 - 3.83) 0.032 
Severe  (0-17)   11.79 (4.24 - 32.81) <0.001 
GP Disease Count   1.31 (1.14 - 1.51) <0.001 
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Table 6.8: Path analysis of IADL score and FEV1 from ages 85 to 90 
 FEV1 IADL Score 
Earlier Life on age 85 OR (95% CI) P-Value OR (95% CI) P-Value 
Sex      
Female 0.56 (0.52 - 0.59) <0.001   
Education     
0 - 9 Years 1 (Ref)   
10 - 11 Years 1.02 (0.95 - 1.10) 0.568   
12+ Years 1.15 (1.04 - 1.26) 0.006   
Smoking Status     
Never 1 (Ref)   
Former Smoker 0.90 (0.85 - 0.97) 0.004   
Current Smoker 0.76 (0.66 - 0.88) <0.001   
Respiratory Disease 0.77 (0.71 - 0.83) <0.001   
GP Disease Count - - 1.51  (1.35 - 1.68) <0.001 
     
Age 85 on age 86.5     
FEV1   0.66 (0.52 - 0.84) <0.001 
IADL Score 0.92 (0.89 - 0.95) <0.001 - - 
Physical Activity     
High 1 (Ref) 1 (Ref) 
Medium  0.76 (0.69 - 0.83) <0.001 3.59 (2.72 - 4.75) <0.001 
Low 0.90 (0.77 - 1.06) 0.200 15.30 (10.11 - 23.17) <0.001 
MMSE Score     
Normal (26-30)   1 (Ref) 
Mild  (22-25)   2.21 (1.53 - 3.18) <0.001 
Moderate  (18-21)   4.74 (2.59 - 8.69) <0.001 
Severe  (0-17)   9.07 (4.30 - 19.12) <0.001 
GP Disease Count   1.16 (1.04 - 1.29) 0.009 
Respiratory Disease 0.78 (0.71 - 0.85) <0.001 - - 
     
Age 86.5 on age 88     
FEV1   0.64 (0.47 - 0.86) 0.003 
Physical Activity     
High  1 (Ref) 1 (Ref) 
Medium 0.77 (0.69 - 0.86) <0.001 4.02 (2.84 - 5.69) <0.001 
Low 0.74 (0.63 - 0.86) <0.001 16.48 (10.30 - 26.35) <0.001 
GP Disease Count   1.32 (1.15 - 1.51) <0.001 
Respiratory Disease 0.76 (0.68 - 0.85) <0.001 - - 
BMI   - - 
Underweight (<18.5) 0.82 (0.70 - 0.97) 0.022   
Normal (18.5 - 25) 1 (Ref)   
Overweight (25 - 30) 1.05 (0.95 - 1.17) 0.324   
Obese (30+) 1.20 (1.00 - 1.43) 0.053   
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Age 88 on age 90     
FEV1   0.46 (0.32 - 0.67) <0.001 
Physical Activity     
High   1 (Ref) 
Medium   2.32 (1.47 - 3.64) <0.001 
Low   7.47 (4.36 - 12.78) <0.001 
MMSE Score     
Normal (26-30)   1 (Ref) 
Mild  (22-25)   2.13 (1.30 - 3.49) 0.003 
Moderate  (18-21)   4.40 (2.15 - 9.03) <0.001 
Severe  (0-17)   14.16 (4.49 - 44.63) <0.001 
GP Disease Count   1.29 (1.10 - 1.51) 0.001 
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Table 6.9: Path analysis of Mobility score and FEV1 from ages 85 to 90 
 FEV1 Mobility Score 
Earlier life on age 85  OR (95% CI) P-Value OR (95% CI) P-Value 
Sex      
Female 0.56 (0.52 - 0.59) <0.001   
Education     
0 - 9 Years 1 (Ref)   
10 - 11 Years 1.02 (0.95 - 1.10) 0.568   
12+ Years 1.15 (1.04 - 1.26) 0.006   
Smoking Status     
Never 1 (Ref)   
Former Smoker 0.90 (0.85 - 0.97) 0.004   
Current Smoker 0.76 (0.66 - 0.88) <0.001   
Respiratory Disease 0.77 (0.71 - 0.83) <0.001   
GP Disease Count - - 1.529 (1.21 - 1.39) <0.001 
     
Age 85 on age 86.5     
FEV1   0.75 (0.64 - 0.89) 0.001 
Mobility Score 0.94 (0.90 - 0.98) 0.005 - - 
Physical Activity     
High 1 (Ref) 1 (Ref) 
Medium  0.72 (0.66 - 0.79) <0.001 2.02 (1.68 - 2.43) <0.001 
Low 0.76 (0.66 - 0.88) <0.001 3.52 (2.66 - 4.66) <0.001 
BMI     
Underweight (<18.5)   1.19 (0.83 - 1.69) 0.343 
Normal (18.5 - 25)   1 (Ref) 
Overweight (25 - 30)   1.41 (1.78 - 1.69) <0.001 
Obese (30+)   1.60 (1.20 - 2.13) 0.001 
GP Disease Count   1.19 (1.11 - 1.28) <0.001 
Respiratory Disease 0.78 (0.71 - 0.86) <0.001 - - 
     
Age 86.5 on age 88     
FEV1   0.77 (0.65 - 0.91) 0.003 
Physical Activity     
High  1 (Ref) 1 (Ref) 
Medium 0.77 (0.69 - 0.86) <0.001 2.35 (1.92 - 2.86) <0.001 
Low 0.74 (0.63 - 0.86) <0.001 4.28 (3.27 - 5.61) <0.001 
GP Disease Count   1.17 (1.08 - 1.27) <0.001 
Respiratory Disease 0.76 (0.68 - 0.85) <0.001 - - 
BMI   - - 
Underweight (<18.5) 0.82 (0.70 - 0.97) 0.022   
Normal (18.5 - 25) 1 (Ref)   
Overweight (25 - 30) 1.05 (0.95 - 1.17) 0.324   
Obese (30+) 1.20 (1.00 - 1.43) 0.053   
     
126 
 
Age 88 on age 90     
FEV1     
Physical Activity     
High   1 (Ref) 
Medium   1.88 (1.40 - 2.52) <0.001 
Low   3.96 (2.77 - 5.65) <0.001 
BMI     
Underweight (<18.5)   1.24  (0.84 - 1.83) 0.288 
Normal (18.5 - 25)   1 (Ref) 
Overweight (25 - 30)   1.01 (0.77 - 1.31) 0.969 
Obese (30+)   1.66 (1.03 - 2.67) 0.036 
GP Disease Count   1.14 (1.03 - 1.27) 0.016 
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Figure 6.1: Path diagram showing the direct and indirect predictors of Basic Activities of Daily 
Living (BADLs) score and FEV1 from age 85 to 90
Phase 1 - FEV1
1.9
ε1 .19
12+ Years Education
multinomial
logit
GP Disease Count
Phase 2 - FEV1
1.8
ε2 .23
Phase 3 - FEV1
1.7
ε3 .23
Medium Physical Activity
multinomial
logit
1.3
Low Physical Activity
multinomial
logit
Respiratory Disease 10 - 11 Years Education
multinomial
logit
Phase 2 - ADL Score
.94
ε4 2
Underweight (BMI<18.5)
multinomial
logit
Phase 1 - ADL Score
.74
ε5 2.3
Low Physical Activity
multinomial
logit
.37
Former Smoker
multinomial
logit
Current Smoker
multinomial
logit
GP Disease Count
Respiratory Disease
Respiratory Disease
Medium Physical Activity
multinomial
logit
1.7
MMSE Score 22 - 25
multinomial
logit
-1.4
Medium Physical Activity
multinomial
logit
MMSE Score <18
multinomial
logit
Overweight (BMI 25 - 30)
multinomial
logit
Female
Low Physical Activity
multinomial
logit
.84
MMSE Score 18 - 21
multinomial
logit
-1.2
MMSE Score <18
multinomial
logit
-.94
Obese (BMI > 30)
multinomial
logit
MMSE Score 18 - 21
multinomial
logit
MMSE Score 22 - 25
multinomial
logit
GP Disease Count
GP Disease Count
Phase 3 - ADL Score
1.3
ε6 2
Phase 4 - ADL Score
1.4
ε7 2
.14
-.26
.022
-.1 -.27
-.59
-.28
-.045
-.26
-.34
-.26
-.2
-.24
.053
-.31
.18
-.93 .55-.26
2.3
.22
1
.48
-.72
-.16
.31
-1.1
1.2
-.93
.55
.027
-1.5 .88
-.71
-1.1
-.37.79
2.5
.24
.25
-.48
2 .65
-.38
.59
2.4
128 
 
 
Figure 6.2: Path diagram showing the direct and indirect predictors of Instrumental Activities 
of Daily Living (IADLs) score and FEV1 from age 85 to 90
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Figure 6.3: Path diagram showing the direct and indirect predictors of Mobility score and 
FEV1 from age 85 to 90 
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Chapter 7. Discussion 
This section aims to provide an overarching response to the research questions posed at the 
conception of this thesis.  
7.1 Summary of main findings 
This thesis was driven by the inadequate research conducted on lung function, its impact and 
implications in the very old. The data from the Newcastle 85+ (N85+) study, a longitudinal 
cohort study of 85 year olds, provided the means to address the research aim and objectives of 
this thesis. Lung function measured at age 85 provided the answer to the question, ‘Are lung 
function prediction methods applicable and appropriate at this advanced age?’ Adequate 
spirometry data was available for 87.3% (737/845) of the N85+ cohort, demonstrating that lung 
function tests can be performed by this age group.  From the spirometry data, participants were 
assigned obstructive lung status using the standard criteria of GOLD (Wen and He, 2012) and 
GLI (Quanjer et al., 2012)  in addition to their GP diagnosed COPD, and comparison of all 
three methods revealed  an over diagnosis of COPD from GP records compared to GOLD and 
GLI. Furthermore, GOLD overestimated obstructive spirometry when compared to GLI 
prediction in the N85+ cohort.   
Spirometry was also measured at 18 months and 36 months follow-up in addition to the 
available death data (median survival 5.4 years). Investigating the observed lung function 
measures (FEV1, FVC and PEF) along with GLI and GOLD predicted (percent predicted FEV1 
and FVC) values both in the whole spirometry cohort and a healthy reference group (HRG) 
with no respiratory related symptoms, disease or conditions, generated interesting results. The 
observed measures all predicted survival in women in the overall spirometry cohort, but not in 
men. Furthermore, none of the lung function measures observed or otherwise, predicted 
survival in either men or women of the HRG. 
Examination of lung function trajectories between ages 85 and 88 years found that men’s lung 
function declined significantly (though non-linearly) whilst there was no significant change 
over time for women. Smoking and cognitive impairment were associated with worsening 
FEV1 in both men and women of the whole spirometry cohort, with cognitive impairment also 
being associated with worsening FEV1 in the survivor group. Body mass index (BMI) and 
physical activity had the strongest association with lung function in women. With regard to 
131 
 
biomarkers of ageing, higher CRP was associated with lower FEV1, FVC and PEF in men of 
the whole spirometry cohort.  
These findings contributed to the final research question examining the direction of the 
relationship between lung function and disability, using three disability measures that 
differentiate severity:  basic activities of daily living (BADL); instrumental activities of daily 
living (IADL) and mobility. Higher levels of FEV1 were found to predict better BADL and 
IADL scores at later follow-ups, but, additionally, all three measures of disability at baseline 
(age 85) predicted an increased risk of lower FEV1. Thus, the relationship between FEV1 and 
disability is bidirectional. Cognitive impairment mediated the FEV1- BADL and FEV1- IADL 
pathways but not the FEV1-mobility pathway.      
7.2 Lung function at age 85 
The objective in this section of the study was to assess the respiratory symptoms, disease 
prevalence and objective measures of lung function of the very old for the first time using a 
single year birth cohort of 85 year olds in the UK, the N85+ study data. The study population 
had success in challenging the misconception that the very old cannot perform spirometry 
successfully with 93% undertaking the test with a 93% success rate (Fisher et al., 2016).  
There is an increased risk of respiratory impairment associated with age due to the 
accumulation of environmental insults experienced over the life course such as air pollution, 
occupational dusts, smoking and infections (Vaz Fragoso and Lee, 2012). This risk is 
compounded further by the changes in lung function as part of normal ageing including 
reduction in muscle strength, ventilatory control, movement of chest wall and increased 
compliance (Vignola et al., 2003) and it is therefore anticipated that symptoms of wheeze, 
cough and dyspnoea will be common amongst older people. However, it was discovered that 
despite the high prevalence of chronic lung disease and respiratory symptoms in this cohort, 
significant proportions of men (50%) and women (40%) reported no limitations due to 
breathlessness (MRC dyspnoea score of 1) which suggested that they were either able to 
function very well or had a poor perception of symptoms. 
The participants of this study have survived significant historical events, born not long after 
WW1 and the 1918 Spanish Flu pandemic. This was a time of high depravation levels with 
unemployment having reached 17% in 1921. They lived through WW2 and witnessed the 
introduction of legislation aimed to improve living standards such that of the Housing Act 
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(1930) and the Clean Air Act (1956). Most of these participants were close to retirement before 
the 1986 WHO: Ottawa Charter for Health Promotion and as already observed quite a high 
proportion of this population were smokers, especially men. The experience of such major 
events by the N85+ cohort led to plausible findings such as the high prevalence of physician-
diagnosed COPD (16.7%) compared to the national average of 10% in 65-74 year olds based on 
self-reported COPD in the 2010 Health Survey for England (Miller and Levy, 2015).  
Further investigation of the subgroup with physician-diagnosed COPD revealed that just under 
25% of this group showed no sign obstructive spirometry, with a significant proportion 
exhibiting no evidence of smoking or occupational history with minimal symptoms (Fisher et 
al., 2016). Such findings suggested potential COPD misdiagnosis in this age group, confirming 
the findings from a community Respiratory Assessment unit (Roberts et al., 2015). This led to 
the examination of the GOLD/NICE guidelines (Vestbo et al., 2012) and the GLI prediction 
models and lower limits of normal (LLN) (Quanjer et al., 2012) methodology in the whole 
cohort and the HRG (n=151) and the physician diagnosed COPD (n=123) subgroups. In the 
COPD subgroup, just over 75% presented with obstructive spirometry when using GOLD 
criteria and about half using the GLI prediction and LLN criteria. The highest level of 
agreement was between the physician diagnosed COPD and GLI obstructive classification 
(Kappa = excellent,  75.9%), perhaps in part because the GLI coefficients were derived to 
include people up to age of 95 whereas the ERS 1993 (Quanjer et al., 1993) coefficients used 
by the GOLD criteria were derived for a population up to the age of 69. COPD diagnosis by a 
physician may be more useful as they have access to more information about a patient’s health 
than the few indicators GLI and GOLD methods rely on.  
A review of people aged 40 and over in England and Wales found evidence of over diagnosis of 
COPD by up to 13% when using GOLD instead of LLN methodology (Miller and Levy, 2015). 
Interestingly, in the N85+ study, a higher proportion of the HRG fulfilled spirometry criteria for 
COPD using current GOLD/NICE guidelines, whilst the use of GLI prediction models and LLN 
methodology of identifying airflow obstruction may reduce chances of misdiagnosis. The 
results from this study gives further evidence that the use of current NICE guidelines may no 
longer be adequate and the more recent GLI prediction formulae and LLN definition should be 
adapted through a more unified process, especially in this age group to increase accuracy of 
COPD diagnosis. 
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7.3 Lung function as a predictor of mortality in the very old 
It has previously been established that lung function is a predictor of mortality at a younger 
ages on its own (Sabia et al., 2010) or mediated through respiratory disease (Romme et al., 
2013) (Ranieri et al., 2001; Gudmundsson et al., 2006; van den Borst et al., 2012; Ajmera et 
al., 2013). Vital capacity (VC) and mortality was explored in a Finnish cohort (n=388) of 75 
year olds revealing an increased risk of mortality for the middle VC tertile (compared to 
highest) of 49% in men and 25% in women, and an even higher risk for those in the lowest VC 
tertile (compared to the highest) of 52% in men and 49% in women (Lyyra et al., 2005).  
An investigation of lung function equations and their suitability in an older cohort explored the 
relationship between observed and predicted values mortality using the Danish 1905 cohort 
(Miller et al., 2014). Lung function was found to inversely predict mortality using either 
standardised residual values using all prediction formulae and as a proportion of height 
(FEV1/height
2 and FEV1/height
3) after controlling for sex, MMSE and grip strength (Miller et 
al., 2014). The effect of FEV1/height
3 as a predictor was further explored in a cohort of 80 years 
and older adults in Belgium. It was found that those in the lowest quartile had increased risk of 
all-cause mortality (HR: 1.69, 95% CI: 1.10 – 2.60) after adjusting for age, sex, smoking status, 
co-morbidities, anaemia, CRP and creatinine levels (Turkeshi et al., 2015). These results were 
similar to the N85+ study though only for women and not in men.  
The aforementioned studies of lung function and mortality all showed lung function to be 
predictive of mortality in the very old, however they all employed different confounding factors 
hindering comparisons. The Finnish cohort were aged 10 years younger in comparison to the 
N85+ cohort and only adjusted for the number of fatal diseases and cognitive capacity (Lyyra et 
al., 2005). The Danish 1905 cohort, similar to the N85+ study, found  the GLI predicted values 
to be a predictor of mortality (Miller et al., 2014).  
The Whitehall II study investigated the link between FEV1 and mortality in a population of civil 
servants aged 35 – 55 years old  and found that people in the lowest tertile of FEV1/height2 had 
an increased risk of mortality (HR: 1.52, 95% CI: 1.05 – 2.19) compared to rest of the study 
population (Sabia et al., 2010). Although Whitehall II was a study of a younger age group, it 
had a more complete set of confounders, and it therefore formed the model analysis for the 
N85+ study in order to examine whether the Whitehall II study findings held true for very old 
age. The two differences between the methodological approaches was that in the N85+ analyses 
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lung function measures were updated at each follow-up  prior to death, and secondly,  observed 
values were used as continuous measures rather than tertiles.  
The major difference in findings between the N85+ study and Whitehall II was that FEV1 was 
only predictive of mortality in women in the former compared to the latter after adjusting for all 
potential factors which may have acted as confounders or mediators (Sabia et al., 2010).  A 
major advantage of the N85+  study was the ability to update measurements during the follow-
up period,  in comparison to Whitehall II where they only used baseline measures (Sabia et al., 
2010).  Indeed all other very old cohorts, as Whitehall II, adjusted for sex rather than analysing 
men and women separately as the N85+ study. Thus, the N85+ study has added to the 
knowledge base in finding that lung function was only predictive of survival in very old 
women. Analysing  men and women separately was considered a better approach as it has 
already been established, especially in this cohort, that lung function is significantly different 
between the sexes at baseline (Fisher et al., 2016) and mortality rates are known to be higher in 
men than women, even at very old ages (Miller et al., 2014). However, despite the smaller 
number of men than women in the N85+ cohort, and therefore wider confidence intervals 
around the hazard ratios for mortality, the same effects were observed in the HRG men but not 
women. This is indicative of existing diseases diluting the effect of mortality as higher 
proportion of women had a respiratory diseases diagnosis and higher disease count in general.  
7.4 Trajectories of lung function from age 85 
Exploring lung function changes over time in the very old and its potential predictors could lead 
to better understanding of early indicators of respiratory decline at this age, and, as previously 
mentioned, possibly reduction of the risk of mortality in women. As previously demonstrated, 
studies of lung function and its predictors have been scarce in the very old. The use of potential 
predictors was informed from similar studies of all older people (aged 65 years and over) in 
addition to the findings from previous chapters of this thesis.  
It is interesting to note that even at age 85,  new lung disease was diagnosed, with  13 new 
physician diagnosis between ages 85 and 86.5 and  with COPD accounting for just over a third 
(5/13). Between ages 86.5 and 88 years, a further 11 physician diagnoses were made of which 
64% were COPD. However, in the healthy group who had no respiratory symptoms, disease or 
related conditions at age 85, there was only three new diagnoses over the 36 months follow-up 
with no cases of COPD (1 bronchiectasis and 1 pulmonary fibrosis).  
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Lung function measures included FEV1, FVC and PEF with the addition of FEV1/FVC to 
investigate changes in lung physiology. Multilevel modelling was employed to account for the 
multiple measures over time and men and women were analysed separately as previously since 
they had significantly different lung function at baseline. Separate analyses for HRG and 
survivor groups (those who were present at all three time points) allowed the examination of a 
survivor effect and the strength of association between certain predictors if they were 
significant in the overall population and these subgroups. The non-linear decline over time 
found for FEV1, PEF and FEV1/FVC  in men overall is indicative of significant change in lung 
physiology at advanced age , although these associations did not hold for the HRG or the 
survivor group, perhaps because of smaller numbers.   
 Lower fat free mass (FFM) and higher sagittal abdominal diameter (SAG) were found to be 
associated with lower lung function (FEV1 and FVC) over a 7 year follow-up of a cohort of old 
adults (mean age of 71) (Rossi et al., 2008). This was confirmed in the N85+ whole spirometry 
cohort,  although with BMI rather than FFM or SAG, and with being underweight associated 
with lower PEF in both men and women, although this only held true in  the whole spirometry 
cohort. Compared to the N85+, Rossi et al followed their participants for 7 years rather than 
five, although they had a total population sample of 77 to this study’s 737 at baseline (Rossi et 
al., 2008).  
Education was used as a proxy for socio-economic status (SES) in the N85+ analyses with 
higher education being associated with higher FEV1 levels in men of both the complete 
spirometry cohort and the HRG. Socio-economic status has also been found to be a predictor of 
better  lung function at 15 years old in both boys and girls (Menezes et al., 2011), suggesting 
that socio-economic status might act on lung function throughout the life course.  
Cognitive impairment was associated with poorer lung function (FEV1, FVC and PEF) in the 
complete spirometry cohort in both men and women, except for FVC in women. This confirms 
other studies that have shown significant association between higher FEV1 levels and better 
cognitive function or lower incidence of Alzheimer’s disease,  (Weuve et al., 2011; Emery et 
al., 2012; Vidal et al., 2013), although all presumed a pathway from lung function to cognitive 
function. These together with the findings in this thesis suggests a possible bidirectional 
relationship between pulmonary and cognitive function. Cognitive impairment may be an early 
sign of a neurodegenerative process that ultimately affects pulmonary function, or, more likely, 
lower pulmonary function may result from those with cognitive impairment not performing 
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tests as well. The N85+ study gives credence to the latter since those unable to provide 
adequate spirometry were more cognitively impaired (32.4% with severe cognitive impairment 
in the whole N85+ study, as opposed to 3.4% in spirometry cohort).  
In the N85+ study, three biomarkers of systemic inflammation, tumour necrosis factor alpha 
(TNFα), interleukin-6 (IL-6) and C-reactive protein (CRP) were among those collected in 
addition to telomere length which is a biomarker of ageing (Martin-Ruiz et al., 2011). These 
were used to validate associations with lung function based on previous literature which was 
mostly on younger populations (Katz et al., 1963; Gimeno et al., 2011; Ahmadi-Abhari et al., 
2014; Baldi et al., 2014; Hancox et al., 2016). 
Telomere length in the N85+ study was inversely associated with FVC in men and PEF in 
women of whole spirometry cohort. Examination of 386 Danish twins revealed no association 
between telomere length and FEV1 in keeping with the N85+ results,  although both were of 
these measures were found to be affected by genetic factors (Sillanpaa et al., 2016). However, 
associations between short telomere length and decreased FEV1 and FVC were observed in 
participants of two prospective observational studies in Denmark (Rode et al., 2013). This can 
be explained by the large sample (n=46396) allowing for more power in the analysis of such 
associations (Rode et al., 2013).  
CRP was inversely associated with FEV1 for men and FVC for men and women of the whole 
spirometry cohort, and  PEF of men in all three groups (whole cohort, HRG, survivor group), 
confirming the inverse relation that others have found (Gimeno et al., 2011; Ahmadi-Abhari et 
al., 2014; Hancox et al., 2016) (Baldi et al., 2014). Findings of N85+ study and association of 
lung function measures with IL-6 and TNFα were inconsistent as the effect was not carried 
through all three groups. Since IL-6 was only associated with PEF in the HRG and the survivor 
group but not the whole spirometry cohort, it can be argued that the effect of IL-6 was 
attenuated due to existing respiratory disease which was significantly associated with PEF in 
the whole spirometry cohort. Similarly, disease count could be attributed to diluting the effect 
of TNFα in the whole spirometry cohort. However, the associations observed were which 
indicated increased inflammation with lower lung function were akin to other findings (Gimeno 
et al., 2011; Baldi et al., 2014).  
The major difference between this study and other literature was  the method of analysis by 
multilevel modelling, separate analysis for men and women (which allows an assumption of 
different intercepts as well as different functional forms with time and covariate effects), as 
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well as the older age group and shorter follow-up of 3 years in the N85+study compared to 
minimum of 6 years in other studies (Gimeno et al., 2011; Ahmadi-Abhari et al., 2014; Baldi et 
al., 2014; Hancox et al., 2016).  
7.5 Relationship between lung function and disability 
Previous chapters explored the baseline lung function at age 85, its impact on mortality and 
potential predictors of lung function using multiple lung function measures. In the N85+ study, 
we could examine how lung function, as one measure of intrinsic capacity,  related to functional 
ability, measured by the self-report of 17 different activities participants would carry out on a 
daily basis (Jagger et al., 2011).  
The effect of poor lung function through breathlessness on carrying out certain tasks that are 
part of the ADLs has been explored with The MRC Dyspnoea score  (Fletcher et al., 1959). A 
large cohort of old adults aged 70 years and over (n=5002) who were breathless (scores 3 – 5 on 
dyspnoea scale) had poorer quality of life, physically and mentally with higher risk of 
depression and anxiety (Ho et al., 2001). In the N85+ study, just under 40% of the spirometry 
cohort scored 3 and over on the MRC dyspnoea scale. Other studies found associations between 
COPD and reduction in ability to perform ADLs (Pitta et al., 2008; Lahaije et al., 2010; Locke 
et al., 2013; van Helvoort et al., 2016), but all were cross-sectional in design.  
Few longitudinal studies have investigated the  association of lung function on activity 
limitations and all assuming lung function decline precedes disability (Ahacic et al., 2007; 
Buchman et al., 2009; Locke et al., 2013; Hegendorfer et al., 2017a). The N85+ study analysis 
tried to take this a step further and analyse the cause and effect pathway between lung function 
and disability without prior assumption of direction through Structural Equation Modelling 
(SEM). Only a few studies have used SEM, and then to investigate lung function and cognitive 
impairment  (Finkel and Pedersen, 2004; Emery et al., 2012; Finkel et al., 2013) or cognitive 
impairment and disability  (Infurna et al., 2011). Moreover three separate disability scores 
(BADL, IADL and mobility) were derived from the ADL questionnaire items in the N85+ 
study, to allow for different severity levels of disability to be explored;  separate models were 
fitted for each score.  
The main finding was bidirectional cause and effect pathways. Lower BADL, IADL and 
mobility scores at age 85 were predictive of higher FEV1 levels at age 86.5. The BADL and 
IADL models had very similar cause and effect pathways with higher FEV1 at each time point 
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(ages 85, 86.5 and 88) predicting lower disability at each subsequent follow-up (ages 86.5, 88 
and 90), whereas higher FEV1 levels (at age 85 and 86.5) was predictive of better mobility at 
ages 86.5 and 88 respectively. Cognitive impairment, physical activity and disease count were 
also predictors of BADL and IADL scores between baseline and age 86.5. FEV1 was predictive 
of mobility up to age 88 whilst physical ability, BMI and disease count were also predictive of 
mobility at subsequent follow-up.   Sex, smoking, education and respiratory disease earlier in 
life mediated through FEV1 at baseline (age 85) and early life disease count had a direct effect 
on disability at baseline. These findings were true for all three of the disability measures. 
This study had the ability to apply  the findings from the other studies of cognitive impairment 
with disability or lung function and incorporate them all into one pathway (Finkel and 
Pedersen, 2004; Infurna et al., 2011; Emery et al., 2012; Finkel et al., 2013). Study of the 
SATSA population revealed the association between decline in lung function where they found 
lower respiratory function to be associated with subsequent poorer spatial performance and 
processing speed (Emery et al., 2012). Direct links between cognition and functional limitations 
were observed in that better memory reduces functional limitations both at intercept and over 
time (Infurna et al., 2011). Furthermore they found that the effect size was larger in adults aged 
80 – 95 when compared to those aged 70 – 79 (Infurna et al., 2011). The N85+ study pathways 
showed cognitive impairment to have no direct effect on lung function, whereas the effect of 
lung function at age 86.5 mediated through cognitive impairment at age 88 to disability at age 
90 for BADL and IADL but not mobility. This suggests that some of the relationship between 
impaired cognition affecting the ability to perform daily tasks such as shopping or dressing, is 
due to worsening lung function adversely affecting brain function. The direct (inverse) 
relationship between lung function and mobility score adds further credence since cognitive 
function has little effect on mobility.  The advantage of  the SATSA and the AHEAD studies 
was the larger cohorts and seven waves of data collected over at least 12 years in comparison to 
the N85+ study with only three time points for lung function and four for disability (Finkel and 
Pedersen, 2004; Collerton et al., 2009; Infurna et al., 2011; Emery et al., 2012; Finkel et al., 
2013; Fisher et al., 2016).  
7.6 Implications of the findings and further research  
Respiratory diseases is a major health concern in the world accounting for just over 15% of all 
death worldwide and a burden on the health services with over 6 million hospital admission in 
EU amounting to a total cost of just under  €380 billion with €200 billion being COPD related 
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(Gibson et al., 2013). The cost of respiratory disease to the UK in 2004 was £6.6 billion of 
which £1.9 billion was mortality cost and £1.7 billion spent on morbidity with the remainder 
spent on NHS care (Hubbard, 2006). The cost difference between primary and secondary care is 
over £1700 (Punekar et al., 2015) with medications ranging anywhere between £3.30 and 
£48.64, further supporting the importance of correct and early diagnosis. Our study, as others 
(Roberts et al., 2015) have established that misdiagnosis of COPD in the very old may be 
contributing to these high costs. Furthermore, removal of the misconception that the very old 
are unable to perform spirometry, as well as the use of correct prediction methodology, could 
lead to diagnosis that is more accurate and reduced healthcare costs. Further research is 
recommended to examine the cost effectiveness of providing regular spirometry for patients 
that present with symptoms of restrictive and more so obstructive lung function. Our findings 
that lower lung function predicts later disability partly through cognitive impairment may also 
provide an impetus for regular lung function tests for older people, since this may also be 
indicative of early cognitive decline. 
Smoking rates in Great Britain have been on the decline in adults aged 16 and over since 1974, 
however 2014 saw an slight increase in prevalence for women in two youngest age groups (16-
24 and 25-34)(ONS, 2016).  In the N85+ study up to 65% of participants had a history of 
smoking and smoking remained a predictor of mortality and lower lung function even in this 
cohort who had survived to age 85.  
The implication and clinical relevance of such finding can be related to the fact that worsening 
or faster decline in lung function results in more hospital admissions (Mannino and Davis, 
2006; Garcia-Aymerich et al., 2011). There is a clear message that protection of good lung 
function leads to favourable health outcomes at older ages. Good lung function at older ages 
can be attained by maintenance of healthy behaviours ( not smoking, increasing physical 
activity) from a young age. This is especially true for women where lung function was 
predictive of mortality even when adjusting for all potential confounders.  
Increases in biomarkers of systemic inflammations were consistently associated with lower 
lung function (Finkel et al., 2003; Ahmadi-Abhari et al., 2014; Baldi et al., 2014). In line with 
the findings from the N85+ study, this merits the use of CRP as an indicator of worsening lung 
function in the very old. Replication of the survival analysis and the trajectories of change in a 
larger cohort where there is enough power to investigate the interaction of time with predictors 
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of lung function and also  where there is a large enough cohort to meet the proportional hazard 
assumption would be worthy to explore whether these findings hold true or not.  
Since the population is ageing with increased life expectancy, it would be an advantage to focus 
on both intrinsic and functional ability to live longer without disability (Office for National 
Statistics, 2015). The findings in this study found that better lung function reduced the risk of 
disability. Furthermore, higher levels of physical activity and normal BMI were associated with 
reduced disability and increased lung function levels. These are modifiable health behaviours in 
addition to smoking which can improved at any stage of life.    
7.7 Strengths and limitations  
The main strengths of this study are the high participation and retention, the disease and 
spirometry measures and multiple time points, the advanced analytical methods and the 
different severity levels for disability. The N85+ study provided a comprehensive assessment of 
respiratory health and lung disease in the very old that was socio-demographically 
representative of England and Wales birth cohort of 845 participants (Collerton et al., 2009). 
Participants were interviewed in their homes achieving higher participation and retention rates. , 
and there was little withdrawal other than death and withdrawal did not appear to be linked to 
any particular participant health or demographic characteristic (Davies et al., 2014). 
Disease was ascertained from general practice record instead of self-report of doctor diagnoses 
thereby removing the risk of recall bias in this age group with higher rates of cognitive 
impairment. A key strength of this study was the uptake of spirometry conducted at the 
participants’ place of residence with multiple tests performed by a trained research nurse and 
later individually validated by an experienced physiology nurse (Fisher et al., 2016). Although 
the participants opting in were not a random sample, there was little evidence to suggest any 
difference in respiratory disease between the two groups (Fisher et al., 2016).  The availability 
of multiple longitudinal measures of health behaviours and characteristics in addition to 
spirometry was a major strength which enabled this study to investigate the role of lung 
function and its predictors over a three-year period and even longer follow-up for mortality 
(median 5.4 years).  
The survival analysis used for the N85+ data was more precise in estimating mortality as the 
lung function measures and most covariates (except early life fixed such as education) were 
updated for each follow-up until death compared to other studies where only baseline measures 
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were used (Sabia et al., 2010). A possible limitation of this analysis was that, in the earlier 
models before adjusting for all covariates, some models did not meet the proportional hazards 
assumption due to the spread of results for in certain covariates.   
Multilevel modelling was used to analyse how lung function changes over time from age 85 
years and path analysis to investigate the direction of the relationship between lung function 
and disability and how cognitive impairment may impact this. Few studies have been able to 
use these advanced statistical techniques, partly because of the lack of sufficient repeated 
measures of lung function. However, one limitation with the multilevel modelling undertaken 
was that, since men and women were analysed separately to allow for different functional forms 
of lung function over time (including baseline values at age 85). The relatively low numbers in 
each group did not allow the testing of interactions between time and potential predictors since 
models would not converge due to lack of statistical power.  
As there were 17 ADL items available at each follow-up including 60 months (where 
spirometry was not) used to calculate three different measures of disability in investigating 
different aspects of capability and dependency in participants. The use of path models in 
comparison to standard regression model is the ability to quantify the influence of both direct 
and indirect variables. The availability of more than one follow-up allowed this study not to 
assume the direction of relationship between lung function and disability is a strength compared 
to other studies with only one follow-up period, which proved crucial as the study revealed 
bidirectional associations between lung function and disability.  
A further limitation of this study is that those who agreed to participate may be comparatively 
healthier and less frail than those refusing to take part with a possible under-representation of 
those with cognitive impairment. The ability to opt in or out of the GPRR allowed for some 
investigation of participation to whole study (MDHA and GPRR) or part (GPRR only) and it 
was revealed that the rate for non-response and refusal to take part due to poor health was 30% 
for health assessment and 28% for GPRR (Collerton et al., 2009).   
7.8 Conclusion 
The ageing population worldwide is placing an enormous burden on health care systems. Poor 
respiratory function is adding more strain and there are opportunities to lift some of this burden 
through better prediction and diagnosis of costly diseases such as COPD. As lung function is a 
predictor of both clinical and social care outcomes such as hospital admissions, disability and 
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mortality frequent lung function test could used to prevent or reduce the burden on the health 
and social care systems.There is a need for recognition that the modification of certain health 
and lifestyle behaviours could improve quality of life through maintenance of good lung 
function which leads to better cognitive and function al status during an individual’s lifetime.    
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Appendices 
Appendix A: Excerpts of Newcastle 85+ Study Questionnaire 
Complete questionnaires available at: https://research.ncl.ac.uk/85plus/
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Appendix B: MRC Dyspnoea Questionnaire 
1959 MRC Breathlessness Scale 
Grade 1 Are you ever troubled by breathlessness except on strenuous exertion? 
Grade 2 (If yes) Are you short of breath when hurrying on the level or walking up a 
slight hill? 
Grade 3 Do you have to walk slower than most people on the level? Do you have to 
stop after a mile or so (or after ¼ hour) on the level at your own pace? 
Grade 4 (If yes to either) Do you have to stop for breath after walking about 100 
yds. (or after a few minutes) on the level? 
Grade 5 (If yes) Are you too breathless to leave the house, or breathless after 
undressing? 
(Fletcher et al., 1959)
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Appendix C: Journal article emanating from this PhD 
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